GESTATIONAL TROPHOBLASTIC DISEASE GUIDELINES



GESTATIONAL TROPHOBLASTIC DISEASE New Zealand Gynaecologic Cancer GroupGUIDELINESCONTENTS:PAGE:1Background and Introduction22Pathogenesis; Ploidy2 3Clinical Presentation24Diagnostic features of GTD subtypes35Surgical Treatment of Molar Pregnancy3 6Histological examination of Products of Conception47Initial Assessment48Follow-up in Molar Pregnancy4 9Referral criteria to Gynaecology Oncology for (suspected) GTN510Hysterectomy for Persistent GTD?511Prophylactic Chemotherapy in Molar Pregnancy612Contraception in Molar Pregnancy613Pregnancy Advice after Molar Pregnancy614Pregnancy during Follow-up after Molar Pregnancy715Co-existing Viable Pregnancy and Molar Pregnancy7Gestational Trophoblastic Neoplasia (GTN)16Diagnosis of Gestational Trophoblastic Neoplasia 717Staging of GTN818Risk Assessment in GTN8 19Chemotherapy in GTN820Follow-up post chemotherapy9 21Advice to Patients after chemotherapy922Pregnancy after chemotherapy for GTN1123Prognosis in GTN11Acknowledgements, Version, Authors13References13 1BACKGROUND AND INTRODUCTIONGestational trophoblastic disease (GTD) is a group of disorders derived from a pregnancy. This term covers hydatidiform mole (including complete and partial moles), invasive mole, gestational choriocarcinoma, and placental site trophoblastic tumour (PSTT). Gestational trophoblastic neoplasia (GTN) is a term used to describe GTD requiring chemotherapy.GTN follows hydatidiform mole (60%), previous miscarriage/abortion (30%), normal pregnancy or ectopic gestation (10%). GTN most commonly follows hydatidiform mole as a persistently elevated hCG titre. The incidence of GTD is 1:200-1000 pregnancies, with evidence of ethnic variation. Women from Asia have a higher incidence than non-Asian women (1/390 and 1/750 respectively). The incidence after a live birth is 1/50,000. Incidence is higher at both ends of the reproductive spectrum, ie, in women younger than 15 and older than 45. 2PATHOGENESIS; PLOIDYPartial moles are triploid, with 2 sets of paternal and 1 maternal haploid set. An embryo is usually present that dies by week 8-9. They most often occur following dispermic fertilisation. Complete moles are usually diploid, derived from paternal duplication or dispermic fertilisation of an ‘empty’ ovum (lacking in maternal genes). The chromosome count is either 46XX, from one sperm (75%) that duplicates its DNA, or 46XX or 46XY from the presence of two different sperms (25%). Placental site tumour is diploid from either the normal conceptus or a complete mole.3CLINICAL PRESENTATIONDuring Pregnancy Per vaginal bleeding in the first trimesterHigh hCG values Large for dates uterus, hyperemesis, preeclampsia and hyperthyroidismUltrasound: pathognomonic ultrasonographic changes, more often seen in complete molesMacroscopic tissue appearancePartial mole often looks like normal products of conception and so the diagnosis may be missed. The characteristic ‘bunch of grapes’ appearance in complete moles is only seen in the second trimester and as most cases are diagnosed earlier, this is now rarely seen. After Pregnancy EventAny woman who develops persistent vaginal bleeding after a pregnancy event is at risk of having GTNA urine pregnancy test should be performed in all cases of persistent or irregular vaginal bleeding after a pregnancy eventSymptoms of metastatic disease like dyspnoea or abnormal neurology occur rarelyVaginal GTN is most commonly located in the fornices or suburethrally. They are highly vascular and bleed heavily, and biopsy should be avoided.4DIAGNOSTIC FEATURES OF GTD SUBTYPESHydatidiform moles are separated into complete and partial moles based on genetic and histopathological features. In early pregnancy (less than 8 -12 weeks gestation) it may be difficult to separate complete and partial moles on H&E microscopy, and other tests (e.g. ploidy, p57) will often be required to make the diagnosis. Invasive moles usually present with hCG elevation following a molar pregnancy, clinical features can include PV bleeding, abdominal pain or swelling. Quantitative estimation of hCG or tumour hCG (t -hCG) will be of use in the diagnosis. Gestational choriocarcinoma most commonly follows a complete molar pregnancy (25-50%), within 12 months of a non-molar abortion (25%), or after a term pregnancy (25-50%). Symptoms may include PV bleeding, pelvic mass, or symptoms from distant metastases such as liver, lung and brain metastases. hCG is always elevated. It may be a difficult pathological diagnosis because of the frequent haemorrhage and necrosis, which accompany it.Placental Site Trophoblastic Tumour (PSTT) is very rare. This frequently presents as a slow growing tumour a number of years after a molar pregnancy, non-molar abortion or term pregnancy. Usually PSTT presents with gynaecologic symptoms, about 1/3 present with metastases, and some patients present with hyperprolactinaemia or nephrotic syndrome. Usually the hCG levels are relatively low or normal in PSTT relative to the volume of the disease, and HPL is seen in cells on microscopy. This tumour is relatively chemoresistant.Epithelioid Trophoblastic Tumour (ETT) is extremely rare. It may be misdiagnosed as squamous cell cancer of the cervix, choriocarcinoma or PSTT. About 1/3 patients present with metastatic disease, usually in the lungs. The hCG levels are relatively low. It behaves most similarly to PSTT, has a spectrum of behaviour from benign to malignant, and is relatively chemoresistant.5SURGICAL TREATMENT OF MOLAR PREGNANCIESEvacuation of the uterus.Suction evacuation of the uterus is the preferred initial management regardless of uterine size.Medical methods of uterine evacuation have been associated with higher rates of chemotherapy PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5UaWR5PC9BdXRob3I+PFllYXI+MjAwMDwvWWVhcj48UmVj

TnVtPjIwODc8L1JlY051bT48RGlzcGxheVRleHQ+KDEpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxy

ZWMtbnVtYmVyPjIwODc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0iMTUz

NTY4Mjk1NiI+MjA4Nzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFs

IEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+VGlk

eSwgSi4gQS48L2F1dGhvcj48YXV0aG9yPkdpbGxlc3BpZSwgQS4gTS48L2F1dGhvcj48YXV0aG9y

PkJyaWdodCwgTi48L2F1dGhvcj48YXV0aG9yPlJhZHN0b25lLCBDLiBSLjwvYXV0aG9yPjxhdXRo

b3I+Q29sZW1hbiwgUi4gRS48L2F1dGhvcj48YXV0aG9yPkhhbmNvY2ssIEIuIFcuPC9hdXRob3I+

PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RGVwYXJ0bWVudCBvZiBHeW5h

ZWNvbG9naWNhbCBPbmNvbG9neSwgTm9ydGhlcm4gR2VuZXJhbCBIb3NwaXRhbCwgU2hlZmZpZWxk

LCBTNSA3QVUsIFVuaXRlZCBLaW5nZG9tLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkdl

c3RhdGlvbmFsIHRyb3Bob2JsYXN0aWMgZGlzZWFzZTogYSBzdHVkeSBvZiBtb2RlIG9mIGV2YWN1

YXRpb24gYW5kIHN1YnNlcXVlbnQgbmVlZCBmb3IgdHJlYXRtZW50IHdpdGggY2hlbW90aGVyYXB5

PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkd5bmVjb2wgT25jb2w8L3NlY29uZGFyeS10aXRsZT48

YWx0LXRpdGxlPkd5bmVjb2xvZ2ljIG9uY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+R3luZWNvbCBPbmNvbDwvZnVsbC10aXRsZT48YWJici0xPkd5bmVj

b2xvZ2ljIG9uY29sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVs

bC10aXRsZT5HeW5lY29sIE9uY29sPC9mdWxsLXRpdGxlPjxhYmJyLTE+R3luZWNvbG9naWMgb25j

b2xvZ3k8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4zMDktMTI8L3BhZ2VzPjx2b2x1

bWU+Nzg8L3ZvbHVtZT48bnVtYmVyPjMgUHQgMTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5B

Ym9ydGlmYWNpZW50IEFnZW50cywgU3Rlcm9pZGFsL2FkdmVyc2UgZWZmZWN0cy90aGVyYXBldXRp

YyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+RGlsYXRhdGlvbiBhbmQgQ3VyZXR0YWdlL2FkdmVyc2Ug

ZWZmZWN0cy8qbWV0aG9kcy90cmVuZHM8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3Jk

PjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5IeWRhdGlkaWZvcm0gTW9sZS8qZHJ1

ZyB0aGVyYXB5LypzdXJnZXJ5PC9rZXl3b3JkPjxrZXl3b3JkPk1pZmVwcmlzdG9uZS9hZHZlcnNl

IGVmZmVjdHMvdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPk94eXRvY2luL2FkdmVy

c2UgZWZmZWN0cy90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9r

ZXl3b3JkPjxrZXl3b3JkPlByb3N0YWdsYW5kaW5zL2FkdmVyc2UgZWZmZWN0cy90aGVyYXBldXRp

YyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+UmV0cm9zcGVjdGl2ZSBTdHVkaWVzPC9rZXl3b3JkPjxr

ZXl3b3JkPlV0ZXJpbmUgTmVvcGxhc21zLypkcnVnIHRoZXJhcHkvKnN1cmdlcnk8L2tleXdvcmQ+

PGtleXdvcmQ+VmFjdXVtIEN1cmV0dGFnZS9hZHZlcnNlIGVmZmVjdHMvbWV0aG9kcy90cmVuZHM8

L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwMDwveWVhcj48cHViLWRhdGVzPjxk

YXRlPlNlcDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwOTAtODI1OCAoUHJpbnQp

JiN4RDswMDkwLTgyNTggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjEwOTg1ODg1PC9h

Y2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxt

Lm5paC5nb3YvcHVibWVkLzEwOTg1ODg1PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVj

dHJvbmljLXJlc291cmNlLW51bT4xMC4xMDA2L2d5bm8uMjAwMC41ODM5PC9lbGVjdHJvbmljLXJl

c291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5UaWR5PC9BdXRob3I+PFllYXI+MjAwMDwvWWVhcj48UmVj

TnVtPjIwODc8L1JlY051bT48RGlzcGxheVRleHQ+KDEpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxy

ZWMtbnVtYmVyPjIwODc8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0iMTUz

NTY4Mjk1NiI+MjA4Nzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFs

IEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+VGlk

eSwgSi4gQS48L2F1dGhvcj48YXV0aG9yPkdpbGxlc3BpZSwgQS4gTS48L2F1dGhvcj48YXV0aG9y

PkJyaWdodCwgTi48L2F1dGhvcj48YXV0aG9yPlJhZHN0b25lLCBDLiBSLjwvYXV0aG9yPjxhdXRo

b3I+Q29sZW1hbiwgUi4gRS48L2F1dGhvcj48YXV0aG9yPkhhbmNvY2ssIEIuIFcuPC9hdXRob3I+

PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RGVwYXJ0bWVudCBvZiBHeW5h

ZWNvbG9naWNhbCBPbmNvbG9neSwgTm9ydGhlcm4gR2VuZXJhbCBIb3NwaXRhbCwgU2hlZmZpZWxk

LCBTNSA3QVUsIFVuaXRlZCBLaW5nZG9tLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkdl

c3RhdGlvbmFsIHRyb3Bob2JsYXN0aWMgZGlzZWFzZTogYSBzdHVkeSBvZiBtb2RlIG9mIGV2YWN1

YXRpb24gYW5kIHN1YnNlcXVlbnQgbmVlZCBmb3IgdHJlYXRtZW50IHdpdGggY2hlbW90aGVyYXB5

PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkd5bmVjb2wgT25jb2w8L3NlY29uZGFyeS10aXRsZT48

YWx0LXRpdGxlPkd5bmVjb2xvZ2ljIG9uY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+R3luZWNvbCBPbmNvbDwvZnVsbC10aXRsZT48YWJici0xPkd5bmVj

b2xvZ2ljIG9uY29sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVs

bC10aXRsZT5HeW5lY29sIE9uY29sPC9mdWxsLXRpdGxlPjxhYmJyLTE+R3luZWNvbG9naWMgb25j

b2xvZ3k8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4zMDktMTI8L3BhZ2VzPjx2b2x1

bWU+Nzg8L3ZvbHVtZT48bnVtYmVyPjMgUHQgMTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5B

Ym9ydGlmYWNpZW50IEFnZW50cywgU3Rlcm9pZGFsL2FkdmVyc2UgZWZmZWN0cy90aGVyYXBldXRp

YyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+RGlsYXRhdGlvbiBhbmQgQ3VyZXR0YWdlL2FkdmVyc2Ug

ZWZmZWN0cy8qbWV0aG9kcy90cmVuZHM8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3Jk

PjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5IeWRhdGlkaWZvcm0gTW9sZS8qZHJ1

ZyB0aGVyYXB5LypzdXJnZXJ5PC9rZXl3b3JkPjxrZXl3b3JkPk1pZmVwcmlzdG9uZS9hZHZlcnNl

IGVmZmVjdHMvdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPk94eXRvY2luL2FkdmVy

c2UgZWZmZWN0cy90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9r

ZXl3b3JkPjxrZXl3b3JkPlByb3N0YWdsYW5kaW5zL2FkdmVyc2UgZWZmZWN0cy90aGVyYXBldXRp

YyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+UmV0cm9zcGVjdGl2ZSBTdHVkaWVzPC9rZXl3b3JkPjxr

ZXl3b3JkPlV0ZXJpbmUgTmVvcGxhc21zLypkcnVnIHRoZXJhcHkvKnN1cmdlcnk8L2tleXdvcmQ+

PGtleXdvcmQ+VmFjdXVtIEN1cmV0dGFnZS9hZHZlcnNlIGVmZmVjdHMvbWV0aG9kcy90cmVuZHM8

L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwMDwveWVhcj48cHViLWRhdGVzPjxk

YXRlPlNlcDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwOTAtODI1OCAoUHJpbnQp

JiN4RDswMDkwLTgyNTggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjEwOTg1ODg1PC9h

Y2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxt

Lm5paC5nb3YvcHVibWVkLzEwOTg1ODg1PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVj

dHJvbmljLXJlc291cmNlLW51bT4xMC4xMDA2L2d5bm8uMjAwMC41ODM5PC9lbGVjdHJvbmljLXJl

c291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA (1). Preparation of the cervix immediately prior to the evacuation is safe.The cervix should be carefully dilated to accommodate a cannula appropriate for the volume of trophoblastic tissue. A suction catheter up to a maximum of 12mm is satisfactory for the rapid evacuation and involution of the uterus. Oxytocin infusion can be used after evacuation, especially if brisk bleeding occurs.Concern has been raised that oxytocin may promote metastases of trophoblastic tissue ADDIN EN.CITE <EndNote><Cite><Author>Attwood</Author><Year>1961</Year><RecNum>2093</RecNum><DisplayText>(2)</DisplayText><record><rec-number>2093</rec-number><foreign-keys><key app="EN" db-id="0fs5a0t5drvzvveffz1vawr8tzrvpw00tp2v" timestamp="1535683086">2093</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Attwood, H. D.</author><author>Park, W. W.</author></authors></contributors><titles><title>Embolism to the lungs by trophoblast</title><secondary-title>J Obstet Gynaecol Br Commonw</secondary-title><alt-title>The Journal of obstetrics and gynaecology of the British Commonwealth</alt-title></titles><periodical><full-title>J Obstet Gynaecol Br Commonw</full-title><abbr-1>The Journal of obstetrics and gynaecology of the British Commonwealth</abbr-1></periodical><alt-periodical><full-title>J Obstet Gynaecol Br Commonw</full-title><abbr-1>The Journal of obstetrics and gynaecology of the British Commonwealth</abbr-1></alt-periodical><pages>611-7</pages><volume>68</volume><keywords><keyword>*Embolism</keyword><keyword>*Extraembryonic Membranes</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Pregnancy</keyword><keyword>*Pregnancy Complications</keyword><keyword>*Pulmonary Embolism</keyword><keyword>*Trophoblasts</keyword></keywords><dates><year>1961</year><pub-dates><date>Aug</date></pub-dates></dates><isbn>0022-3204 (Print)&#xD;0022-3204 (Linking)</isbn><accession-num>13685013</accession-num><urls><related-urls><url>;(2). However it has been reported that stimulation before evacuation did not increase the risk of persistent disease ADDIN EN.CITE <EndNote><Cite><Author>Hancock</Author><Year>2003</Year><RecNum>2094</RecNum><DisplayText>(3)</DisplayText><record><rec-number>2094</rec-number><foreign-keys><key app="EN" db-id="0fs5a0t5drvzvveffz1vawr8tzrvpw00tp2v" timestamp="1535683809">2094</key></foreign-keys><ref-type name="Book">6</ref-type><contributors><authors><author>Hancock, B.W.</author><author>Newlands, E.S.</author><author>Berkowitz, R.S.</author><author>Cole, L.A.</author></authors></contributors><titles><title>Gestational Trophoblastic Diseases. </title></titles><edition>2nd</edition><dates><year>2003</year></dates><pub-location>Sheffield</pub-location><publisher>International Society for the Study of Trophoblastic Diseases</publisher><urls></urls></record></Cite></EndNote>(3).It is advisable for the procedure to be carried out in the presence of, or by an experienced colleague, especially if the uterine size is large. Patients who are Rh –ve should receive Rh immunoglobulinThe Rh factor is expressed in the trophoblast. Second evacuation of the uterusSecond curettage evacuation of the uterus may be considered in select low risk patients after discussion at a Multidisciplinary meeting. Patients meeting the following criteria may be considered.Hydatidiform mole following initial curettagePersistently elevated b HCGNo evidence of metastatic GTN (CxR)FIGO risk score of 0-4A multicentre prospective phase 2 trial of 85 pts showed that 40% of patients avoided chemotherapy with second curettage. There was 1 uterine perforation (1.6%) managed conservatively PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Pc2Jvcm5lPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48

UmVjTnVtPjIwOTU8L1JlY051bT48RGlzcGxheVRleHQ+KDQpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjIwOTU8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0i

MTUzNTY4Mzk2NiI+MjA5NTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

T3Nib3JuZSwgUi4gSi48L2F1dGhvcj48YXV0aG9yPkZpbGlhY2ksIFYuIEwuPC9hdXRob3I+PGF1

dGhvcj5TY2hpbmssIEouIEMuPC9hdXRob3I+PGF1dGhvcj5NYW5uZWwsIFIuIFMuPC9hdXRob3I+

PGF1dGhvcj5CZWhiYWtodCwgSy48L2F1dGhvcj48YXV0aG9yPkhvZmZtYW4sIEouIFMuPC9hdXRo

b3I+PGF1dGhvcj5TcGlydG9zLCBOLiBNLjwvYXV0aG9yPjxhdXRob3I+Q2hhbiwgSi4gSy48L2F1

dGhvcj48YXV0aG9yPlRpZHksIEouIEEuPC9hdXRob3I+PGF1dGhvcj5NaWxsZXIsIEQuIFMuPC9h

dXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+U3Vubnlicm9vayBI

ZWFsdGggU2NpZW5jZXMgQ2VudGVyLCBUb3JvbnRvLCBPbnRhcmlvLCBDYW5hZGE7IHRoZSBOUkcg

T25jb2xvZ3kgU3RhdGlzdGljcyBhbmQgRGF0YSBNYW5hZ2VtZW50IENlbnRlciwgUm9zd2VsbCBQ

YXJrIENhbmNlciBJbnN0aXR1dGUsIEJ1ZmZhbG8sIE5ldyBZb3JrOyBTcGVjdHJ1bSBIZWFsdGgg

TWVkaWNhbCBHcm91cCwgR3JhbmQgUmFwaWRzLCBNaWNoaWdhbjsgdGhlIFVuaXZlcnNpdHkgb2Yg

T2tsYWhvbWEgSGVhbHRoIFNjaWVuY2VzIENlbnRlciwgT2tsYWhvbWEgQ2l0eSwgT2tsYWhvbWE7

IHRoZSBVbml2ZXJzaXR5IG9mIENvbG9yYWRvIENhbmNlciBDZW50ZXIsIEF1cm9yYSwgQ29sb3Jh

ZG87IE5ldyBCcml0YWluIEdlbmVyYWwgSG9zcGl0YWwsIFBsYWludmlsbGUsIENvbm5lY3RpY3V0

OyBXb21lbiZhcG9zO3MgQ2FuY2VyIENlbnRlciwgTGFzIFZlZ2FzLCBOZXZhZGE7IFVDU0YgSGVs

ZW4gRGlsbGVyIENvbXByZWhlbnNpdmUgQ2FuY2VyIENlbnRlciwgU2FuIEZyYW5jaXNjbywgQ2Fs

aWZvcm5pYTsgUm95YWwgSGFsbGFtc2hpcmUgSG9zcGl0YWwsIFNoZWZmaWVsZCwgVW5pdGVkIEtp

bmdkb207IGFuZCB0aGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBTb3V0aHdlc3Rlcm4gTWVkaWNhbCBD

ZW50ZXIsIERhbGxhcywgVGV4YXMuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+U2Vjb25k

IEN1cmV0dGFnZSBmb3IgTG93LVJpc2sgTm9ubWV0YXN0YXRpYyBHZXN0YXRpb25hbCBUcm9waG9i

bGFzdGljIE5lb3BsYXNpYTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5PYnN0ZXQgR3luZWNvbDwv

c2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+T2JzdGV0cmljcyBhbmQgZ3luZWNvbG9neTwvYWx0

LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPk9ic3RldCBHeW5lY29sPC9m

dWxsLXRpdGxlPjxhYmJyLTE+T2JzdGV0cmljcyBhbmQgZ3luZWNvbG9neTwvYWJici0xPjwvcGVy

aW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+T2JzdGV0IEd5bmVjb2w8L2Z1bGwt

dGl0bGU+PGFiYnItMT5PYnN0ZXRyaWNzIGFuZCBneW5lY29sb2d5PC9hYmJyLTE+PC9hbHQtcGVy

aW9kaWNhbD48cGFnZXM+NTM1LTQyPC9wYWdlcz48dm9sdW1lPjEyODwvdm9sdW1lPjxudW1iZXI+

MzwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3Jk

PkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkNob3Jpb25pYyBHb25hZG90cm9waW4vYW5hbHlzaXM8

L2tleXdvcmQ+PGtleXdvcmQ+KkN1cmV0dGFnZS9hZHZlcnNlIGVmZmVjdHMvbWV0aG9kcy9zdGF0

aXN0aWNzICZhbXA7IG51bWVyaWNhbCBkYXRhPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5

d29yZD48a2V5d29yZD4qR2VzdGF0aW9uYWwgVHJvcGhvYmxhc3RpYyBEaXNlYXNlL2Jsb29kL2Rp

YWdub3Npcy9lcGlkZW1pb2xvZ3kvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwv

a2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD5OZW9wbGFzbSBJ

bnZhc2l2ZW5lc3M8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20gU3RhZ2luZzwva2V5d29yZD48

a2V5d29yZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJvZ25vc2lzPC9rZXl3b3JkPjxr

ZXl3b3JkPlByb3NwZWN0aXZlIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+KlJlb3BlcmF0aW9u

L21ldGhvZHMvc3RhdGlzdGljcyAmYW1wOyBudW1lcmljYWwgZGF0YTwva2V5d29yZD48a2V5d29y

ZD5SaXNrIEFzc2Vzc21lbnQ8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBGYWN0b3JzPC9rZXl3b3Jk

PjxrZXl3b3JkPlVsdHJhc29ub2dyYXBoeS9tZXRob2RzPC9rZXl3b3JkPjxrZXl3b3JkPlVuaXRl

ZCBTdGF0ZXMvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIw

MTY8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5TZXA8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48

aXNibj4xODczLTIzM1ggKEVsZWN0cm9uaWMpJiN4RDswMDI5LTc4NDQgKExpbmtpbmcpPC9pc2Ju

PjxhY2Nlc3Npb24tbnVtPjI3NTAwMzI5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVy

bHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI3NTAwMzI5PC91cmw+

PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPjQ5OTM2NjM8L2N1c3RvbTI+PGVsZWN0cm9u

aWMtcmVzb3VyY2UtbnVtPjEwLjEwOTcvQU9HLjAwMDAwMDAwMDAwMDE1NTQ8L2VsZWN0cm9uaWMt

cmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Pc2Jvcm5lPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48

UmVjTnVtPjIwOTU8L1JlY051bT48RGlzcGxheVRleHQ+KDQpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjIwOTU8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0i

MTUzNTY4Mzk2NiI+MjA5NTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

T3Nib3JuZSwgUi4gSi48L2F1dGhvcj48YXV0aG9yPkZpbGlhY2ksIFYuIEwuPC9hdXRob3I+PGF1

dGhvcj5TY2hpbmssIEouIEMuPC9hdXRob3I+PGF1dGhvcj5NYW5uZWwsIFIuIFMuPC9hdXRob3I+

PGF1dGhvcj5CZWhiYWtodCwgSy48L2F1dGhvcj48YXV0aG9yPkhvZmZtYW4sIEouIFMuPC9hdXRo

b3I+PGF1dGhvcj5TcGlydG9zLCBOLiBNLjwvYXV0aG9yPjxhdXRob3I+Q2hhbiwgSi4gSy48L2F1

dGhvcj48YXV0aG9yPlRpZHksIEouIEEuPC9hdXRob3I+PGF1dGhvcj5NaWxsZXIsIEQuIFMuPC9h

dXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+U3Vubnlicm9vayBI

ZWFsdGggU2NpZW5jZXMgQ2VudGVyLCBUb3JvbnRvLCBPbnRhcmlvLCBDYW5hZGE7IHRoZSBOUkcg

T25jb2xvZ3kgU3RhdGlzdGljcyBhbmQgRGF0YSBNYW5hZ2VtZW50IENlbnRlciwgUm9zd2VsbCBQ

YXJrIENhbmNlciBJbnN0aXR1dGUsIEJ1ZmZhbG8sIE5ldyBZb3JrOyBTcGVjdHJ1bSBIZWFsdGgg

TWVkaWNhbCBHcm91cCwgR3JhbmQgUmFwaWRzLCBNaWNoaWdhbjsgdGhlIFVuaXZlcnNpdHkgb2Yg

T2tsYWhvbWEgSGVhbHRoIFNjaWVuY2VzIENlbnRlciwgT2tsYWhvbWEgQ2l0eSwgT2tsYWhvbWE7

IHRoZSBVbml2ZXJzaXR5IG9mIENvbG9yYWRvIENhbmNlciBDZW50ZXIsIEF1cm9yYSwgQ29sb3Jh

ZG87IE5ldyBCcml0YWluIEdlbmVyYWwgSG9zcGl0YWwsIFBsYWludmlsbGUsIENvbm5lY3RpY3V0

OyBXb21lbiZhcG9zO3MgQ2FuY2VyIENlbnRlciwgTGFzIFZlZ2FzLCBOZXZhZGE7IFVDU0YgSGVs

ZW4gRGlsbGVyIENvbXByZWhlbnNpdmUgQ2FuY2VyIENlbnRlciwgU2FuIEZyYW5jaXNjbywgQ2Fs

aWZvcm5pYTsgUm95YWwgSGFsbGFtc2hpcmUgSG9zcGl0YWwsIFNoZWZmaWVsZCwgVW5pdGVkIEtp

bmdkb207IGFuZCB0aGUgVW5pdmVyc2l0eSBvZiBUZXhhcyBTb3V0aHdlc3Rlcm4gTWVkaWNhbCBD

ZW50ZXIsIERhbGxhcywgVGV4YXMuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+U2Vjb25k

IEN1cmV0dGFnZSBmb3IgTG93LVJpc2sgTm9ubWV0YXN0YXRpYyBHZXN0YXRpb25hbCBUcm9waG9i

bGFzdGljIE5lb3BsYXNpYTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5PYnN0ZXQgR3luZWNvbDwv

c2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+T2JzdGV0cmljcyBhbmQgZ3luZWNvbG9neTwvYWx0

LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPk9ic3RldCBHeW5lY29sPC9m

dWxsLXRpdGxlPjxhYmJyLTE+T2JzdGV0cmljcyBhbmQgZ3luZWNvbG9neTwvYWJici0xPjwvcGVy

aW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+T2JzdGV0IEd5bmVjb2w8L2Z1bGwt

dGl0bGU+PGFiYnItMT5PYnN0ZXRyaWNzIGFuZCBneW5lY29sb2d5PC9hYmJyLTE+PC9hbHQtcGVy

aW9kaWNhbD48cGFnZXM+NTM1LTQyPC9wYWdlcz48dm9sdW1lPjEyODwvdm9sdW1lPjxudW1iZXI+

MzwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3Jk

PkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkNob3Jpb25pYyBHb25hZG90cm9waW4vYW5hbHlzaXM8

L2tleXdvcmQ+PGtleXdvcmQ+KkN1cmV0dGFnZS9hZHZlcnNlIGVmZmVjdHMvbWV0aG9kcy9zdGF0

aXN0aWNzICZhbXA7IG51bWVyaWNhbCBkYXRhPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5

d29yZD48a2V5d29yZD4qR2VzdGF0aW9uYWwgVHJvcGhvYmxhc3RpYyBEaXNlYXNlL2Jsb29kL2Rp

YWdub3Npcy9lcGlkZW1pb2xvZ3kvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwv

a2V5d29yZD48a2V5d29yZD5NaWRkbGUgQWdlZDwva2V5d29yZD48a2V5d29yZD5OZW9wbGFzbSBJ

bnZhc2l2ZW5lc3M8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20gU3RhZ2luZzwva2V5d29yZD48

a2V5d29yZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJvZ25vc2lzPC9rZXl3b3JkPjxr

ZXl3b3JkPlByb3NwZWN0aXZlIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+KlJlb3BlcmF0aW9u

L21ldGhvZHMvc3RhdGlzdGljcyAmYW1wOyBudW1lcmljYWwgZGF0YTwva2V5d29yZD48a2V5d29y

ZD5SaXNrIEFzc2Vzc21lbnQ8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBGYWN0b3JzPC9rZXl3b3Jk

PjxrZXl3b3JkPlVsdHJhc29ub2dyYXBoeS9tZXRob2RzPC9rZXl3b3JkPjxrZXl3b3JkPlVuaXRl

ZCBTdGF0ZXMvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIw

MTY8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5TZXA8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48

aXNibj4xODczLTIzM1ggKEVsZWN0cm9uaWMpJiN4RDswMDI5LTc4NDQgKExpbmtpbmcpPC9pc2Ju

PjxhY2Nlc3Npb24tbnVtPjI3NTAwMzI5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVy

bHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzI3NTAwMzI5PC91cmw+

PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPjQ5OTM2NjM8L2N1c3RvbTI+PGVsZWN0cm9u

aWMtcmVzb3VyY2UtbnVtPjEwLjEwOTcvQU9HLjAwMDAwMDAwMDAwMDE1NTQ8L2VsZWN0cm9uaWMt

cmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE.DATA (4). 6HISTOLOGICAL EXAMINATION OF PRODUCTS OF CONCEPTIONAll spontaneous miscarriages and retained products of conception managed through a hospital should undergo histological examination. Routine termination of pregnancy does not require histological review.If no histological examination was performed after medical evacuation, hCG test is recommended after three weeks (urine test sufficient)Because GTD can also develop after any pregnancy, it is recommended that products of conception obtained after any repeat evacuation are also examined histologically. Expert pathological opinion, by a pathologist with an interest in gynaecologic pathology, is always recommended in the diagnosis of GTD. Pathology must be reviewed at a multidisciplinary meeting. 7INITIAL ASSESSMENTAll patients diagnosed with a molar pregnancy should be seen for consultation by a local, named clinician responsible for the local GTD Service, typically a gynaecologist. This should happen in conjunction with the Regional GTD Service The establishment of a local registry to capture all GTD patients is recommended. All patients should be asked to consent to centralised registration once a central registry is available. Visit should include:full history, including antecedent and all pregnancies, LMP date, evacuation date, oral contraceptive intake and symptoms Information and discussion about the diagnosis and the need for regular follow upWritten information (see appendix 1)Clinical examination for metastatic disease, pelvic examChest X-ray tumour hCG test as new baselineOffering of counselling PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TdGFmZm9yZDwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+

PFJlY051bT4yMTAwPC9SZWNOdW0+PERpc3BsYXlUZXh0Pig1KTwvRGlzcGxheVRleHQ+PHJlY29y

ZD48cmVjLW51bWJlcj4yMTAwPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9

IjE1MzU2ODQxMzYiPjIxMDA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PlN0YWZmb3JkLCBMLjwvYXV0aG9yPjxhdXRob3I+TWNOYWxseSwgTy4gTS48L2F1dGhvcj48YXV0

aG9yPkdpYnNvbiwgUC48L2F1dGhvcj48YXV0aG9yPkp1ZGQsIEYuPC9hdXRob3I+PC9hdXRob3Jz

PjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+Q2VudHJlIGZvciBXb21lbiZhcG9zO3MgTWVu

dGFsIEhlYWx0aCwgUm95YWwgV29tZW4mYXBvcztzIEhvc3BpdGFsLCBQYXJrdmlsbGUsIEF1c3Ry

YWxpYS4gbGVzbGV5QGxlc2xleXN0YWZmb3JkLmNvbTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRp

dGxlPkxvbmctdGVybSBwc3ljaG9sb2dpY2FsIG1vcmJpZGl0eSwgc2V4dWFsIGZ1bmN0aW9uaW5n

LCBhbmQgcmVsYXRpb25zaGlwIG91dGNvbWVzIGluIHdvbWVuIHdpdGggZ2VzdGF0aW9uYWwgdHJv

cGhvYmxhc3RpYyBkaXNlYXNlPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkludCBKIEd5bmVjb2wg

Q2FuY2VyPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5JbnRlcm5hdGlvbmFsIGpvdXJuYWwg

b2YgZ3luZWNvbG9naWNhbCBjYW5jZXIgOiBvZmZpY2lhbCBqb3VybmFsIG9mIHRoZSBJbnRlcm5h

dGlvbmFsIEd5bmVjb2xvZ2ljYWwgQ2FuY2VyIFNvY2lldHk8L2FsdC10aXRsZT48L3RpdGxlcz48

cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5JbnQgSiBHeW5lY29sIENhbmNlcjwvZnVsbC10aXRsZT48

YWJici0xPkludGVybmF0aW9uYWwgam91cm5hbCBvZiBneW5lY29sb2dpY2FsIGNhbmNlciA6IG9m

ZmljaWFsIGpvdXJuYWwgb2YgdGhlIEludGVybmF0aW9uYWwgR3luZWNvbG9naWNhbCBDYW5jZXIg

U29jaWV0eTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

SW50IEogR3luZWNvbCBDYW5jZXI8L2Z1bGwtdGl0bGU+PGFiYnItMT5JbnRlcm5hdGlvbmFsIGpv

dXJuYWwgb2YgZ3luZWNvbG9naWNhbCBjYW5jZXIgOiBvZmZpY2lhbCBqb3VybmFsIG9mIHRoZSBJ

bnRlcm5hdGlvbmFsIEd5bmVjb2xvZ2ljYWwgQ2FuY2VyIFNvY2lldHk8L2FiYnItMT48L2FsdC1w

ZXJpb2RpY2FsPjxwYWdlcz4xMjU2LTYzPC9wYWdlcz48dm9sdW1lPjIxPC92b2x1bWU+PG51bWJl

cj43PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkFu

eGlldHkvZXBpZGVtaW9sb2d5LypldGlvbG9neTwva2V5d29yZD48a2V5d29yZD5BdXN0cmFsaWEv

ZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkNyb3NzLVNlY3Rpb25hbCBTdHVkaWVzPC9r

ZXl3b3JkPjxrZXl3b3JkPkRlcHJlc3Npb24vZXBpZGVtaW9sb2d5LypldGlvbG9neTwva2V5d29y

ZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3

b3JkPkh5ZGF0aWRpZm9ybSBNb2xlL2NvbXBsaWNhdGlvbnMvZXBpZGVtaW9sb2d5Lypwc3ljaG9s

b2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1hcnJpYWdlL3BzeWNob2xvZ3k8L2tleXdvcmQ+PGtleXdv

cmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3

b3JkPlJlZ2lzdHJpZXM8L2tleXdvcmQ+PGtleXdvcmQ+U2V4dWFsIER5c2Z1bmN0aW9ucywgUHN5

Y2hvbG9naWNhbC9lcGlkZW1pb2xvZ3kvKmV0aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPlV0ZXJp

bmUgTmVvcGxhc21zL2NvbXBsaWNhdGlvbnMvZXBpZGVtaW9sb2d5Lypwc3ljaG9sb2d5PC9rZXl3

b3JkPjxrZXl3b3JkPllvdW5nIEFkdWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFy

PjIwMTE8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5PY3Q8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRl

cz48aXNibj4xNTI1LTE0MzggKEVsZWN0cm9uaWMpJiN4RDsxMDQ4LTg5MVggKExpbmtpbmcpPC9p

c2JuPjxhY2Nlc3Npb24tbnVtPjIxODExMTc0PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVk

LXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzIxODExMTc0PC91

cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDk3

L0lHQy4wYjAxM2UzMTgyMjU5YzA0PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48

L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TdGFmZm9yZDwvQXV0aG9yPjxZZWFyPjIwMTE8L1llYXI+

PFJlY051bT4yMTAwPC9SZWNOdW0+PERpc3BsYXlUZXh0Pig1KTwvRGlzcGxheVRleHQ+PHJlY29y

ZD48cmVjLW51bWJlcj4yMTAwPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9

IjE1MzU2ODQxMzYiPjIxMDA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PlN0YWZmb3JkLCBMLjwvYXV0aG9yPjxhdXRob3I+TWNOYWxseSwgTy4gTS48L2F1dGhvcj48YXV0

aG9yPkdpYnNvbiwgUC48L2F1dGhvcj48YXV0aG9yPkp1ZGQsIEYuPC9hdXRob3I+PC9hdXRob3Jz

PjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+Q2VudHJlIGZvciBXb21lbiZhcG9zO3MgTWVu

dGFsIEhlYWx0aCwgUm95YWwgV29tZW4mYXBvcztzIEhvc3BpdGFsLCBQYXJrdmlsbGUsIEF1c3Ry

YWxpYS4gbGVzbGV5QGxlc2xleXN0YWZmb3JkLmNvbTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRp

dGxlPkxvbmctdGVybSBwc3ljaG9sb2dpY2FsIG1vcmJpZGl0eSwgc2V4dWFsIGZ1bmN0aW9uaW5n

LCBhbmQgcmVsYXRpb25zaGlwIG91dGNvbWVzIGluIHdvbWVuIHdpdGggZ2VzdGF0aW9uYWwgdHJv

cGhvYmxhc3RpYyBkaXNlYXNlPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkludCBKIEd5bmVjb2wg

Q2FuY2VyPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5JbnRlcm5hdGlvbmFsIGpvdXJuYWwg

b2YgZ3luZWNvbG9naWNhbCBjYW5jZXIgOiBvZmZpY2lhbCBqb3VybmFsIG9mIHRoZSBJbnRlcm5h

dGlvbmFsIEd5bmVjb2xvZ2ljYWwgQ2FuY2VyIFNvY2lldHk8L2FsdC10aXRsZT48L3RpdGxlcz48

cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5JbnQgSiBHeW5lY29sIENhbmNlcjwvZnVsbC10aXRsZT48

YWJici0xPkludGVybmF0aW9uYWwgam91cm5hbCBvZiBneW5lY29sb2dpY2FsIGNhbmNlciA6IG9m

ZmljaWFsIGpvdXJuYWwgb2YgdGhlIEludGVybmF0aW9uYWwgR3luZWNvbG9naWNhbCBDYW5jZXIg

U29jaWV0eTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

SW50IEogR3luZWNvbCBDYW5jZXI8L2Z1bGwtdGl0bGU+PGFiYnItMT5JbnRlcm5hdGlvbmFsIGpv

dXJuYWwgb2YgZ3luZWNvbG9naWNhbCBjYW5jZXIgOiBvZmZpY2lhbCBqb3VybmFsIG9mIHRoZSBJ

bnRlcm5hdGlvbmFsIEd5bmVjb2xvZ2ljYWwgQ2FuY2VyIFNvY2lldHk8L2FiYnItMT48L2FsdC1w

ZXJpb2RpY2FsPjxwYWdlcz4xMjU2LTYzPC9wYWdlcz48dm9sdW1lPjIxPC92b2x1bWU+PG51bWJl

cj43PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkFu

eGlldHkvZXBpZGVtaW9sb2d5LypldGlvbG9neTwva2V5d29yZD48a2V5d29yZD5BdXN0cmFsaWEv

ZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkNyb3NzLVNlY3Rpb25hbCBTdHVkaWVzPC9r

ZXl3b3JkPjxrZXl3b3JkPkRlcHJlc3Npb24vZXBpZGVtaW9sb2d5LypldGlvbG9neTwva2V5d29y

ZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3

b3JkPkh5ZGF0aWRpZm9ybSBNb2xlL2NvbXBsaWNhdGlvbnMvZXBpZGVtaW9sb2d5Lypwc3ljaG9s

b2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1hcnJpYWdlL3BzeWNob2xvZ3k8L2tleXdvcmQ+PGtleXdv

cmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3

b3JkPlJlZ2lzdHJpZXM8L2tleXdvcmQ+PGtleXdvcmQ+U2V4dWFsIER5c2Z1bmN0aW9ucywgUHN5

Y2hvbG9naWNhbC9lcGlkZW1pb2xvZ3kvKmV0aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPlV0ZXJp

bmUgTmVvcGxhc21zL2NvbXBsaWNhdGlvbnMvZXBpZGVtaW9sb2d5Lypwc3ljaG9sb2d5PC9rZXl3

b3JkPjxrZXl3b3JkPllvdW5nIEFkdWx0PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFy

PjIwMTE8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5PY3Q8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRl

cz48aXNibj4xNTI1LTE0MzggKEVsZWN0cm9uaWMpJiN4RDsxMDQ4LTg5MVggKExpbmtpbmcpPC9p

c2JuPjxhY2Nlc3Npb24tbnVtPjIxODExMTc0PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVk

LXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzIxODExMTc0PC91

cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDk3

L0lHQy4wYjAxM2UzMTgyMjU5YzA0PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48

L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA (5)Socially disadvantaged women and those who do not conceive subsequent to GTD diagnosis require greater psychosocial support.8FOLLOW-UP IN MOLAR PREGNANCY (Partial and Complete Mole)General AspectsPatients must be followed up with regular tumour hCG after any diagnosis of molar pregnancy.Follow-up should preferably be undertaken in consultation with or by a specialist centre (Gynaecological Oncologist, and/or Medical Oncologist) with experience in the management of GTD. Responsibility for follow up of tumour hCG results must be delegated to a specific clinician or GTD Clinical Nurse Specialist, with robust procedures in place for the monitoring of the results.Tumour Marker follow-upTake serum tumour hCG Differs from pregnancy test with beta-hCG (β-hCG) , as it measures all hCG isoformsThe 2 assays are not comparablePatients undergoing follow-up after diagnosis of GTD should preferably have tumour hCG measured. Consistency is essential as treatment decisions might be based on small changes in the hCG.The serum half-life of hCG is ~24-36 hours. The level is roughly linked to the number of tumour cells; 5IU/l ~104 – 105 tumour cells. Schedule t-hCGOn the day of diagnosisWeekly thereafter until normal levels are obtained twiceMonthly once normal levels are obtained.Duration The duration of Follow up should be dependent on type of GTD PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TY2htaXR0PC9BdXRob3I+PFllYXI+MjAxMzwvWWVhcj48

UmVjTnVtPjIxMDI8L1JlY051bT48RGlzcGxheVRleHQ+KDYpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjIxMDI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0i

MTUzNTY4NDI4MSI+MjEwMjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

U2NobWl0dCwgQy48L2F1dGhvcj48YXV0aG9yPkRvcmV0LCBNLjwvYXV0aG9yPjxhdXRob3I+TWFz

c2FyZGllciwgSi48L2F1dGhvcj48YXV0aG9yPkhhanJpLCBULjwvYXV0aG9yPjxhdXRob3I+U2No

b3R0LCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+UmF1ZHJhbnQsIEQuPC9hdXRob3I+PGF1dGhvcj5H

b2xmaWVyLCBGLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNz

PlVuaXZlcnNpdHkgb2YgTHlvbiAxLCBEZXBhcnRtZW50IG9mIEd5bmFlY29sb2dpY2FsIGFuZCBP

bmNvbG9naWNhbCBTdXJnZXJ5LU9ic3RldHJpY3MsIEx5b24gU3VkIFVuaXZlcnNpdHkgSG9zcGl0

YWwsIEx5b24sIEZyYW5jZS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5SaXNrIG9mIGdl

c3RhdGlvbmFsIHRyb3Bob2JsYXN0aWMgbmVvcGxhc2lhIGFmdGVyIGhDRyBub3JtYWxpc2F0aW9u

IGFjY29yZGluZyB0byBoeWRhdGlkaWZvcm0gbW9sZSB0eXBlPC90aXRsZT48c2Vjb25kYXJ5LXRp

dGxlPkd5bmVjb2wgT25jb2w8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkd5bmVjb2xvZ2lj

IG9uY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+R3lu

ZWNvbCBPbmNvbDwvZnVsbC10aXRsZT48YWJici0xPkd5bmVjb2xvZ2ljIG9uY29sb2d5PC9hYmJy

LTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5HeW5lY29sIE9uY29s

PC9mdWxsLXRpdGxlPjxhYmJyLTE+R3luZWNvbG9naWMgb25jb2xvZ3k8L2FiYnItMT48L2FsdC1w

ZXJpb2RpY2FsPjxwYWdlcz44Ni05PC9wYWdlcz48dm9sdW1lPjEzMDwvdm9sdW1lPjxudW1iZXI+

MTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5DaG9y

aW9uaWMgR29uYWRvdHJvcGluLypibG9vZDwva2V5d29yZD48a2V5d29yZD5Db2hvcnQgU3R1ZGll

czwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+RnJhbmNlL2VwaWRl

bWlvbG9neTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBUcm9waG9ibGFzdGljIERpc2Vh

c2UvKmJsb29kL2VwaWRlbWlvbG9neS9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5z

PC9rZXl3b3JkPjxrZXl3b3JkPkh5ZGF0aWRpZm9ybSBNb2xlLypibG9vZC9lcGlkZW1pb2xvZ3kv

cGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3Jk

PlByZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5Qcm9zcGVjdGl2ZSBTdHVkaWVzPC9rZXl3b3Jk

PjxrZXl3b3JkPlJpc2s8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxMzwveWVh

cj48cHViLWRhdGVzPjxkYXRlPkp1bDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjEw

OTUtNjg1OSAoRWxlY3Ryb25pYykmI3hEOzAwOTAtODI1OCAoTGlua2luZyk8L2lzYm4+PGFjY2Vz

c2lvbi1udW0+MjM1MjM2MTc8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJs

Pmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjM1MjM2MTc8L3VybD48L3JlbGF0

ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMTYvai55Z3luby4y

MDEzLjAzLjAxMDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5k

Tm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TY2htaXR0PC9BdXRob3I+PFllYXI+MjAxMzwvWWVhcj48

UmVjTnVtPjIxMDI8L1JlY051bT48RGlzcGxheVRleHQ+KDYpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjIxMDI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0i

MTUzNTY4NDI4MSI+MjEwMjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

U2NobWl0dCwgQy48L2F1dGhvcj48YXV0aG9yPkRvcmV0LCBNLjwvYXV0aG9yPjxhdXRob3I+TWFz

c2FyZGllciwgSi48L2F1dGhvcj48YXV0aG9yPkhhanJpLCBULjwvYXV0aG9yPjxhdXRob3I+U2No

b3R0LCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+UmF1ZHJhbnQsIEQuPC9hdXRob3I+PGF1dGhvcj5H

b2xmaWVyLCBGLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNz

PlVuaXZlcnNpdHkgb2YgTHlvbiAxLCBEZXBhcnRtZW50IG9mIEd5bmFlY29sb2dpY2FsIGFuZCBP

bmNvbG9naWNhbCBTdXJnZXJ5LU9ic3RldHJpY3MsIEx5b24gU3VkIFVuaXZlcnNpdHkgSG9zcGl0

YWwsIEx5b24sIEZyYW5jZS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5SaXNrIG9mIGdl

c3RhdGlvbmFsIHRyb3Bob2JsYXN0aWMgbmVvcGxhc2lhIGFmdGVyIGhDRyBub3JtYWxpc2F0aW9u

IGFjY29yZGluZyB0byBoeWRhdGlkaWZvcm0gbW9sZSB0eXBlPC90aXRsZT48c2Vjb25kYXJ5LXRp

dGxlPkd5bmVjb2wgT25jb2w8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkd5bmVjb2xvZ2lj

IG9uY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+R3lu

ZWNvbCBPbmNvbDwvZnVsbC10aXRsZT48YWJici0xPkd5bmVjb2xvZ2ljIG9uY29sb2d5PC9hYmJy

LTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5HeW5lY29sIE9uY29s

PC9mdWxsLXRpdGxlPjxhYmJyLTE+R3luZWNvbG9naWMgb25jb2xvZ3k8L2FiYnItMT48L2FsdC1w

ZXJpb2RpY2FsPjxwYWdlcz44Ni05PC9wYWdlcz48dm9sdW1lPjEzMDwvdm9sdW1lPjxudW1iZXI+

MTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5DaG9y

aW9uaWMgR29uYWRvdHJvcGluLypibG9vZDwva2V5d29yZD48a2V5d29yZD5Db2hvcnQgU3R1ZGll

czwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+RnJhbmNlL2VwaWRl

bWlvbG9neTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBUcm9waG9ibGFzdGljIERpc2Vh

c2UvKmJsb29kL2VwaWRlbWlvbG9neS9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5z

PC9rZXl3b3JkPjxrZXl3b3JkPkh5ZGF0aWRpZm9ybSBNb2xlLypibG9vZC9lcGlkZW1pb2xvZ3kv

cGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3Jk

PlByZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5Qcm9zcGVjdGl2ZSBTdHVkaWVzPC9rZXl3b3Jk

PjxrZXl3b3JkPlJpc2s8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxMzwveWVh

cj48cHViLWRhdGVzPjxkYXRlPkp1bDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjEw

OTUtNjg1OSAoRWxlY3Ryb25pYykmI3hEOzAwOTAtODI1OCAoTGlua2luZyk8L2lzYm4+PGFjY2Vz

c2lvbi1udW0+MjM1MjM2MTc8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJs

Pmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjM1MjM2MTc8L3VybD48L3JlbGF0

ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMTYvai55Z3luby4y

MDEzLjAzLjAxMDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5k

Tm90ZT4A

ADDIN EN.CITE.DATA (6) This follow up plan can be followed if a central/MDM review of pathology has confirmed the diagnosis Partial mole:stop as soon as tHCG negative PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XaWVsc21hPC9BdXRob3I+PFllYXI+MjAwNjwvWWVhcj48

UmVjTnVtPjIxMDM8L1JlY051bT48RGlzcGxheVRleHQ+KDcpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjIxMDM8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0i

MTUzNTY4NDM4NSI+MjEwMzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

V2llbHNtYSwgUy48L2F1dGhvcj48YXV0aG9yPktlcmttZWlqZXIsIEwuPC9hdXRob3I+PGF1dGhv

cj5CZWtrZXJzLCBSLjwvYXV0aG9yPjxhdXRob3I+UHltYW4sIEouPC9hdXRob3I+PGF1dGhvcj5U

YW4sIEouPC9hdXRob3I+PGF1dGhvcj5RdWlubiwgTS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250

cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIE9ic3RldHJpY3MgYW5kIEd5bmFl

Y29sb2d5LCBSYWRib3VkIFVuaXZlcnNpdHksIE5pam1pZ2VuLCBUaGUgTmV0aGVybGFuZHMuPC9h

dXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+UGVyc2lzdGVudCB0cm9waG9ibGFzdCBkaXNlYXNl

IGZvbGxvd2luZyBwYXJ0aWFsIG1vbGFyIHByZWduYW5jeTwvdGl0bGU+PHNlY29uZGFyeS10aXRs

ZT5BdXN0IE4gWiBKIE9ic3RldCBHeW5hZWNvbDwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+

VGhlIEF1c3RyYWxpYW4gJmFtcDsgTmV3IFplYWxhbmQgam91cm5hbCBvZiBvYnN0ZXRyaWNzICZh

bXA7IGd5bmFlY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0

bGU+QXVzdCBOIFogSiBPYnN0ZXQgR3luYWVjb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUgQXVz

dHJhbGlhbiAmYW1wOyBOZXcgWmVhbGFuZCBqb3VybmFsIG9mIG9ic3RldHJpY3MgJmFtcDsgZ3lu

YWVjb2xvZ3k8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxl

PkF1c3QgTiBaIEogT2JzdGV0IEd5bmFlY29sPC9mdWxsLXRpdGxlPjxhYmJyLTE+VGhlIEF1c3Ry

YWxpYW4gJmFtcDsgTmV3IFplYWxhbmQgam91cm5hbCBvZiBvYnN0ZXRyaWNzICZhbXA7IGd5bmFl

Y29sb2d5PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+MTE5LTIzPC9wYWdlcz48dm9s

dW1lPjQ2PC92b2x1bWU+PG51bWJlcj4yPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0

PC9rZXl3b3JkPjxrZXl3b3JkPkF1c3RyYWxpYTwva2V5d29yZD48a2V5d29yZD5CaW9tYXJrZXJz

LCBUdW1vci9ibG9vZDwva2V5d29yZD48a2V5d29yZD5DaG9yaW9uaWMgR29uYWRvdHJvcGluLypi

bG9vZDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+Rm9sbG93LVVw

IFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+R2VzdGF0aW9uYWwgQWdlPC9rZXl3b3JkPjxrZXl3

b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5IeWRhdGlkaWZvcm0gTW9sZS8qZGlhZ25vc2lz

L2RydWcgdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5NYXRlcm5hbCBBZ2U8L2tleXdvcmQ+PGtl

eXdvcmQ+TWV0aG90cmV4YXRlLyp0aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+TmVv

cGxhc20gUmVjdXJyZW5jZSwgTG9jYWwvKmRpYWdub3Npcy9kcnVnIHRoZXJhcHkvZXBpZGVtaW9s

b2d5PC9rZXl3b3JkPjxrZXl3b3JkPlBhcml0eTwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3k8

L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5IENvbXBsaWNhdGlvbnMsIE5lb3BsYXN0aWMvZGlh

Z25vc2lzL2RydWcgdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3kgT3V0Y29tZTwv

a2V5d29yZD48a2V5d29yZD5SZWdpc3RyaWVzPC9rZXl3b3JkPjxrZXl3b3JkPlJldHJvc3BlY3Rp

dmUgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5SaXNrIEFzc2Vzc21lbnQ8L2tleXdvcmQ+PGtl

eXdvcmQ+VHJvcGhvYmxhc3RpYyBOZW9wbGFzbXMvZGlhZ25vc2lzL2RydWcgdGhlcmFweTwva2V5

d29yZD48a2V5d29yZD5VdGVyaW5lIE5lb3BsYXNtcy8qZGlhZ25vc2lzL3RoZXJhcHk8L2tleXdv

cmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkFw

cjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMDQtODY2NiAoUHJpbnQpJiN4RDsw

MDA0LTg2NjYgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjE2NjM4MDMzPC9hY2Nlc3Np

b24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5n

b3YvcHVibWVkLzE2NjM4MDMzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmlj

LXJlc291cmNlLW51bT4xMC4xMTExL2ouMTQ3OS04MjhYLjIwMDYuMDA1MzkueDwvZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XaWVsc21hPC9BdXRob3I+PFllYXI+MjAwNjwvWWVhcj48

UmVjTnVtPjIxMDM8L1JlY051bT48RGlzcGxheVRleHQ+KDcpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjIxMDM8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0i

MTUzNTY4NDM4NSI+MjEwMzwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

V2llbHNtYSwgUy48L2F1dGhvcj48YXV0aG9yPktlcmttZWlqZXIsIEwuPC9hdXRob3I+PGF1dGhv

cj5CZWtrZXJzLCBSLjwvYXV0aG9yPjxhdXRob3I+UHltYW4sIEouPC9hdXRob3I+PGF1dGhvcj5U

YW4sIEouPC9hdXRob3I+PGF1dGhvcj5RdWlubiwgTS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250

cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIE9ic3RldHJpY3MgYW5kIEd5bmFl

Y29sb2d5LCBSYWRib3VkIFVuaXZlcnNpdHksIE5pam1pZ2VuLCBUaGUgTmV0aGVybGFuZHMuPC9h

dXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+UGVyc2lzdGVudCB0cm9waG9ibGFzdCBkaXNlYXNl

IGZvbGxvd2luZyBwYXJ0aWFsIG1vbGFyIHByZWduYW5jeTwvdGl0bGU+PHNlY29uZGFyeS10aXRs

ZT5BdXN0IE4gWiBKIE9ic3RldCBHeW5hZWNvbDwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+

VGhlIEF1c3RyYWxpYW4gJmFtcDsgTmV3IFplYWxhbmQgam91cm5hbCBvZiBvYnN0ZXRyaWNzICZh

bXA7IGd5bmFlY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0

bGU+QXVzdCBOIFogSiBPYnN0ZXQgR3luYWVjb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUgQXVz

dHJhbGlhbiAmYW1wOyBOZXcgWmVhbGFuZCBqb3VybmFsIG9mIG9ic3RldHJpY3MgJmFtcDsgZ3lu

YWVjb2xvZ3k8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxl

PkF1c3QgTiBaIEogT2JzdGV0IEd5bmFlY29sPC9mdWxsLXRpdGxlPjxhYmJyLTE+VGhlIEF1c3Ry

YWxpYW4gJmFtcDsgTmV3IFplYWxhbmQgam91cm5hbCBvZiBvYnN0ZXRyaWNzICZhbXA7IGd5bmFl

Y29sb2d5PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+MTE5LTIzPC9wYWdlcz48dm9s

dW1lPjQ2PC92b2x1bWU+PG51bWJlcj4yPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0

PC9rZXl3b3JkPjxrZXl3b3JkPkF1c3RyYWxpYTwva2V5d29yZD48a2V5d29yZD5CaW9tYXJrZXJz

LCBUdW1vci9ibG9vZDwva2V5d29yZD48a2V5d29yZD5DaG9yaW9uaWMgR29uYWRvdHJvcGluLypi

bG9vZDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+Rm9sbG93LVVw

IFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+R2VzdGF0aW9uYWwgQWdlPC9rZXl3b3JkPjxrZXl3

b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5IeWRhdGlkaWZvcm0gTW9sZS8qZGlhZ25vc2lz

L2RydWcgdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5NYXRlcm5hbCBBZ2U8L2tleXdvcmQ+PGtl

eXdvcmQ+TWV0aG90cmV4YXRlLyp0aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+TmVv

cGxhc20gUmVjdXJyZW5jZSwgTG9jYWwvKmRpYWdub3Npcy9kcnVnIHRoZXJhcHkvZXBpZGVtaW9s

b2d5PC9rZXl3b3JkPjxrZXl3b3JkPlBhcml0eTwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3k8

L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5IENvbXBsaWNhdGlvbnMsIE5lb3BsYXN0aWMvZGlh

Z25vc2lzL2RydWcgdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3kgT3V0Y29tZTwv

a2V5d29yZD48a2V5d29yZD5SZWdpc3RyaWVzPC9rZXl3b3JkPjxrZXl3b3JkPlJldHJvc3BlY3Rp

dmUgU3R1ZGllczwva2V5d29yZD48a2V5d29yZD5SaXNrIEFzc2Vzc21lbnQ8L2tleXdvcmQ+PGtl

eXdvcmQ+VHJvcGhvYmxhc3RpYyBOZW9wbGFzbXMvZGlhZ25vc2lzL2RydWcgdGhlcmFweTwva2V5

d29yZD48a2V5d29yZD5VdGVyaW5lIE5lb3BsYXNtcy8qZGlhZ25vc2lzL3RoZXJhcHk8L2tleXdv

cmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkFw

cjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMDQtODY2NiAoUHJpbnQpJiN4RDsw

MDA0LTg2NjYgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjE2NjM4MDMzPC9hY2Nlc3Np

b24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5n

b3YvcHVibWVkLzE2NjM4MDMzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmlj

LXJlc291cmNlLW51bT4xMC4xMTExL2ouMTQ3OS04MjhYLjIwMDYuMDA1MzkueDwvZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA (7)Complete mole:6 months after normalisation any mole with a multiple pregnancy: monthly for 12 months If no central /MDM pathology review has been performedassume complete mole 6 months after normalisation.See appendix 2 for a form to record tumour hCGs. Clinical Follow-upAfter the initial consultation, and provided the tumour hCG is falling appropriately, the patient should be seen again at 8-10 weeks to check that menstruation has returned, and that adequate contraception is being followed. If t hCG has not fallen to normal by this point patients should be referred to a molar clinic or discussed with a gynaecologic oncologistFor pregnancy advice during follow-up, see “Pregnancy advice after Molar pregnancy” below.In a large series, the risk of GTN after end of follow-up as described above is 0% for partial moles, and 0.3% for complete moles PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TY2htaXR0PC9BdXRob3I+PFllYXI+MjAxMzwvWWVhcj48

UmVjTnVtPjIxMDI8L1JlY051bT48RGlzcGxheVRleHQ+KDYsIDcpPC9EaXNwbGF5VGV4dD48cmVj

b3JkPjxyZWMtbnVtYmVyPjIxMDI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0i

RU4iIGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFt

cD0iMTUzNTY4NDI4MSI+MjEwMjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK

b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo

b3I+U2NobWl0dCwgQy48L2F1dGhvcj48YXV0aG9yPkRvcmV0LCBNLjwvYXV0aG9yPjxhdXRob3I+

TWFzc2FyZGllciwgSi48L2F1dGhvcj48YXV0aG9yPkhhanJpLCBULjwvYXV0aG9yPjxhdXRob3I+

U2Nob3R0LCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+UmF1ZHJhbnQsIEQuPC9hdXRob3I+PGF1dGhv

cj5Hb2xmaWVyLCBGLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRy

ZXNzPlVuaXZlcnNpdHkgb2YgTHlvbiAxLCBEZXBhcnRtZW50IG9mIEd5bmFlY29sb2dpY2FsIGFu

ZCBPbmNvbG9naWNhbCBTdXJnZXJ5LU9ic3RldHJpY3MsIEx5b24gU3VkIFVuaXZlcnNpdHkgSG9z

cGl0YWwsIEx5b24sIEZyYW5jZS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5SaXNrIG9m

IGdlc3RhdGlvbmFsIHRyb3Bob2JsYXN0aWMgbmVvcGxhc2lhIGFmdGVyIGhDRyBub3JtYWxpc2F0

aW9uIGFjY29yZGluZyB0byBoeWRhdGlkaWZvcm0gbW9sZSB0eXBlPC90aXRsZT48c2Vjb25kYXJ5

LXRpdGxlPkd5bmVjb2wgT25jb2w8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkd5bmVjb2xv

Z2ljIG9uY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

R3luZWNvbCBPbmNvbDwvZnVsbC10aXRsZT48YWJici0xPkd5bmVjb2xvZ2ljIG9uY29sb2d5PC9h

YmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5HeW5lY29sIE9u

Y29sPC9mdWxsLXRpdGxlPjxhYmJyLTE+R3luZWNvbG9naWMgb25jb2xvZ3k8L2FiYnItMT48L2Fs

dC1wZXJpb2RpY2FsPjxwYWdlcz44Ni05PC9wYWdlcz48dm9sdW1lPjEzMDwvdm9sdW1lPjxudW1i

ZXI+MTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5D

aG9yaW9uaWMgR29uYWRvdHJvcGluLypibG9vZDwva2V5d29yZD48a2V5d29yZD5Db2hvcnQgU3R1

ZGllczwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+RnJhbmNlL2Vw

aWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBUcm9waG9ibGFzdGljIERp

c2Vhc2UvKmJsb29kL2VwaWRlbWlvbG9neS9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+SHVt

YW5zPC9rZXl3b3JkPjxrZXl3b3JkPkh5ZGF0aWRpZm9ybSBNb2xlLypibG9vZC9lcGlkZW1pb2xv

Z3kvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3

b3JkPlByZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5Qcm9zcGVjdGl2ZSBTdHVkaWVzPC9rZXl3

b3JkPjxrZXl3b3JkPlJpc2s8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxMzwv

eWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju

PjEwOTUtNjg1OSAoRWxlY3Ryb25pYykmI3hEOzAwOTAtODI1OCAoTGlua2luZyk8L2lzYm4+PGFj

Y2Vzc2lvbi1udW0+MjM1MjM2MTc8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48

dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjM1MjM2MTc8L3VybD48L3Jl

bGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMTYvai55Z3lu

by4yMDEzLjAzLjAxMDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjxD

aXRlPjxBdXRob3I+V2llbHNtYTwvQXV0aG9yPjxZZWFyPjIwMDY8L1llYXI+PFJlY051bT4yMTAz

PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4yMTAzPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtl

eXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0

cDJ2IiB0aW1lc3RhbXA9IjE1MzU2ODQzODUiPjIxMDM8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVm

LXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48

YXV0aG9ycz48YXV0aG9yPldpZWxzbWEsIFMuPC9hdXRob3I+PGF1dGhvcj5LZXJrbWVpamVyLCBM

LjwvYXV0aG9yPjxhdXRob3I+QmVra2VycywgUi48L2F1dGhvcj48YXV0aG9yPlB5bWFuLCBKLjwv

YXV0aG9yPjxhdXRob3I+VGFuLCBKLjwvYXV0aG9yPjxhdXRob3I+UXVpbm4sIE0uPC9hdXRob3I+

PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RGVwYXJ0bWVudCBvZiBPYnN0

ZXRyaWNzIGFuZCBHeW5hZWNvbG9neSwgUmFkYm91ZCBVbml2ZXJzaXR5LCBOaWptaWdlbiwgVGhl

IE5ldGhlcmxhbmRzLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlBlcnNpc3RlbnQgdHJv

cGhvYmxhc3QgZGlzZWFzZSBmb2xsb3dpbmcgcGFydGlhbCBtb2xhciBwcmVnbmFuY3k8L3RpdGxl

PjxzZWNvbmRhcnktdGl0bGU+QXVzdCBOIFogSiBPYnN0ZXQgR3luYWVjb2w8L3NlY29uZGFyeS10

aXRsZT48YWx0LXRpdGxlPlRoZSBBdXN0cmFsaWFuICZhbXA7IE5ldyBaZWFsYW5kIGpvdXJuYWwg

b2Ygb2JzdGV0cmljcyAmYW1wOyBneW5hZWNvbG9neTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJp

b2RpY2FsPjxmdWxsLXRpdGxlPkF1c3QgTiBaIEogT2JzdGV0IEd5bmFlY29sPC9mdWxsLXRpdGxl

PjxhYmJyLTE+VGhlIEF1c3RyYWxpYW4gJmFtcDsgTmV3IFplYWxhbmQgam91cm5hbCBvZiBvYnN0

ZXRyaWNzICZhbXA7IGd5bmFlY29sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9k

aWNhbD48ZnVsbC10aXRsZT5BdXN0IE4gWiBKIE9ic3RldCBHeW5hZWNvbDwvZnVsbC10aXRsZT48

YWJici0xPlRoZSBBdXN0cmFsaWFuICZhbXA7IE5ldyBaZWFsYW5kIGpvdXJuYWwgb2Ygb2JzdGV0

cmljcyAmYW1wOyBneW5hZWNvbG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjEx

OS0yMzwvcGFnZXM+PHZvbHVtZT40Njwvdm9sdW1lPjxudW1iZXI+MjwvbnVtYmVyPjxrZXl3b3Jk

cz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BdXN0cmFsaWE8L2tleXdvcmQ+PGtl

eXdvcmQ+QmlvbWFya2VycywgVHVtb3IvYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+Q2hvcmlvbmlj

IEdvbmFkb3Ryb3Bpbi8qYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxr

ZXl3b3JkPkZvbGxvdy1VcCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPkdlc3RhdGlvbmFsIEFn

ZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SHlkYXRpZGlmb3Jt

IE1vbGUvKmRpYWdub3Npcy9kcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+TWF0ZXJuYWwg

QWdlPC9rZXl3b3JkPjxrZXl3b3JkPk1ldGhvdHJleGF0ZS8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3

b3JkPjxrZXl3b3JkPk5lb3BsYXNtIFJlY3VycmVuY2UsIExvY2FsLypkaWFnbm9zaXMvZHJ1ZyB0

aGVyYXB5L2VwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5QYXJpdHk8L2tleXdvcmQ+PGtl

eXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeSBDb21wbGljYXRpb25z

LCBOZW9wbGFzdGljL2RpYWdub3Npcy9kcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+UHJl

Z25hbmN5IE91dGNvbWU8L2tleXdvcmQ+PGtleXdvcmQ+UmVnaXN0cmllczwva2V5d29yZD48a2V5

d29yZD5SZXRyb3NwZWN0aXZlIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBBc3Nlc3Nt

ZW50PC9rZXl3b3JkPjxrZXl3b3JkPlRyb3Bob2JsYXN0aWMgTmVvcGxhc21zL2RpYWdub3Npcy9k

cnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBOZW9wbGFzbXMvKmRpYWdub3Np

cy90aGVyYXB5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDY8L3llYXI+PHB1

Yi1kYXRlcz48ZGF0ZT5BcHI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMDA0LTg2

NjYgKFByaW50KSYjeEQ7MDAwNC04NjY2IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4x

NjYzODAzMzwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3

dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8xNjYzODAzMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwv

dXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTExMS9qLjE0NzktODI4WC4yMDA2LjAw

NTM5Lng8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TY2htaXR0PC9BdXRob3I+PFllYXI+MjAxMzwvWWVhcj48

UmVjTnVtPjIxMDI8L1JlY051bT48RGlzcGxheVRleHQ+KDYsIDcpPC9EaXNwbGF5VGV4dD48cmVj

b3JkPjxyZWMtbnVtYmVyPjIxMDI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0i

RU4iIGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFt

cD0iMTUzNTY4NDI4MSI+MjEwMjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK

b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo

b3I+U2NobWl0dCwgQy48L2F1dGhvcj48YXV0aG9yPkRvcmV0LCBNLjwvYXV0aG9yPjxhdXRob3I+

TWFzc2FyZGllciwgSi48L2F1dGhvcj48YXV0aG9yPkhhanJpLCBULjwvYXV0aG9yPjxhdXRob3I+

U2Nob3R0LCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+UmF1ZHJhbnQsIEQuPC9hdXRob3I+PGF1dGhv

cj5Hb2xmaWVyLCBGLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRy

ZXNzPlVuaXZlcnNpdHkgb2YgTHlvbiAxLCBEZXBhcnRtZW50IG9mIEd5bmFlY29sb2dpY2FsIGFu

ZCBPbmNvbG9naWNhbCBTdXJnZXJ5LU9ic3RldHJpY3MsIEx5b24gU3VkIFVuaXZlcnNpdHkgSG9z

cGl0YWwsIEx5b24sIEZyYW5jZS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5SaXNrIG9m

IGdlc3RhdGlvbmFsIHRyb3Bob2JsYXN0aWMgbmVvcGxhc2lhIGFmdGVyIGhDRyBub3JtYWxpc2F0

aW9uIGFjY29yZGluZyB0byBoeWRhdGlkaWZvcm0gbW9sZSB0eXBlPC90aXRsZT48c2Vjb25kYXJ5

LXRpdGxlPkd5bmVjb2wgT25jb2w8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkd5bmVjb2xv

Z2ljIG9uY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

R3luZWNvbCBPbmNvbDwvZnVsbC10aXRsZT48YWJici0xPkd5bmVjb2xvZ2ljIG9uY29sb2d5PC9h

YmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5HeW5lY29sIE9u

Y29sPC9mdWxsLXRpdGxlPjxhYmJyLTE+R3luZWNvbG9naWMgb25jb2xvZ3k8L2FiYnItMT48L2Fs

dC1wZXJpb2RpY2FsPjxwYWdlcz44Ni05PC9wYWdlcz48dm9sdW1lPjEzMDwvdm9sdW1lPjxudW1i

ZXI+MTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5D

aG9yaW9uaWMgR29uYWRvdHJvcGluLypibG9vZDwva2V5d29yZD48a2V5d29yZD5Db2hvcnQgU3R1

ZGllczwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+RnJhbmNlL2Vw

aWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBUcm9waG9ibGFzdGljIERp

c2Vhc2UvKmJsb29kL2VwaWRlbWlvbG9neS9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+SHVt

YW5zPC9rZXl3b3JkPjxrZXl3b3JkPkh5ZGF0aWRpZm9ybSBNb2xlLypibG9vZC9lcGlkZW1pb2xv

Z3kvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3

b3JkPlByZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5Qcm9zcGVjdGl2ZSBTdHVkaWVzPC9rZXl3

b3JkPjxrZXl3b3JkPlJpc2s8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxMzwv

eWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju

PjEwOTUtNjg1OSAoRWxlY3Ryb25pYykmI3hEOzAwOTAtODI1OCAoTGlua2luZyk8L2lzYm4+PGFj

Y2Vzc2lvbi1udW0+MjM1MjM2MTc8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48

dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMjM1MjM2MTc8L3VybD48L3Jl

bGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjEwMTYvai55Z3lu

by4yMDEzLjAzLjAxMDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjxD

aXRlPjxBdXRob3I+V2llbHNtYTwvQXV0aG9yPjxZZWFyPjIwMDY8L1llYXI+PFJlY051bT4yMTAz

PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4yMTAzPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtl

eXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0

cDJ2IiB0aW1lc3RhbXA9IjE1MzU2ODQzODUiPjIxMDM8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVm

LXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48

YXV0aG9ycz48YXV0aG9yPldpZWxzbWEsIFMuPC9hdXRob3I+PGF1dGhvcj5LZXJrbWVpamVyLCBM

LjwvYXV0aG9yPjxhdXRob3I+QmVra2VycywgUi48L2F1dGhvcj48YXV0aG9yPlB5bWFuLCBKLjwv

YXV0aG9yPjxhdXRob3I+VGFuLCBKLjwvYXV0aG9yPjxhdXRob3I+UXVpbm4sIE0uPC9hdXRob3I+

PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RGVwYXJ0bWVudCBvZiBPYnN0

ZXRyaWNzIGFuZCBHeW5hZWNvbG9neSwgUmFkYm91ZCBVbml2ZXJzaXR5LCBOaWptaWdlbiwgVGhl

IE5ldGhlcmxhbmRzLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPlBlcnNpc3RlbnQgdHJv

cGhvYmxhc3QgZGlzZWFzZSBmb2xsb3dpbmcgcGFydGlhbCBtb2xhciBwcmVnbmFuY3k8L3RpdGxl

PjxzZWNvbmRhcnktdGl0bGU+QXVzdCBOIFogSiBPYnN0ZXQgR3luYWVjb2w8L3NlY29uZGFyeS10

aXRsZT48YWx0LXRpdGxlPlRoZSBBdXN0cmFsaWFuICZhbXA7IE5ldyBaZWFsYW5kIGpvdXJuYWwg

b2Ygb2JzdGV0cmljcyAmYW1wOyBneW5hZWNvbG9neTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJp

b2RpY2FsPjxmdWxsLXRpdGxlPkF1c3QgTiBaIEogT2JzdGV0IEd5bmFlY29sPC9mdWxsLXRpdGxl

PjxhYmJyLTE+VGhlIEF1c3RyYWxpYW4gJmFtcDsgTmV3IFplYWxhbmQgam91cm5hbCBvZiBvYnN0

ZXRyaWNzICZhbXA7IGd5bmFlY29sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9k

aWNhbD48ZnVsbC10aXRsZT5BdXN0IE4gWiBKIE9ic3RldCBHeW5hZWNvbDwvZnVsbC10aXRsZT48

YWJici0xPlRoZSBBdXN0cmFsaWFuICZhbXA7IE5ldyBaZWFsYW5kIGpvdXJuYWwgb2Ygb2JzdGV0

cmljcyAmYW1wOyBneW5hZWNvbG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjEx

OS0yMzwvcGFnZXM+PHZvbHVtZT40Njwvdm9sdW1lPjxudW1iZXI+MjwvbnVtYmVyPjxrZXl3b3Jk

cz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BdXN0cmFsaWE8L2tleXdvcmQ+PGtl

eXdvcmQ+QmlvbWFya2VycywgVHVtb3IvYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+Q2hvcmlvbmlj

IEdvbmFkb3Ryb3Bpbi8qYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxr

ZXl3b3JkPkZvbGxvdy1VcCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPkdlc3RhdGlvbmFsIEFn

ZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SHlkYXRpZGlmb3Jt

IE1vbGUvKmRpYWdub3Npcy9kcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+TWF0ZXJuYWwg

QWdlPC9rZXl3b3JkPjxrZXl3b3JkPk1ldGhvdHJleGF0ZS8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3

b3JkPjxrZXl3b3JkPk5lb3BsYXNtIFJlY3VycmVuY2UsIExvY2FsLypkaWFnbm9zaXMvZHJ1ZyB0

aGVyYXB5L2VwaWRlbWlvbG9neTwva2V5d29yZD48a2V5d29yZD5QYXJpdHk8L2tleXdvcmQ+PGtl

eXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeSBDb21wbGljYXRpb25z

LCBOZW9wbGFzdGljL2RpYWdub3Npcy9kcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+UHJl

Z25hbmN5IE91dGNvbWU8L2tleXdvcmQ+PGtleXdvcmQ+UmVnaXN0cmllczwva2V5d29yZD48a2V5

d29yZD5SZXRyb3NwZWN0aXZlIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBBc3Nlc3Nt

ZW50PC9rZXl3b3JkPjxrZXl3b3JkPlRyb3Bob2JsYXN0aWMgTmVvcGxhc21zL2RpYWdub3Npcy9k

cnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBOZW9wbGFzbXMvKmRpYWdub3Np

cy90aGVyYXB5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDY8L3llYXI+PHB1

Yi1kYXRlcz48ZGF0ZT5BcHI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMDA0LTg2

NjYgKFByaW50KSYjeEQ7MDAwNC04NjY2IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4x

NjYzODAzMzwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3

dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8xNjYzODAzMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwv

dXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTExMS9qLjE0NzktODI4WC4yMDA2LjAw

NTM5Lng8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE.DATA (6, 7).9 CRITERIA FOR REFERRAL TO MEDICAL ONCOLOGY FOR (SUSPECTED) GTNThe following criteria for immediate referral apply at any time during diagnosis or follow-up:Histological diagnosis invasive mole, choriocarcinoma, placental site trophoblastic tumour (PSTT).Plateau of tumour hCG lasts for 4 measurements over a period of 3 weeks or longer, ie, days 1,7,14,21 (plateau is usually defined as +/- 10%)Rise of tumour hCG on three consecutive weekly measurements, over a period of two weeks or longer, days 1,7,14 (usually defined as > 10%) Consider possibility of new pregnancy if tumour hCG is risingSerum hCG >20,000 >4 weeks after evacuation (because of risk of uterine perforation)Evidence of metastases in the brain, liver or GI tract, or >2cm on Chest X-ray.Most molar pregnancies spontaneously remit after evacuation; however persistence or change into malignant disease requiring chemotherapy (Gestational trophoblastic neoplasia or GTN) occurs in:0.5 - 4% Partial moles15 - 20% Complete moles.10 HYSTERECTOMY FOR PERSISTENT GESTATIONAL TROPHOBLASTIC DISEASE?Hysterectomy for treatment of molar pregnancy is not recommended as routine practicePatients who have completed their families may ask about hysterectomy to avoid the possibility of chemotherapy or surveillance. Two small American studies PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DdXJyeTwvQXV0aG9yPjxZZWFyPjE5NzU8L1llYXI+PFJl

Y051bT4yMTA0PC9SZWNOdW0+PERpc3BsYXlUZXh0Pig4LCA5KTwvRGlzcGxheVRleHQ+PHJlY29y

ZD48cmVjLW51bWJlcj4yMTA0PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9

IjE1MzkyMjg0MDEiPjIxMDQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PkN1cnJ5LCBTLiBMLjwvYXV0aG9yPjxhdXRob3I+SGFtbW9uZCwgQy4gQi48L2F1dGhvcj48YXV0

aG9yPlR5cmV5LCBMLjwvYXV0aG9yPjxhdXRob3I+Q3JlYXNtYW4sIFcuIFQuPC9hdXRob3I+PGF1

dGhvcj5QYXJrZXIsIFIuIFQuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRs

ZXM+PHRpdGxlPkh5ZGF0aWRpZm9ybSBtb2xlOiBkaWFnbm9zaXMsIG1hbmFnZW1lbnQsIGFuZCBs

b25nLXRlcm0gZm9sbG93dXAgb2YgMzQ3IHBhdGllbnRzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl

Pk9ic3RldCBHeW5lY29sPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5PYnN0ZXRyaWNzIGFu

ZCBneW5lY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

T2JzdGV0IEd5bmVjb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5PYnN0ZXRyaWNzIGFuZCBneW5lY29s

b2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5PYnN0

ZXQgR3luZWNvbDwvZnVsbC10aXRsZT48YWJici0xPk9ic3RldHJpY3MgYW5kIGd5bmVjb2xvZ3k8

L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4xLTg8L3BhZ2VzPjx2b2x1bWU+NDU8L3Zv

bHVtZT48bnVtYmVyPjE8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWJvcnRpb24sIEluZHVj

ZWQ8L2tleXdvcmQ+PGtleXdvcmQ+QWRvbGVzY2VudDwva2V5d29yZD48a2V5d29yZD5BbmltYWxz

PC9rZXl3b3JkPjxrZXl3b3JkPkJsb29kIEdyb3VwIEFudGlnZW5zPC9rZXl3b3JkPjxrZXl3b3Jk

PkNob3Jpb25pYyBHb25hZG90cm9waW4vdXJpbmU8L2tleXdvcmQ+PGtleXdvcmQ+Q3VyZXR0YWdl

PC9rZXl3b3JkPjxrZXl3b3JkPkRpbGF0YXRpb248L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9r

ZXl3b3JkPjxrZXl3b3JkPkZvbGxvdy1VcCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPkdlc3Rh

dGlvbmFsIEFnZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+Kkh5

ZGF0aWRpZm9ybSBNb2xlL2RpYWdub3Npcy9wYXRob2xvZ3kvc3VyZ2VyeTwva2V5d29yZD48a2V5

d29yZD5NYXRlcm5hbCBBZ2U8L2tleXdvcmQ+PGtleXdvcmQ+TWV0aG90cmV4YXRlL3RoZXJhcGV1

dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5NaWNlPC9rZXl3b3JkPjxrZXl3b3JkPk5lb3BsYXNt

IE1ldGFzdGFzaXM8L2tleXdvcmQ+PGtleXdvcmQ+Tm9ydGggQ2Fyb2xpbmE8L2tleXdvcmQ+PGtl

eXdvcmQ+T3ZhcnkvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPlBhcml0eTwva2V5d29yZD48

a2V5d29yZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5IFRyaW1lc3Rlciwg

Rmlyc3Q8L2tleXdvcmQ+PGtleXdvcmQ+UmFkaW9pbW11bm9hc3NheTwva2V5d29yZD48a2V5d29y

ZD5SZW1pc3Npb24sIFNwb250YW5lb3VzPC9rZXl3b3JkPjxrZXl3b3JkPlV0ZXJ1cy9wYXRob2xv

Z3k8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MTk3NTwveWVhcj48cHViLWRhdGVz

PjxkYXRlPkphbjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMjktNzg0NCAoUHJp

bnQpJiN4RDswMDI5LTc4NDQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjExNjc0MTM8

L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5u

bG0ubmloLmdvdi9wdWJtZWQvMTE2NzQxMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3Jl

Y29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5CYWhhcjwvQXV0aG9yPjxZZWFyPjE5ODk8L1llYXI+

PFJlY051bT4yMTA1PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4yMTA1PC9yZWMtbnVtYmVy

Pjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZh

d3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9IjE1MzkyMjg0OTUiPjIxMDU8L2tleT48L2ZvcmVp

Z24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNv

bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkJhaGFyLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+

ZWwtQXNobmVoaSwgTS4gUy48L2F1dGhvcj48YXV0aG9yPlNlbnRoaWxzZWx2YW4sIEEuPC9hdXRo

b3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RGVwYXJ0bWVudCBvZiBP

YnN0ZXRyaWNzIGFuZCBHeW5hZWNvbG9neSwgVW5pdmVyc2l0eSBvZiBLdXdhaXQsIFNhZmF0Ljwv

YXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkh5ZGF0aWRpZm9ybSBtb2xlIGluIHRoZSBlbGRl

cmx5OiBoeXN0ZXJlY3RvbXkgb3IgZXZhY3VhdGlvbj88L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+

SW50IEogR3luYWVjb2wgT2JzdGV0PC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5JbnRlcm5h

dGlvbmFsIGpvdXJuYWwgb2YgZ3luYWVjb2xvZ3kgYW5kIG9ic3RldHJpY3M6IHRoZSBvZmZpY2lh

bCBvcmdhbiBvZiB0aGUgSW50ZXJuYXRpb25hbCBGZWRlcmF0aW9uIG9mIEd5bmFlY29sb2d5IGFu

ZCBPYnN0ZXRyaWNzPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

SW50IEogR3luYWVjb2wgT2JzdGV0PC9mdWxsLXRpdGxlPjxhYmJyLTE+SW50ZXJuYXRpb25hbCBq

b3VybmFsIG9mIGd5bmFlY29sb2d5IGFuZCBvYnN0ZXRyaWNzOiB0aGUgb2ZmaWNpYWwgb3JnYW4g

b2YgdGhlIEludGVybmF0aW9uYWwgRmVkZXJhdGlvbiBvZiBHeW5hZWNvbG9neSBhbmQgT2JzdGV0

cmljczwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SW50

IEogR3luYWVjb2wgT2JzdGV0PC9mdWxsLXRpdGxlPjxhYmJyLTE+SW50ZXJuYXRpb25hbCBqb3Vy

bmFsIG9mIGd5bmFlY29sb2d5IGFuZCBvYnN0ZXRyaWNzOiB0aGUgb2ZmaWNpYWwgb3JnYW4gb2Yg

dGhlIEludGVybmF0aW9uYWwgRmVkZXJhdGlvbiBvZiBHeW5hZWNvbG9neSBhbmQgT2JzdGV0cmlj

czwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjIzMy04PC9wYWdlcz48dm9sdW1lPjI5

PC92b2x1bWU+PG51bWJlcj4zPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0PC9rZXl3

b3JkPjxrZXl3b3JkPkFnZSBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPkNvbWJpbmVkIE1vZGFs

aXR5IFRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+KkRpbGF0YXRpb24gYW5kIEN1cmV0dGFnZTwv

a2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3Jk

PjxrZXl3b3JkPkh5ZGF0aWRpZm9ybSBNb2xlL2RydWcgdGhlcmFweS8qc3VyZ2VyeTwva2V5d29y

ZD48a2V5d29yZD4qSHlzdGVyZWN0b215PC9rZXl3b3JkPjxrZXl3b3JkPkt1d2FpdDwva2V5d29y

ZD48a2V5d29yZD5NYXRlcm5hbCBBZ2U8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3

b3JkPjxrZXl3b3JkPlByZWduYW5jeSwgSGlnaC1SaXNrPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sg

RmFjdG9yczwva2V5d29yZD48a2V5d29yZD5VdGVyaW5lIE5lb3BsYXNtcy9kcnVnIHRoZXJhcHkv

KnN1cmdlcnk8L2tleXdvcmQ+PGtleXdvcmQ+KlZhY3V1bSBDdXJldHRhZ2U8L2tleXdvcmQ+PC9r

ZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MTk4OTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bDwvZGF0

ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMjAtNzI5MiAoUHJpbnQpJiN4RDswMDIwLTcy

OTIgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI1Njk0MjA8L2FjY2Vzc2lvbi1udW0+

PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJt

ZWQvMjU2OTQyMDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PC9F

bmROb3RlPn==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5DdXJyeTwvQXV0aG9yPjxZZWFyPjE5NzU8L1llYXI+PFJl

Y051bT4yMTA0PC9SZWNOdW0+PERpc3BsYXlUZXh0Pig4LCA5KTwvRGlzcGxheVRleHQ+PHJlY29y

ZD48cmVjLW51bWJlcj4yMTA0PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9

IjE1MzkyMjg0MDEiPjIxMDQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PkN1cnJ5LCBTLiBMLjwvYXV0aG9yPjxhdXRob3I+SGFtbW9uZCwgQy4gQi48L2F1dGhvcj48YXV0

aG9yPlR5cmV5LCBMLjwvYXV0aG9yPjxhdXRob3I+Q3JlYXNtYW4sIFcuIFQuPC9hdXRob3I+PGF1

dGhvcj5QYXJrZXIsIFIuIFQuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRs

ZXM+PHRpdGxlPkh5ZGF0aWRpZm9ybSBtb2xlOiBkaWFnbm9zaXMsIG1hbmFnZW1lbnQsIGFuZCBs

b25nLXRlcm0gZm9sbG93dXAgb2YgMzQ3IHBhdGllbnRzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxl

Pk9ic3RldCBHeW5lY29sPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5PYnN0ZXRyaWNzIGFu

ZCBneW5lY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

T2JzdGV0IEd5bmVjb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5PYnN0ZXRyaWNzIGFuZCBneW5lY29s

b2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5PYnN0

ZXQgR3luZWNvbDwvZnVsbC10aXRsZT48YWJici0xPk9ic3RldHJpY3MgYW5kIGd5bmVjb2xvZ3k8

L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4xLTg8L3BhZ2VzPjx2b2x1bWU+NDU8L3Zv

bHVtZT48bnVtYmVyPjE8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWJvcnRpb24sIEluZHVj

ZWQ8L2tleXdvcmQ+PGtleXdvcmQ+QWRvbGVzY2VudDwva2V5d29yZD48a2V5d29yZD5BbmltYWxz

PC9rZXl3b3JkPjxrZXl3b3JkPkJsb29kIEdyb3VwIEFudGlnZW5zPC9rZXl3b3JkPjxrZXl3b3Jk

PkNob3Jpb25pYyBHb25hZG90cm9waW4vdXJpbmU8L2tleXdvcmQ+PGtleXdvcmQ+Q3VyZXR0YWdl

PC9rZXl3b3JkPjxrZXl3b3JkPkRpbGF0YXRpb248L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9r

ZXl3b3JkPjxrZXl3b3JkPkZvbGxvdy1VcCBTdHVkaWVzPC9rZXl3b3JkPjxrZXl3b3JkPkdlc3Rh

dGlvbmFsIEFnZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+Kkh5

ZGF0aWRpZm9ybSBNb2xlL2RpYWdub3Npcy9wYXRob2xvZ3kvc3VyZ2VyeTwva2V5d29yZD48a2V5

d29yZD5NYXRlcm5hbCBBZ2U8L2tleXdvcmQ+PGtleXdvcmQ+TWV0aG90cmV4YXRlL3RoZXJhcGV1

dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5NaWNlPC9rZXl3b3JkPjxrZXl3b3JkPk5lb3BsYXNt

IE1ldGFzdGFzaXM8L2tleXdvcmQ+PGtleXdvcmQ+Tm9ydGggQ2Fyb2xpbmE8L2tleXdvcmQ+PGtl

eXdvcmQ+T3ZhcnkvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPlBhcml0eTwva2V5d29yZD48

a2V5d29yZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5IFRyaW1lc3Rlciwg

Rmlyc3Q8L2tleXdvcmQ+PGtleXdvcmQ+UmFkaW9pbW11bm9hc3NheTwva2V5d29yZD48a2V5d29y

ZD5SZW1pc3Npb24sIFNwb250YW5lb3VzPC9rZXl3b3JkPjxrZXl3b3JkPlV0ZXJ1cy9wYXRob2xv

Z3k8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MTk3NTwveWVhcj48cHViLWRhdGVz

PjxkYXRlPkphbjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMjktNzg0NCAoUHJp

bnQpJiN4RDswMDI5LTc4NDQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjExNjc0MTM8

L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5u

bG0ubmloLmdvdi9wdWJtZWQvMTE2NzQxMzwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3Jl

Y29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5CYWhhcjwvQXV0aG9yPjxZZWFyPjE5ODk8L1llYXI+

PFJlY051bT4yMTA1PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4yMTA1PC9yZWMtbnVtYmVy

Pjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZh

d3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9IjE1MzkyMjg0OTUiPjIxMDU8L2tleT48L2ZvcmVp

Z24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNv

bnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkJhaGFyLCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+

ZWwtQXNobmVoaSwgTS4gUy48L2F1dGhvcj48YXV0aG9yPlNlbnRoaWxzZWx2YW4sIEEuPC9hdXRo

b3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+RGVwYXJ0bWVudCBvZiBP

YnN0ZXRyaWNzIGFuZCBHeW5hZWNvbG9neSwgVW5pdmVyc2l0eSBvZiBLdXdhaXQsIFNhZmF0Ljwv

YXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkh5ZGF0aWRpZm9ybSBtb2xlIGluIHRoZSBlbGRl

cmx5OiBoeXN0ZXJlY3RvbXkgb3IgZXZhY3VhdGlvbj88L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+

SW50IEogR3luYWVjb2wgT2JzdGV0PC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5JbnRlcm5h

dGlvbmFsIGpvdXJuYWwgb2YgZ3luYWVjb2xvZ3kgYW5kIG9ic3RldHJpY3M6IHRoZSBvZmZpY2lh

bCBvcmdhbiBvZiB0aGUgSW50ZXJuYXRpb25hbCBGZWRlcmF0aW9uIG9mIEd5bmFlY29sb2d5IGFu

ZCBPYnN0ZXRyaWNzPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

SW50IEogR3luYWVjb2wgT2JzdGV0PC9mdWxsLXRpdGxlPjxhYmJyLTE+SW50ZXJuYXRpb25hbCBq

b3VybmFsIG9mIGd5bmFlY29sb2d5IGFuZCBvYnN0ZXRyaWNzOiB0aGUgb2ZmaWNpYWwgb3JnYW4g

b2YgdGhlIEludGVybmF0aW9uYWwgRmVkZXJhdGlvbiBvZiBHeW5hZWNvbG9neSBhbmQgT2JzdGV0

cmljczwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SW50

IEogR3luYWVjb2wgT2JzdGV0PC9mdWxsLXRpdGxlPjxhYmJyLTE+SW50ZXJuYXRpb25hbCBqb3Vy

bmFsIG9mIGd5bmFlY29sb2d5IGFuZCBvYnN0ZXRyaWNzOiB0aGUgb2ZmaWNpYWwgb3JnYW4gb2Yg

dGhlIEludGVybmF0aW9uYWwgRmVkZXJhdGlvbiBvZiBHeW5hZWNvbG9neSBhbmQgT2JzdGV0cmlj

czwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjIzMy04PC9wYWdlcz48dm9sdW1lPjI5

PC92b2x1bWU+PG51bWJlcj4zPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFkdWx0PC9rZXl3

b3JkPjxrZXl3b3JkPkFnZSBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPkNvbWJpbmVkIE1vZGFs

aXR5IFRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+KkRpbGF0YXRpb24gYW5kIEN1cmV0dGFnZTwv

a2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3Jk

PjxrZXl3b3JkPkh5ZGF0aWRpZm9ybSBNb2xlL2RydWcgdGhlcmFweS8qc3VyZ2VyeTwva2V5d29y

ZD48a2V5d29yZD4qSHlzdGVyZWN0b215PC9rZXl3b3JkPjxrZXl3b3JkPkt1d2FpdDwva2V5d29y

ZD48a2V5d29yZD5NYXRlcm5hbCBBZ2U8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3

b3JkPjxrZXl3b3JkPlByZWduYW5jeSwgSGlnaC1SaXNrPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sg

RmFjdG9yczwva2V5d29yZD48a2V5d29yZD5VdGVyaW5lIE5lb3BsYXNtcy9kcnVnIHRoZXJhcHkv

KnN1cmdlcnk8L2tleXdvcmQ+PGtleXdvcmQ+KlZhY3V1bSBDdXJldHRhZ2U8L2tleXdvcmQ+PC9r

ZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MTk4OTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkp1bDwvZGF0

ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMjAtNzI5MiAoUHJpbnQpJiN4RDswMDIwLTcy

OTIgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI1Njk0MjA8L2FjY2Vzc2lvbi1udW0+

PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJt

ZWQvMjU2OTQyMDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PC9F

bmROb3RlPn==

ADDIN EN.CITE.DATA (8, 9) have shown that the chances of needing chemotherapy after hysterectomy for molar pregnancy are 3-10%, i.e. about halved, but certainly not eliminatedNeed for careful surveillance remains essential after hysterectomyIn patients being considered for hysterectomy, full staging investigation including CT thorax/ abdomen/pelvis and MRI pelvis should be performed to exclude obvious evidence of extra-uterine spread which would be a contra-indication to treatment by hysterectomy.! A Gynaecologic Oncologist must be consulted before deciding to proceed to an elective hysterectomy!11PROPHYLACTIC CHEMOTHERAPY IN MOLAR PREGNANCY?Prophylactic chemotherapy is not recommended as routine practice PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XYW5nPC9BdXRob3I+PFllYXI+MjAxNzwvWWVhcj48UmVj

TnVtPjIxNTE8L1JlY051bT48RGlzcGxheVRleHQ+KDEwKTwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj4yMTUxPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9IjE1

MzkyMzA5MTYiPjIxNTE8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5h

bCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPldh

bmcsIFEuPC9hdXRob3I+PGF1dGhvcj5GdSwgSi48L2F1dGhvcj48YXV0aG9yPkh1LCBMLjwvYXV0

aG9yPjxhdXRob3I+RmFuZywgRi48L2F1dGhvcj48YXV0aG9yPlhpZSwgTC48L2F1dGhvcj48YXV0

aG9yPkNoZW4sIEguPC9hdXRob3I+PGF1dGhvcj5IZSwgRi48L2F1dGhvcj48YXV0aG9yPld1LCBU

LjwvYXV0aG9yPjxhdXRob3I+TGF3cmllLCBULiBBLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRy

aWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgT2JzdGV0cmljcyBhbmQgR3luZWNv

bG9neSwgV2VzdCBDaGluYSBTZWNvbmQgVW5pdmVyc2l0eSBIb3NwaXRhbCwgV2VzdCBDaGluYSBX

b21lbiZhcG9zO3MgYW5kIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCwgMiBKaWFuZ3RpYW5sdSwg

Q2hlbmdkdSwgU2ljaHVhbiwgQ2hpbmEsIDYxMDA0MS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0

aXRsZT5Qcm9waHlsYWN0aWMgY2hlbW90aGVyYXB5IGZvciBoeWRhdGlkaWZvcm0gbW9sZSB0byBw

cmV2ZW50IGdlc3RhdGlvbmFsIHRyb3Bob2JsYXN0aWMgbmVvcGxhc2lhPC90aXRsZT48c2Vjb25k

YXJ5LXRpdGxlPkNvY2hyYW5lIERhdGFiYXNlIFN5c3QgUmV2PC9zZWNvbmRhcnktdGl0bGU+PGFs

dC10aXRsZT5UaGUgQ29jaHJhbmUgZGF0YWJhc2Ugb2Ygc3lzdGVtYXRpYyByZXZpZXdzPC9hbHQt

dGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Q29jaHJhbmUgRGF0YWJhc2Ug

U3lzdCBSZXY8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUgQ29jaHJhbmUgZGF0YWJhc2Ugb2Ygc3lz

dGVtYXRpYyByZXZpZXdzPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVs

bC10aXRsZT5Db2NocmFuZSBEYXRhYmFzZSBTeXN0IFJldjwvZnVsbC10aXRsZT48YWJici0xPlRo

ZSBDb2NocmFuZSBkYXRhYmFzZSBvZiBzeXN0ZW1hdGljIHJldmlld3M8L2FiYnItMT48L2FsdC1w

ZXJpb2RpY2FsPjxwYWdlcz5DRDAwNzI4OTwvcGFnZXM+PHZvbHVtZT45PC92b2x1bWU+PGtleXdv

cmRzPjxrZXl3b3JkPkFudGluZW9wbGFzdGljIEFnZW50cy8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3

b3JkPjxrZXl3b3JkPkRhY3Rpbm9teWNpbi8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3

b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBUcm9waG9ibGFzdGljIERp

c2Vhc2UvZXBpZGVtaW9sb2d5LypwcmV2ZW50aW9uICZhbXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtl

eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkh5ZGF0aWRpZm9ybSBNb2xlLypkcnVnIHRo

ZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+SW5jaWRlbmNlPC9rZXl3b3JkPjxrZXl3b3JkPk1ldGhv

dHJleGF0ZS8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeTwva2V5

d29yZD48a2V5d29yZD5SYW5kb21pemVkIENvbnRyb2xsZWQgVHJpYWxzIGFzIFRvcGljPC9rZXl3

b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTc8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5T

ZXAgMTE8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNDY5LTQ5M1ggKEVsZWN0cm9u

aWMpJiN4RDsxMzYxLTYxMzcgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI4ODkyMTE5

PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmku

bmxtLm5paC5nb3YvcHVibWVkLzI4ODkyMTE5PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxl

bGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDAyLzE0NjUxODU4LkNEMDA3Mjg5LnB1YjM8L2Vs

ZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XYW5nPC9BdXRob3I+PFllYXI+MjAxNzwvWWVhcj48UmVj

TnVtPjIxNTE8L1JlY051bT48RGlzcGxheVRleHQ+KDEwKTwvRGlzcGxheVRleHQ+PHJlY29yZD48

cmVjLW51bWJlcj4yMTUxPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9IjE1

MzkyMzA5MTYiPjIxNTE8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5h

bCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPldh

bmcsIFEuPC9hdXRob3I+PGF1dGhvcj5GdSwgSi48L2F1dGhvcj48YXV0aG9yPkh1LCBMLjwvYXV0

aG9yPjxhdXRob3I+RmFuZywgRi48L2F1dGhvcj48YXV0aG9yPlhpZSwgTC48L2F1dGhvcj48YXV0

aG9yPkNoZW4sIEguPC9hdXRob3I+PGF1dGhvcj5IZSwgRi48L2F1dGhvcj48YXV0aG9yPld1LCBU

LjwvYXV0aG9yPjxhdXRob3I+TGF3cmllLCBULiBBLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRy

aWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgT2JzdGV0cmljcyBhbmQgR3luZWNv

bG9neSwgV2VzdCBDaGluYSBTZWNvbmQgVW5pdmVyc2l0eSBIb3NwaXRhbCwgV2VzdCBDaGluYSBX

b21lbiZhcG9zO3MgYW5kIENoaWxkcmVuJmFwb3M7cyBIb3NwaXRhbCwgMiBKaWFuZ3RpYW5sdSwg

Q2hlbmdkdSwgU2ljaHVhbiwgQ2hpbmEsIDYxMDA0MS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0

aXRsZT5Qcm9waHlsYWN0aWMgY2hlbW90aGVyYXB5IGZvciBoeWRhdGlkaWZvcm0gbW9sZSB0byBw

cmV2ZW50IGdlc3RhdGlvbmFsIHRyb3Bob2JsYXN0aWMgbmVvcGxhc2lhPC90aXRsZT48c2Vjb25k

YXJ5LXRpdGxlPkNvY2hyYW5lIERhdGFiYXNlIFN5c3QgUmV2PC9zZWNvbmRhcnktdGl0bGU+PGFs

dC10aXRsZT5UaGUgQ29jaHJhbmUgZGF0YWJhc2Ugb2Ygc3lzdGVtYXRpYyByZXZpZXdzPC9hbHQt

dGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+Q29jaHJhbmUgRGF0YWJhc2Ug

U3lzdCBSZXY8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUgQ29jaHJhbmUgZGF0YWJhc2Ugb2Ygc3lz

dGVtYXRpYyByZXZpZXdzPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVs

bC10aXRsZT5Db2NocmFuZSBEYXRhYmFzZSBTeXN0IFJldjwvZnVsbC10aXRsZT48YWJici0xPlRo

ZSBDb2NocmFuZSBkYXRhYmFzZSBvZiBzeXN0ZW1hdGljIHJldmlld3M8L2FiYnItMT48L2FsdC1w

ZXJpb2RpY2FsPjxwYWdlcz5DRDAwNzI4OTwvcGFnZXM+PHZvbHVtZT45PC92b2x1bWU+PGtleXdv

cmRzPjxrZXl3b3JkPkFudGluZW9wbGFzdGljIEFnZW50cy8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3

b3JkPjxrZXl3b3JkPkRhY3Rpbm9teWNpbi8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3

b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5HZXN0YXRpb25hbCBUcm9waG9ibGFzdGljIERp

c2Vhc2UvZXBpZGVtaW9sb2d5LypwcmV2ZW50aW9uICZhbXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtl

eXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkh5ZGF0aWRpZm9ybSBNb2xlLypkcnVnIHRo

ZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+SW5jaWRlbmNlPC9rZXl3b3JkPjxrZXl3b3JkPk1ldGhv

dHJleGF0ZS8qdGhlcmFwZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeTwva2V5

d29yZD48a2V5d29yZD5SYW5kb21pemVkIENvbnRyb2xsZWQgVHJpYWxzIGFzIFRvcGljPC9rZXl3

b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTc8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5T

ZXAgMTE8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNDY5LTQ5M1ggKEVsZWN0cm9u

aWMpJiN4RDsxMzYxLTYxMzcgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI4ODkyMTE5

PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmku

bmxtLm5paC5nb3YvcHVibWVkLzI4ODkyMTE5PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxl

bGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDAyLzE0NjUxODU4LkNEMDA3Mjg5LnB1YjM8L2Vs

ZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE.DATA (10).Four prospective randomised trials PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LYXNoaW11cmE8L0F1dGhvcj48WWVhcj4xOTg2PC9ZZWFy

PjxSZWNOdW0+MjEwNjwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oMTEtMTQpPC9EaXNwbGF5VGV4dD48

cmVjb3JkPjxyZWMtbnVtYmVyPjIxMDY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFw

cD0iRU4iIGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVz

dGFtcD0iMTUzOTIyODg1MCI+MjEwNjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1l

PSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxh

dXRob3I+S2FzaGltdXJhLCBZLjwvYXV0aG9yPjxhdXRob3I+S2FzaGltdXJhLCBNLjwvYXV0aG9y

PjxhdXRob3I+U3VnaW1vcmksIEguPC9hdXRob3I+PGF1dGhvcj5Uc3VrYW1vdG8sIE4uPC9hdXRo

b3I+PGF1dGhvcj5NYXRzdXlhbWEsIFQuPC9hdXRob3I+PGF1dGhvcj5NYXRzdWt1bWEsIEsuPC9h

dXRob3I+PGF1dGhvcj5LYW11cmEsIFQuPC9hdXRob3I+PGF1dGhvcj5TYWl0bywgVC48L2F1dGhv

cj48YXV0aG9yPkthd2FubywgSC48L2F1dGhvcj48YXV0aG9yPk5vc2UsIFIuPC9hdXRob3I+PGF1

dGhvcj5ldCBhbC4sPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRp

dGxlPlByb3BoeWxhY3RpYyBjaGVtb3RoZXJhcHkgZm9yIGh5ZGF0aWRpZm9ybSBtb2xlLiBGaXZl

IHRvIDE1IHllYXJzIGZvbGxvdy11cDwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5DYW5jZXI8L3Nl

Y29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkNhbmNlcjwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJp

b2RpY2FsPjxmdWxsLXRpdGxlPkNhbmNlcjwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PGFsdC1w

ZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkNhbmNlcjwvZnVsbC10aXRsZT48L2FsdC1wZXJpb2RpY2Fs

PjxwYWdlcz42MjQtOTwvcGFnZXM+PHZvbHVtZT41ODwvdm9sdW1lPjxudW1iZXI+MzwvbnVtYmVy

PjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9r

ZXl3b3JkPjxrZXl3b3JkPkNob3Jpb2NhcmNpbm9tYS9lcGlkZW1pb2xvZ3kvKnByZXZlbnRpb24g

JmFtcDsgY29udHJvbC9zZWNvbmRhcnk8L2tleXdvcmQ+PGtleXdvcmQ+Q2hvcmlvbmljIEdvbmFk

b3Ryb3Bpbi91cmluZTwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+

Rm9sbG93LVVwIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3

b3JkPkh5ZGF0aWRpZm9ybSBNb2xlLypkcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+SmFw

YW48L2tleXdvcmQ+PGtleXdvcmQ+TWV0aG90cmV4YXRlL2FkdmVyc2UgZWZmZWN0cy90aGVyYXBl

dXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+

UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlByb3NwZWN0aXZlIFN0dWRpZXM8L2tleXdvcmQ+

PGtleXdvcmQ+VGltZSBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlRyb3Bob2JsYXN0aWMgTmVv

cGxhc21zL2VwaWRlbWlvbG9neS8qcHJldmVudGlvbiAmYW1wOyBjb250cm9sL3NlY29uZGFyeTwv

a2V5d29yZD48a2V5d29yZD5VdGVyaW5lIE5lb3BsYXNtcy8qZHJ1ZyB0aGVyYXB5PC9rZXl3b3Jk

Pjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjE5ODY8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BdWcg

MTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMDgtNTQzWCAoUHJpbnQpJiN4RDsw

MDA4LTU0M1ggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMwMTUzNjg8L2FjY2Vzc2lv

bi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdv

di9wdWJtZWQvMzAxNTM2ODwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3JlY29yZD48L0Np

dGU+PENpdGU+PEF1dGhvcj5CZXJrb3dpdHo8L0F1dGhvcj48WWVhcj4xOTg3PC9ZZWFyPjxSZWNO

dW0+MjEwNzwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MjEwNzwvcmVjLW51bWJlcj48Zm9y

ZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjBmczVhMHQ1ZHJ2enZ2ZWZmejF2YXdyOHR6

cnZwdzAwdHAydiIgdGltZXN0YW1wPSIxNTM5MjI4OTA0Ij4yMTA3PC9rZXk+PC9mb3JlaWduLWtl

eXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmli

dXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5CZXJrb3dpdHosIFIuIFMuPC9hdXRob3I+PGF1dGhvcj5H

b2xkc3RlaW4sIEQuIFAuPC9hdXRob3I+PGF1dGhvcj5EdUJlc2h0ZXIsIEIuPC9hdXRob3I+PGF1

dGhvcj5CZXJuc3RlaW4sIE0uIFIuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxh

dXRoLWFkZHJlc3M+TmV3IEVuZ2xhbmQgVHJvcGhvYmxhc3RpYyBEaXNlYXNlIENlbnRlciwgRGl2

aXNpb24gb2YgR3luZWNvbG9naWMgT25jb2xvZ3ksIEJyaWdoYW0gYW5kIFdvbWVuJmFwb3M7cyBI

b3NwaXRhbCwgQm9zdG9uLCBNQSAwMjExNS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5N

YW5hZ2VtZW50IG9mIGNvbXBsZXRlIG1vbGFyIHByZWduYW5jeTwvdGl0bGU+PHNlY29uZGFyeS10

aXRsZT5KIFJlcHJvZCBNZWQ8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPlRoZSBKb3VybmFs

IG9mIHJlcHJvZHVjdGl2ZSBtZWRpY2luZTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2Fs

PjxmdWxsLXRpdGxlPkogUmVwcm9kIE1lZDwvZnVsbC10aXRsZT48YWJici0xPlRoZSBKb3VybmFs

IG9mIHJlcHJvZHVjdGl2ZSBtZWRpY2luZTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+SiBSZXByb2QgTWVkPC9mdWxsLXRpdGxlPjxhYmJyLTE+VGhlIEpv

dXJuYWwgb2YgcmVwcm9kdWN0aXZlIG1lZGljaW5lPC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48

cGFnZXM+NjM0LTk8L3BhZ2VzPjx2b2x1bWU+MzI8L3ZvbHVtZT48bnVtYmVyPjk8L251bWJlcj48

a2V5d29yZHM+PGtleXdvcmQ+RGlhZ25vc2lzLCBEaWZmZXJlbnRpYWw8L2tleXdvcmQ+PGtleXdv

cmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD4qSHlk

YXRpZGlmb3JtIE1vbGUvZGlhZ25vc2lzL3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25h

bmN5PC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgRmFjdG9yczwva2V5d29yZD48a2V5d29yZD4qVXRl

cmluZSBOZW9wbGFzbXMvZGlhZ25vc2lzL3RoZXJhcHk8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0

ZXM+PHllYXI+MTk4NzwveWVhcj48cHViLWRhdGVzPjxkYXRlPlNlcDwvZGF0ZT48L3B1Yi1kYXRl

cz48L2RhdGVzPjxpc2JuPjAwMjQtNzc1OCAoUHJpbnQpJiN4RDswMDI0LTc3NTggKExpbmtpbmcp

PC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMzMTI1OTk8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0

ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMzMxMjU5OTwv

dXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5M

aW1wb25nc2FudXJhazwvQXV0aG9yPjxZZWFyPjIwMDE8L1llYXI+PFJlY051bT4yMTA5PC9SZWNO

dW0+PHJlY29yZD48cmVjLW51bWJlcj4yMTA5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtl

eSBhcHA9IkVOIiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0

aW1lc3RhbXA9IjE1MzkyMjg5NDYiPjIxMDk8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUg

bmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9y

cz48YXV0aG9yPkxpbXBvbmdzYW51cmFrLCBTLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1

dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgT2JzdGV0cmljcyBhbmQgR3luZWNvbG9n

eSwgRmFjdWx0eSBvZiBNZWRpY2luZSwgQ2h1bGFsb25na29ybiBVbml2ZXJzaXR5LCBCYW5na29r

IDEwMzMwLCBUaGFpbGFuZC48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Qcm9waHlsYWN0

aWMgYWN0aW5vbXljaW4gRCBmb3IgaGlnaC1yaXNrIGNvbXBsZXRlIGh5ZGF0aWRpZm9ybSBtb2xl

PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkogUmVwcm9kIE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjxh

bHQtdGl0bGU+VGhlIEpvdXJuYWwgb2YgcmVwcm9kdWN0aXZlIG1lZGljaW5lPC9hbHQtdGl0bGU+

PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SiBSZXByb2QgTWVkPC9mdWxsLXRpdGxl

PjxhYmJyLTE+VGhlIEpvdXJuYWwgb2YgcmVwcm9kdWN0aXZlIG1lZGljaW5lPC9hYmJyLTE+PC9w

ZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIFJlcHJvZCBNZWQ8L2Z1bGwt

dGl0bGU+PGFiYnItMT5UaGUgSm91cm5hbCBvZiByZXByb2R1Y3RpdmUgbWVkaWNpbmU8L2FiYnIt

MT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4xMTAtNjwvcGFnZXM+PHZvbHVtZT40Njwvdm9sdW1l

PjxudW1iZXI+MjwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3Jk

PjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkFudGliaW90aWNzLCBBbnRpbmVvcGxh

c3RpYy9hZHZlcnNlIGVmZmVjdHMvKnRoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5D

aGVtb3RoZXJhcHksIEFkanV2YW50PC9rZXl3b3JkPjxrZXl3b3JkPkRhY3Rpbm9teWNpbi9hZHZl

cnNlIGVmZmVjdHMvKnRoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5Eb3VibGUtQmxp

bmQgTWV0aG9kPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1h

bnM8L2tleXdvcmQ+PGtleXdvcmQ+SHlkYXRpZGlmb3JtIE1vbGUvY29tcGxpY2F0aW9ucy8qcHJl

dmVudGlvbiAmYW1wOyBjb250cm9sL3N1cmdlcnk8L2tleXdvcmQ+PGtleXdvcmQ+SW5jaWRlbmNl

PC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3Rv

cnM8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBOZW9wbGFzbXMvY29tcGxpY2F0aW9ucy8qcHJl

dmVudGlvbiAmYW1wOyBjb250cm9sL3N1cmdlcnk8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+

PHllYXI+MjAwMTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkZlYjwvZGF0ZT48L3B1Yi1kYXRlcz48

L2RhdGVzPjxpc2JuPjAwMjQtNzc1OCAoUHJpbnQpJiN4RDswMDI0LTc3NTggKExpbmtpbmcpPC9p

c2JuPjxhY2Nlc3Npb24tbnVtPjExMjU1ODA5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVk

LXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzExMjU1ODA5PC91

cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPktp

bTwvQXV0aG9yPjxZZWFyPjE5ODY8L1llYXI+PFJlY051bT4yMTEwPC9SZWNOdW0+PHJlY29yZD48

cmVjLW51bWJlcj4yMTEwPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9IjE1

MzkyMjkwNDMiPjIxMTA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5h

bCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPktp

bSwgRC4gUy48L2F1dGhvcj48YXV0aG9yPk1vb24sIEguPC9hdXRob3I+PGF1dGhvcj5LaW0sIEsu

IFQuPC9hdXRob3I+PGF1dGhvcj5Nb29uLCBZLiBKLjwvYXV0aG9yPjxhdXRob3I+SHdhbmcsIFku

IFkuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkVmZmVj

dHMgb2YgcHJvcGh5bGFjdGljIGNoZW1vdGhlcmFweSBmb3IgcGVyc2lzdGVudCB0cm9waG9ibGFz

dGljIGRpc2Vhc2UgaW4gcGF0aWVudHMgd2l0aCBjb21wbGV0ZSBoeWRhdGlkaWZvcm0gbW9sZTwv

dGl0bGU+PHNlY29uZGFyeS10aXRsZT5PYnN0ZXQgR3luZWNvbDwvc2Vjb25kYXJ5LXRpdGxlPjxh

bHQtdGl0bGU+T2JzdGV0cmljcyBhbmQgZ3luZWNvbG9neTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxw

ZXJpb2RpY2FsPjxmdWxsLXRpdGxlPk9ic3RldCBHeW5lY29sPC9mdWxsLXRpdGxlPjxhYmJyLTE+

T2JzdGV0cmljcyBhbmQgZ3luZWNvbG9neTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+T2JzdGV0IEd5bmVjb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5PYnN0

ZXRyaWNzIGFuZCBneW5lY29sb2d5PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+Njkw

LTQ8L3BhZ2VzPjx2b2x1bWU+Njc8L3ZvbHVtZT48bnVtYmVyPjU8L251bWJlcj48a2V5d29yZHM+

PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMgQ29tYmluZWQg

Q2hlbW90aGVyYXB5IFByb3RvY29scy9hZHZlcnNlIGVmZmVjdHMvKnRoZXJhcGV1dGljIHVzZTwv

a2V5d29yZD48a2V5d29yZD5DaG9yaW9uaWMgR29uYWRvdHJvcGluL2Jsb29kPC9rZXl3b3JkPjxr

ZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+

SHlkYXRpZGlmb3JtIE1vbGUvKnN1cmdlcnk8L2tleXdvcmQ+PGtleXdvcmQ+S29yZWE8L2tleXdv

cmQ+PGtleXdvcmQ+TGV1Y292b3Jpbi9hZG1pbmlzdHJhdGlvbiAmYW1wOyBkb3NhZ2U8L2tleXdv

cmQ+PGtleXdvcmQ+TWV0aG90cmV4YXRlL2FkbWluaXN0cmF0aW9uICZhbXA7IGRvc2FnZTwva2V5

d29yZD48a2V5d29yZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1

ZGllczwva2V5d29yZD48a2V5d29yZD5SYW5kb20gQWxsb2NhdGlvbjwva2V5d29yZD48a2V5d29y

ZD5SaXNrPC9rZXl3b3JkPjxrZXl3b3JkPlN1Y3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+VGltZSBG

YWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlRyb3Bob2JsYXN0aWMgTmVvcGxhc21zL2Jsb29kLypw

cmV2ZW50aW9uICZhbXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBOZW9wbGFz

bXMvYmxvb2QvKnByZXZlbnRpb24gJmFtcDsgY29udHJvbC9zdXJnZXJ5PC9rZXl3b3JkPjwva2V5

d29yZHM+PGRhdGVzPjx5ZWFyPjE5ODY8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5NYXk8L2RhdGU+

PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMDI5LTc4NDQgKFByaW50KSYjeEQ7MDAyOS03ODQ0

IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4zMDA4MDU1PC9hY2Nlc3Npb24tbnVtPjx1

cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVk

LzMwMDgwNTU8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5k

Tm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LYXNoaW11cmE8L0F1dGhvcj48WWVhcj4xOTg2PC9ZZWFy

PjxSZWNOdW0+MjEwNjwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oMTEtMTQpPC9EaXNwbGF5VGV4dD48

cmVjb3JkPjxyZWMtbnVtYmVyPjIxMDY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFw

cD0iRU4iIGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVz

dGFtcD0iMTUzOTIyODg1MCI+MjEwNjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1l

PSJKb3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxh

dXRob3I+S2FzaGltdXJhLCBZLjwvYXV0aG9yPjxhdXRob3I+S2FzaGltdXJhLCBNLjwvYXV0aG9y

PjxhdXRob3I+U3VnaW1vcmksIEguPC9hdXRob3I+PGF1dGhvcj5Uc3VrYW1vdG8sIE4uPC9hdXRo

b3I+PGF1dGhvcj5NYXRzdXlhbWEsIFQuPC9hdXRob3I+PGF1dGhvcj5NYXRzdWt1bWEsIEsuPC9h

dXRob3I+PGF1dGhvcj5LYW11cmEsIFQuPC9hdXRob3I+PGF1dGhvcj5TYWl0bywgVC48L2F1dGhv

cj48YXV0aG9yPkthd2FubywgSC48L2F1dGhvcj48YXV0aG9yPk5vc2UsIFIuPC9hdXRob3I+PGF1

dGhvcj5ldCBhbC4sPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRp

dGxlPlByb3BoeWxhY3RpYyBjaGVtb3RoZXJhcHkgZm9yIGh5ZGF0aWRpZm9ybSBtb2xlLiBGaXZl

IHRvIDE1IHllYXJzIGZvbGxvdy11cDwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5DYW5jZXI8L3Nl

Y29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkNhbmNlcjwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJp

b2RpY2FsPjxmdWxsLXRpdGxlPkNhbmNlcjwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PGFsdC1w

ZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkNhbmNlcjwvZnVsbC10aXRsZT48L2FsdC1wZXJpb2RpY2Fs

PjxwYWdlcz42MjQtOTwvcGFnZXM+PHZvbHVtZT41ODwvdm9sdW1lPjxudW1iZXI+MzwvbnVtYmVy

PjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3JkPjxrZXl3b3JkPkFkdWx0PC9r

ZXl3b3JkPjxrZXl3b3JkPkNob3Jpb2NhcmNpbm9tYS9lcGlkZW1pb2xvZ3kvKnByZXZlbnRpb24g

JmFtcDsgY29udHJvbC9zZWNvbmRhcnk8L2tleXdvcmQ+PGtleXdvcmQ+Q2hvcmlvbmljIEdvbmFk

b3Ryb3Bpbi91cmluZTwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+

Rm9sbG93LVVwIFN0dWRpZXM8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3

b3JkPkh5ZGF0aWRpZm9ybSBNb2xlLypkcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+SmFw

YW48L2tleXdvcmQ+PGtleXdvcmQ+TWV0aG90cmV4YXRlL2FkdmVyc2UgZWZmZWN0cy90aGVyYXBl

dXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+

UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlByb3NwZWN0aXZlIFN0dWRpZXM8L2tleXdvcmQ+

PGtleXdvcmQ+VGltZSBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlRyb3Bob2JsYXN0aWMgTmVv

cGxhc21zL2VwaWRlbWlvbG9neS8qcHJldmVudGlvbiAmYW1wOyBjb250cm9sL3NlY29uZGFyeTwv

a2V5d29yZD48a2V5d29yZD5VdGVyaW5lIE5lb3BsYXNtcy8qZHJ1ZyB0aGVyYXB5PC9rZXl3b3Jk

Pjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjE5ODY8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BdWcg

MTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMDgtNTQzWCAoUHJpbnQpJiN4RDsw

MDA4LTU0M1ggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMwMTUzNjg8L2FjY2Vzc2lv

bi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdv

di9wdWJtZWQvMzAxNTM2ODwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3JlY29yZD48L0Np

dGU+PENpdGU+PEF1dGhvcj5CZXJrb3dpdHo8L0F1dGhvcj48WWVhcj4xOTg3PC9ZZWFyPjxSZWNO

dW0+MjEwNzwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MjEwNzwvcmVjLW51bWJlcj48Zm9y

ZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjBmczVhMHQ1ZHJ2enZ2ZWZmejF2YXdyOHR6

cnZwdzAwdHAydiIgdGltZXN0YW1wPSIxNTM5MjI4OTA0Ij4yMTA3PC9rZXk+PC9mb3JlaWduLWtl

eXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmli

dXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5CZXJrb3dpdHosIFIuIFMuPC9hdXRob3I+PGF1dGhvcj5H

b2xkc3RlaW4sIEQuIFAuPC9hdXRob3I+PGF1dGhvcj5EdUJlc2h0ZXIsIEIuPC9hdXRob3I+PGF1

dGhvcj5CZXJuc3RlaW4sIE0uIFIuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxh

dXRoLWFkZHJlc3M+TmV3IEVuZ2xhbmQgVHJvcGhvYmxhc3RpYyBEaXNlYXNlIENlbnRlciwgRGl2

aXNpb24gb2YgR3luZWNvbG9naWMgT25jb2xvZ3ksIEJyaWdoYW0gYW5kIFdvbWVuJmFwb3M7cyBI

b3NwaXRhbCwgQm9zdG9uLCBNQSAwMjExNS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5N

YW5hZ2VtZW50IG9mIGNvbXBsZXRlIG1vbGFyIHByZWduYW5jeTwvdGl0bGU+PHNlY29uZGFyeS10

aXRsZT5KIFJlcHJvZCBNZWQ8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPlRoZSBKb3VybmFs

IG9mIHJlcHJvZHVjdGl2ZSBtZWRpY2luZTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2Fs

PjxmdWxsLXRpdGxlPkogUmVwcm9kIE1lZDwvZnVsbC10aXRsZT48YWJici0xPlRoZSBKb3VybmFs

IG9mIHJlcHJvZHVjdGl2ZSBtZWRpY2luZTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+SiBSZXByb2QgTWVkPC9mdWxsLXRpdGxlPjxhYmJyLTE+VGhlIEpv

dXJuYWwgb2YgcmVwcm9kdWN0aXZlIG1lZGljaW5lPC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48

cGFnZXM+NjM0LTk8L3BhZ2VzPjx2b2x1bWU+MzI8L3ZvbHVtZT48bnVtYmVyPjk8L251bWJlcj48

a2V5d29yZHM+PGtleXdvcmQ+RGlhZ25vc2lzLCBEaWZmZXJlbnRpYWw8L2tleXdvcmQ+PGtleXdv

cmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD4qSHlk

YXRpZGlmb3JtIE1vbGUvZGlhZ25vc2lzL3RoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25h

bmN5PC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgRmFjdG9yczwva2V5d29yZD48a2V5d29yZD4qVXRl

cmluZSBOZW9wbGFzbXMvZGlhZ25vc2lzL3RoZXJhcHk8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0

ZXM+PHllYXI+MTk4NzwveWVhcj48cHViLWRhdGVzPjxkYXRlPlNlcDwvZGF0ZT48L3B1Yi1kYXRl

cz48L2RhdGVzPjxpc2JuPjAwMjQtNzc1OCAoUHJpbnQpJiN4RDswMDI0LTc3NTggKExpbmtpbmcp

PC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMzMTI1OTk8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0

ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMzMxMjU5OTwv

dXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5M

aW1wb25nc2FudXJhazwvQXV0aG9yPjxZZWFyPjIwMDE8L1llYXI+PFJlY051bT4yMTA5PC9SZWNO

dW0+PHJlY29yZD48cmVjLW51bWJlcj4yMTA5PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtl

eSBhcHA9IkVOIiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0

aW1lc3RhbXA9IjE1MzkyMjg5NDYiPjIxMDk8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUg

bmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9y

cz48YXV0aG9yPkxpbXBvbmdzYW51cmFrLCBTLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1

dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgT2JzdGV0cmljcyBhbmQgR3luZWNvbG9n

eSwgRmFjdWx0eSBvZiBNZWRpY2luZSwgQ2h1bGFsb25na29ybiBVbml2ZXJzaXR5LCBCYW5na29r

IDEwMzMwLCBUaGFpbGFuZC48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Qcm9waHlsYWN0

aWMgYWN0aW5vbXljaW4gRCBmb3IgaGlnaC1yaXNrIGNvbXBsZXRlIGh5ZGF0aWRpZm9ybSBtb2xl

PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkogUmVwcm9kIE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjxh

bHQtdGl0bGU+VGhlIEpvdXJuYWwgb2YgcmVwcm9kdWN0aXZlIG1lZGljaW5lPC9hbHQtdGl0bGU+

PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SiBSZXByb2QgTWVkPC9mdWxsLXRpdGxl

PjxhYmJyLTE+VGhlIEpvdXJuYWwgb2YgcmVwcm9kdWN0aXZlIG1lZGljaW5lPC9hYmJyLTE+PC9w

ZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIFJlcHJvZCBNZWQ8L2Z1bGwt

dGl0bGU+PGFiYnItMT5UaGUgSm91cm5hbCBvZiByZXByb2R1Y3RpdmUgbWVkaWNpbmU8L2FiYnIt

MT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4xMTAtNjwvcGFnZXM+PHZvbHVtZT40Njwvdm9sdW1l

PjxudW1iZXI+MjwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZG9sZXNjZW50PC9rZXl3b3Jk

PjxrZXl3b3JkPkFkdWx0PC9rZXl3b3JkPjxrZXl3b3JkPkFudGliaW90aWNzLCBBbnRpbmVvcGxh

c3RpYy9hZHZlcnNlIGVmZmVjdHMvKnRoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5D

aGVtb3RoZXJhcHksIEFkanV2YW50PC9rZXl3b3JkPjxrZXl3b3JkPkRhY3Rpbm9teWNpbi9hZHZl

cnNlIGVmZmVjdHMvKnRoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5Eb3VibGUtQmxp

bmQgTWV0aG9kPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1h

bnM8L2tleXdvcmQ+PGtleXdvcmQ+SHlkYXRpZGlmb3JtIE1vbGUvY29tcGxpY2F0aW9ucy8qcHJl

dmVudGlvbiAmYW1wOyBjb250cm9sL3N1cmdlcnk8L2tleXdvcmQ+PGtleXdvcmQ+SW5jaWRlbmNl

PC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3Rv

cnM8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBOZW9wbGFzbXMvY29tcGxpY2F0aW9ucy8qcHJl

dmVudGlvbiAmYW1wOyBjb250cm9sL3N1cmdlcnk8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+

PHllYXI+MjAwMTwveWVhcj48cHViLWRhdGVzPjxkYXRlPkZlYjwvZGF0ZT48L3B1Yi1kYXRlcz48

L2RhdGVzPjxpc2JuPjAwMjQtNzc1OCAoUHJpbnQpJiN4RDswMDI0LTc3NTggKExpbmtpbmcpPC9p

c2JuPjxhY2Nlc3Npb24tbnVtPjExMjU1ODA5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVk

LXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzExMjU1ODA5PC91

cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPktp

bTwvQXV0aG9yPjxZZWFyPjE5ODY8L1llYXI+PFJlY051bT4yMTEwPC9SZWNOdW0+PHJlY29yZD48

cmVjLW51bWJlcj4yMTEwPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9IjE1

MzkyMjkwNDMiPjIxMTA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5h

bCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPktp

bSwgRC4gUy48L2F1dGhvcj48YXV0aG9yPk1vb24sIEguPC9hdXRob3I+PGF1dGhvcj5LaW0sIEsu

IFQuPC9hdXRob3I+PGF1dGhvcj5Nb29uLCBZLiBKLjwvYXV0aG9yPjxhdXRob3I+SHdhbmcsIFku

IFkuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkVmZmVj

dHMgb2YgcHJvcGh5bGFjdGljIGNoZW1vdGhlcmFweSBmb3IgcGVyc2lzdGVudCB0cm9waG9ibGFz

dGljIGRpc2Vhc2UgaW4gcGF0aWVudHMgd2l0aCBjb21wbGV0ZSBoeWRhdGlkaWZvcm0gbW9sZTwv

dGl0bGU+PHNlY29uZGFyeS10aXRsZT5PYnN0ZXQgR3luZWNvbDwvc2Vjb25kYXJ5LXRpdGxlPjxh

bHQtdGl0bGU+T2JzdGV0cmljcyBhbmQgZ3luZWNvbG9neTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxw

ZXJpb2RpY2FsPjxmdWxsLXRpdGxlPk9ic3RldCBHeW5lY29sPC9mdWxsLXRpdGxlPjxhYmJyLTE+

T2JzdGV0cmljcyBhbmQgZ3luZWNvbG9neTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+T2JzdGV0IEd5bmVjb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5PYnN0

ZXRyaWNzIGFuZCBneW5lY29sb2d5PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+Njkw

LTQ8L3BhZ2VzPjx2b2x1bWU+Njc8L3ZvbHVtZT48bnVtYmVyPjU8L251bWJlcj48a2V5d29yZHM+

PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMgQ29tYmluZWQg

Q2hlbW90aGVyYXB5IFByb3RvY29scy9hZHZlcnNlIGVmZmVjdHMvKnRoZXJhcGV1dGljIHVzZTwv

a2V5d29yZD48a2V5d29yZD5DaG9yaW9uaWMgR29uYWRvdHJvcGluL2Jsb29kPC9rZXl3b3JkPjxr

ZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+

SHlkYXRpZGlmb3JtIE1vbGUvKnN1cmdlcnk8L2tleXdvcmQ+PGtleXdvcmQ+S29yZWE8L2tleXdv

cmQ+PGtleXdvcmQ+TGV1Y292b3Jpbi9hZG1pbmlzdHJhdGlvbiAmYW1wOyBkb3NhZ2U8L2tleXdv

cmQ+PGtleXdvcmQ+TWV0aG90cmV4YXRlL2FkbWluaXN0cmF0aW9uICZhbXA7IGRvc2FnZTwva2V5

d29yZD48a2V5d29yZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3BlY3RpdmUgU3R1

ZGllczwva2V5d29yZD48a2V5d29yZD5SYW5kb20gQWxsb2NhdGlvbjwva2V5d29yZD48a2V5d29y

ZD5SaXNrPC9rZXl3b3JkPjxrZXl3b3JkPlN1Y3Rpb248L2tleXdvcmQ+PGtleXdvcmQ+VGltZSBG

YWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlRyb3Bob2JsYXN0aWMgTmVvcGxhc21zL2Jsb29kLypw

cmV2ZW50aW9uICZhbXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBOZW9wbGFz

bXMvYmxvb2QvKnByZXZlbnRpb24gJmFtcDsgY29udHJvbC9zdXJnZXJ5PC9rZXl3b3JkPjwva2V5

d29yZHM+PGRhdGVzPjx5ZWFyPjE5ODY8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5NYXk8L2RhdGU+

PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMDI5LTc4NDQgKFByaW50KSYjeEQ7MDAyOS03ODQ0

IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4zMDA4MDU1PC9hY2Nlc3Npb24tbnVtPjx1

cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVk

LzMwMDgwNTU8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5k

Tm90ZT4A

ADDIN EN.CITE.DATA (11-14) have shown that the risk of post molar GTD (i.e. persistence, invasion, choriocarcinoma, GTN) dropped in patients with molar pregnancy treated after surgery with prophylactic chemotherapy. However, Prophylactic chemotherapy does not obviate the need to monitor patients after evacuation as the risk does not drop to zero.There is a suggestion that patients who received prophylaxis need more chemotherapy if their disease recurs PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LaW08L0F1dGhvcj48WWVhcj4xOTg2PC9ZZWFyPjxSZWNO

dW0+MjExMDwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oMTQpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxy

ZWMtbnVtYmVyPjIxMTA8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0iMTUz

OTIyOTA0MyI+MjExMDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFs

IEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+S2lt

LCBELiBTLjwvYXV0aG9yPjxhdXRob3I+TW9vbiwgSC48L2F1dGhvcj48YXV0aG9yPktpbSwgSy4g

VC48L2F1dGhvcj48YXV0aG9yPk1vb24sIFkuIEouPC9hdXRob3I+PGF1dGhvcj5Id2FuZywgWS4g

WS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+RWZmZWN0

cyBvZiBwcm9waHlsYWN0aWMgY2hlbW90aGVyYXB5IGZvciBwZXJzaXN0ZW50IHRyb3Bob2JsYXN0

aWMgZGlzZWFzZSBpbiBwYXRpZW50cyB3aXRoIGNvbXBsZXRlIGh5ZGF0aWRpZm9ybSBtb2xlPC90

aXRsZT48c2Vjb25kYXJ5LXRpdGxlPk9ic3RldCBHeW5lY29sPC9zZWNvbmRhcnktdGl0bGU+PGFs

dC10aXRsZT5PYnN0ZXRyaWNzIGFuZCBneW5lY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBl

cmlvZGljYWw+PGZ1bGwtdGl0bGU+T2JzdGV0IEd5bmVjb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5P

YnN0ZXRyaWNzIGFuZCBneW5lY29sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9k

aWNhbD48ZnVsbC10aXRsZT5PYnN0ZXQgR3luZWNvbDwvZnVsbC10aXRsZT48YWJici0xPk9ic3Rl

dHJpY3MgYW5kIGd5bmVjb2xvZ3k8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz42OTAt

NDwvcGFnZXM+PHZvbHVtZT42Nzwvdm9sdW1lPjxudW1iZXI+NTwvbnVtYmVyPjxrZXl3b3Jkcz48

a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BbnRpbmVvcGxhc3RpYyBDb21iaW5lZCBD

aGVtb3RoZXJhcHkgUHJvdG9jb2xzL2FkdmVyc2UgZWZmZWN0cy8qdGhlcmFwZXV0aWMgdXNlPC9r

ZXl3b3JkPjxrZXl3b3JkPkNob3Jpb25pYyBHb25hZG90cm9waW4vYmxvb2Q8L2tleXdvcmQ+PGtl

eXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5I

eWRhdGlkaWZvcm0gTW9sZS8qc3VyZ2VyeTwva2V5d29yZD48a2V5d29yZD5Lb3JlYTwva2V5d29y

ZD48a2V5d29yZD5MZXVjb3ZvcmluL2FkbWluaXN0cmF0aW9uICZhbXA7IGRvc2FnZTwva2V5d29y

ZD48a2V5d29yZD5NZXRob3RyZXhhdGUvYWRtaW5pc3RyYXRpb24gJmFtcDsgZG9zYWdlPC9rZXl3

b3JkPjxrZXl3b3JkPlByZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5Qcm9zcGVjdGl2ZSBTdHVk

aWVzPC9rZXl3b3JkPjxrZXl3b3JkPlJhbmRvbSBBbGxvY2F0aW9uPC9rZXl3b3JkPjxrZXl3b3Jk

PlJpc2s8L2tleXdvcmQ+PGtleXdvcmQ+U3VjdGlvbjwva2V5d29yZD48a2V5d29yZD5UaW1lIEZh

Y3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+VHJvcGhvYmxhc3RpYyBOZW9wbGFzbXMvYmxvb2QvKnBy

ZXZlbnRpb24gJmFtcDsgY29udHJvbDwva2V5d29yZD48a2V5d29yZD5VdGVyaW5lIE5lb3BsYXNt

cy9ibG9vZC8qcHJldmVudGlvbiAmYW1wOyBjb250cm9sL3N1cmdlcnk8L2tleXdvcmQ+PC9rZXl3

b3Jkcz48ZGF0ZXM+PHllYXI+MTk4NjwveWVhcj48cHViLWRhdGVzPjxkYXRlPk1heTwvZGF0ZT48

L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMjktNzg0NCAoUHJpbnQpJiN4RDswMDI5LTc4NDQg

KExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMwMDgwNTU8L2FjY2Vzc2lvbi1udW0+PHVy

bHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQv

MzAwODA1NTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PC9FbmRO

b3RlPn==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5LaW08L0F1dGhvcj48WWVhcj4xOTg2PC9ZZWFyPjxSZWNO

dW0+MjExMDwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oMTQpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxy

ZWMtbnVtYmVyPjIxMTA8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0iMTUz

OTIyOTA0MyI+MjExMDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFs

IEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+S2lt

LCBELiBTLjwvYXV0aG9yPjxhdXRob3I+TW9vbiwgSC48L2F1dGhvcj48YXV0aG9yPktpbSwgSy4g

VC48L2F1dGhvcj48YXV0aG9yPk1vb24sIFkuIEouPC9hdXRob3I+PGF1dGhvcj5Id2FuZywgWS4g

WS48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+RWZmZWN0

cyBvZiBwcm9waHlsYWN0aWMgY2hlbW90aGVyYXB5IGZvciBwZXJzaXN0ZW50IHRyb3Bob2JsYXN0

aWMgZGlzZWFzZSBpbiBwYXRpZW50cyB3aXRoIGNvbXBsZXRlIGh5ZGF0aWRpZm9ybSBtb2xlPC90

aXRsZT48c2Vjb25kYXJ5LXRpdGxlPk9ic3RldCBHeW5lY29sPC9zZWNvbmRhcnktdGl0bGU+PGFs

dC10aXRsZT5PYnN0ZXRyaWNzIGFuZCBneW5lY29sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBl

cmlvZGljYWw+PGZ1bGwtdGl0bGU+T2JzdGV0IEd5bmVjb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5P

YnN0ZXRyaWNzIGFuZCBneW5lY29sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9k

aWNhbD48ZnVsbC10aXRsZT5PYnN0ZXQgR3luZWNvbDwvZnVsbC10aXRsZT48YWJici0xPk9ic3Rl

dHJpY3MgYW5kIGd5bmVjb2xvZ3k8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz42OTAt

NDwvcGFnZXM+PHZvbHVtZT42Nzwvdm9sdW1lPjxudW1iZXI+NTwvbnVtYmVyPjxrZXl3b3Jkcz48

a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BbnRpbmVvcGxhc3RpYyBDb21iaW5lZCBD

aGVtb3RoZXJhcHkgUHJvdG9jb2xzL2FkdmVyc2UgZWZmZWN0cy8qdGhlcmFwZXV0aWMgdXNlPC9r

ZXl3b3JkPjxrZXl3b3JkPkNob3Jpb25pYyBHb25hZG90cm9waW4vYmxvb2Q8L2tleXdvcmQ+PGtl

eXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5I

eWRhdGlkaWZvcm0gTW9sZS8qc3VyZ2VyeTwva2V5d29yZD48a2V5d29yZD5Lb3JlYTwva2V5d29y

ZD48a2V5d29yZD5MZXVjb3ZvcmluL2FkbWluaXN0cmF0aW9uICZhbXA7IGRvc2FnZTwva2V5d29y

ZD48a2V5d29yZD5NZXRob3RyZXhhdGUvYWRtaW5pc3RyYXRpb24gJmFtcDsgZG9zYWdlPC9rZXl3

b3JkPjxrZXl3b3JkPlByZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5Qcm9zcGVjdGl2ZSBTdHVk

aWVzPC9rZXl3b3JkPjxrZXl3b3JkPlJhbmRvbSBBbGxvY2F0aW9uPC9rZXl3b3JkPjxrZXl3b3Jk

PlJpc2s8L2tleXdvcmQ+PGtleXdvcmQ+U3VjdGlvbjwva2V5d29yZD48a2V5d29yZD5UaW1lIEZh

Y3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+VHJvcGhvYmxhc3RpYyBOZW9wbGFzbXMvYmxvb2QvKnBy

ZXZlbnRpb24gJmFtcDsgY29udHJvbDwva2V5d29yZD48a2V5d29yZD5VdGVyaW5lIE5lb3BsYXNt

cy9ibG9vZC8qcHJldmVudGlvbiAmYW1wOyBjb250cm9sL3N1cmdlcnk8L2tleXdvcmQ+PC9rZXl3

b3Jkcz48ZGF0ZXM+PHllYXI+MTk4NjwveWVhcj48cHViLWRhdGVzPjxkYXRlPk1heTwvZGF0ZT48

L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMjktNzg0NCAoUHJpbnQpJiN4RDswMDI5LTc4NDQg

KExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjMwMDgwNTU8L2FjY2Vzc2lvbi1udW0+PHVy

bHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQv

MzAwODA1NTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PC9FbmRO

b3RlPn==

ADDIN EN.CITE.DATA (14).The ‘risk scales’ used to determine high risk patients for prophylaxis have been subject to much criticism.12CONTRACEPTION IN MOLAR PREGNANCYPatients should be strongly counselled to avoid pregnancy during follow-up. Pregnancy masks tumour persistence/recurrence.Oral contraceptives can be taken between evacuation and normalisation of HCG. Recent series and systematic reviews suggests there is NO increased risk of invasive mole or choriocarcinoma developing from the use of oral contraceptives before normalisation of HCG PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Db3N0YTwvQXV0aG9yPjxZZWFyPjIwMDY8L1llYXI+PFJl

Y051bT4yMTEyPC9SZWNOdW0+PERpc3BsYXlUZXh0PigxNSwgMTYpPC9EaXNwbGF5VGV4dD48cmVj

b3JkPjxyZWMtbnVtYmVyPjIxMTI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0i

RU4iIGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFt

cD0iMTUzOTIyOTIzNSI+MjExMjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK

b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo

b3I+Q29zdGEsIEguIEwuPC9hdXRob3I+PGF1dGhvcj5Eb3lsZSwgUC48L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5NYXRlcm5hbCBJbmZhbnQgRGVwYXJ0bWVu

dCwgVW5pdmVyc2l0eSBvZiBQZXJuYW1idWNvLCBCcmF6aWwuIGhlbGlvY29zdGFAZWxvZ2ljYS5j

b20uYnI8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5JbmZsdWVuY2Ugb2Ygb3JhbCBjb250

cmFjZXB0aXZlcyBpbiB0aGUgZGV2ZWxvcG1lbnQgb2YgcG9zdC1tb2xhciB0cm9waG9ibGFzdGlj

IG5lb3BsYXNpYS0tYSBzeXN0ZW1hdGljIHJldmlldzwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5H

eW5lY29sIE9uY29sPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5HeW5lY29sb2dpYyBvbmNv

bG9neTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkd5bmVjb2wg

T25jb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5HeW5lY29sb2dpYyBvbmNvbG9neTwvYWJici0xPjwv

cGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+R3luZWNvbCBPbmNvbDwvZnVs

bC10aXRsZT48YWJici0xPkd5bmVjb2xvZ2ljIG9uY29sb2d5PC9hYmJyLTE+PC9hbHQtcGVyaW9k

aWNhbD48cGFnZXM+NTc5LTg1PC9wYWdlcz48dm9sdW1lPjEwMDwvdm9sdW1lPjxudW1iZXI+Mzwv

bnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5DaG9yaW9uaWMgR29uYWRvdHJvcGluLCBiZXRhIFN1

YnVuaXQsIEh1bWFuL2Jsb29kPC9rZXl3b3JkPjxrZXl3b3JkPkNvbWJpbmVkIE1vZGFsaXR5IFRo

ZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+Q29udHJhY2VwdGl2ZXMsIE9yYWwvKmFkdmVyc2UgZWZm

ZWN0czwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2VzdGF0aW9u

YWwgVHJvcGhvYmxhc3RpYyBEaXNlYXNlL2Jsb29kLypjaGVtaWNhbGx5IGluZHVjZWQ8L2tleXdv

cmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkh5ZGF0aWRpZm9ybSBNb2xlL2Ry

dWcgdGhlcmFweS9zdXJnZXJ5PC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeTwva2V5d29yZD48

a2V5d29yZD5SYW5kb21pemVkIENvbnRyb2xsZWQgVHJpYWxzIGFzIFRvcGljPC9rZXl3b3JkPjxr

ZXl3b3JkPlV0ZXJpbmUgTmVvcGxhc21zL2Jsb29kLypjaGVtaWNhbGx5IGluZHVjZWQ8L2tleXdv

cmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPk1h

cjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwOTAtODI1OCAoUHJpbnQpJiN4RDsw

MDkwLTgyNTggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjE2Mjk3OTcxPC9hY2Nlc3Np

b24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5n

b3YvcHVibWVkLzE2Mjk3OTcxPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmlj

LXJlc291cmNlLW51bT4xMC4xMDE2L2oueWd5bm8uMjAwNS4wOS4wMzE8L2VsZWN0cm9uaWMtcmVz

b3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPkdhZmZpZWxkPC9BdXRob3I+

PFllYXI+MjAwOTwvWWVhcj48UmVjTnVtPjIxMTU8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVy

PjIxMTU8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSIwZnM1

YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0iMTUzOTIyOTMzMSI+

MjExNTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi

PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+R2FmZmllbGQsIE0u

IEUuPC9hdXRob3I+PGF1dGhvcj5LYXBwLCBOLjwvYXV0aG9yPjxhdXRob3I+Q3VydGlzLCBLLiBN

LjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1l

bnQgb2YgUmVwcm9kdWN0aXZlIEhlYWx0aCBhbmQgUmVzZWFyY2gsIFdvcmxkIEhlYWx0aCBPcmdh

bml6YXRpb24sIDEyMTEgR2VuZXZhIDI3LCBTd2l0emVybGFuZC4gZ2FmZmllbGRtQHdoby5pbnQ8

L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Db21iaW5lZCBvcmFsIGNvbnRyYWNlcHRpdmUg

YW5kIGludHJhdXRlcmluZSBkZXZpY2UgdXNlIGFtb25nIHdvbWVuIHdpdGggZ2VzdGF0aW9uYWwg

dHJvcGhvYmxhc3RpYyBkaXNlYXNlPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkNvbnRyYWNlcHRp

b248L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkNvbnRyYWNlcHRpb248L2FsdC10aXRsZT48

L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Db250cmFjZXB0aW9uPC9mdWxsLXRpdGxl

PjxhYmJyLTE+Q29udHJhY2VwdGlvbjwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGlj

YWw+PGZ1bGwtdGl0bGU+Q29udHJhY2VwdGlvbjwvZnVsbC10aXRsZT48YWJici0xPkNvbnRyYWNl

cHRpb248L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4zNjMtNzE8L3BhZ2VzPjx2b2x1

bWU+ODA8L3ZvbHVtZT48bnVtYmVyPjQ8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+Q29udHJh

Y2VwdGl2ZXMsIE9yYWwsIENvbWJpbmVkLyp0aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdv

cmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPipHZXN0YXRpb25hbCBUcm9waG9ibGFzdGljIERp

c2Vhc2U8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPipJbnRyYXV0

ZXJpbmUgRGV2aWNlcywgQ29wcGVyPC9rZXl3b3JkPjxrZXl3b3JkPipJbnRyYXV0ZXJpbmUgRGV2

aWNlcywgTWVkaWNhdGVkPC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeTwva2V5d29yZD48a2V5

d29yZD5SaXNrPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgRmFjdG9yczwva2V5d29yZD48L2tleXdv

cmRzPjxkYXRlcz48eWVhcj4yMDA5PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+T2N0PC9kYXRlPjwv

cHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTg3OS0wNTE4IChFbGVjdHJvbmljKSYjeEQ7MDAxMC03

ODI0IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4xOTc1MTg1OTwvYWNjZXNzaW9uLW51

bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1

Ym1lZC8xOTc1MTg1OTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNv

dXJjZS1udW0+MTAuMTAxNi9qLmNvbnRyYWNlcHRpb24uMjAwOS4wMy4wMjI8L2VsZWN0cm9uaWMt

cmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Db3N0YTwvQXV0aG9yPjxZZWFyPjIwMDY8L1llYXI+PFJl

Y051bT4yMTEyPC9SZWNOdW0+PERpc3BsYXlUZXh0PigxNSwgMTYpPC9EaXNwbGF5VGV4dD48cmVj

b3JkPjxyZWMtbnVtYmVyPjIxMTI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0i

RU4iIGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFt

cD0iMTUzOTIyOTIzNSI+MjExMjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJK

b3VybmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRo

b3I+Q29zdGEsIEguIEwuPC9hdXRob3I+PGF1dGhvcj5Eb3lsZSwgUC48L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5NYXRlcm5hbCBJbmZhbnQgRGVwYXJ0bWVu

dCwgVW5pdmVyc2l0eSBvZiBQZXJuYW1idWNvLCBCcmF6aWwuIGhlbGlvY29zdGFAZWxvZ2ljYS5j

b20uYnI8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5JbmZsdWVuY2Ugb2Ygb3JhbCBjb250

cmFjZXB0aXZlcyBpbiB0aGUgZGV2ZWxvcG1lbnQgb2YgcG9zdC1tb2xhciB0cm9waG9ibGFzdGlj

IG5lb3BsYXNpYS0tYSBzeXN0ZW1hdGljIHJldmlldzwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5H

eW5lY29sIE9uY29sPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5HeW5lY29sb2dpYyBvbmNv

bG9neTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkd5bmVjb2wg

T25jb2w8L2Z1bGwtdGl0bGU+PGFiYnItMT5HeW5lY29sb2dpYyBvbmNvbG9neTwvYWJici0xPjwv

cGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+R3luZWNvbCBPbmNvbDwvZnVs

bC10aXRsZT48YWJici0xPkd5bmVjb2xvZ2ljIG9uY29sb2d5PC9hYmJyLTE+PC9hbHQtcGVyaW9k

aWNhbD48cGFnZXM+NTc5LTg1PC9wYWdlcz48dm9sdW1lPjEwMDwvdm9sdW1lPjxudW1iZXI+Mzwv

bnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5DaG9yaW9uaWMgR29uYWRvdHJvcGluLCBiZXRhIFN1

YnVuaXQsIEh1bWFuL2Jsb29kPC9rZXl3b3JkPjxrZXl3b3JkPkNvbWJpbmVkIE1vZGFsaXR5IFRo

ZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+Q29udHJhY2VwdGl2ZXMsIE9yYWwvKmFkdmVyc2UgZWZm

ZWN0czwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+R2VzdGF0aW9u

YWwgVHJvcGhvYmxhc3RpYyBEaXNlYXNlL2Jsb29kLypjaGVtaWNhbGx5IGluZHVjZWQ8L2tleXdv

cmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkh5ZGF0aWRpZm9ybSBNb2xlL2Ry

dWcgdGhlcmFweS9zdXJnZXJ5PC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeTwva2V5d29yZD48

a2V5d29yZD5SYW5kb21pemVkIENvbnRyb2xsZWQgVHJpYWxzIGFzIFRvcGljPC9rZXl3b3JkPjxr

ZXl3b3JkPlV0ZXJpbmUgTmVvcGxhc21zL2Jsb29kLypjaGVtaWNhbGx5IGluZHVjZWQ8L2tleXdv

cmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPk1h

cjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwOTAtODI1OCAoUHJpbnQpJiN4RDsw

MDkwLTgyNTggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjE2Mjk3OTcxPC9hY2Nlc3Np

b24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5n

b3YvcHVibWVkLzE2Mjk3OTcxPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJvbmlj

LXJlc291cmNlLW51bT4xMC4xMDE2L2oueWd5bm8uMjAwNS4wOS4wMzE8L2VsZWN0cm9uaWMtcmVz

b3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPkdhZmZpZWxkPC9BdXRob3I+

PFllYXI+MjAwOTwvWWVhcj48UmVjTnVtPjIxMTU8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVy

PjIxMTU8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSIwZnM1

YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0iMTUzOTIyOTMzMSI+

MjExNTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi

PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+R2FmZmllbGQsIE0u

IEUuPC9hdXRob3I+PGF1dGhvcj5LYXBwLCBOLjwvYXV0aG9yPjxhdXRob3I+Q3VydGlzLCBLLiBN

LjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkRlcGFydG1l

bnQgb2YgUmVwcm9kdWN0aXZlIEhlYWx0aCBhbmQgUmVzZWFyY2gsIFdvcmxkIEhlYWx0aCBPcmdh

bml6YXRpb24sIDEyMTEgR2VuZXZhIDI3LCBTd2l0emVybGFuZC4gZ2FmZmllbGRtQHdoby5pbnQ8

L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Db21iaW5lZCBvcmFsIGNvbnRyYWNlcHRpdmUg

YW5kIGludHJhdXRlcmluZSBkZXZpY2UgdXNlIGFtb25nIHdvbWVuIHdpdGggZ2VzdGF0aW9uYWwg

dHJvcGhvYmxhc3RpYyBkaXNlYXNlPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkNvbnRyYWNlcHRp

b248L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkNvbnRyYWNlcHRpb248L2FsdC10aXRsZT48

L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Db250cmFjZXB0aW9uPC9mdWxsLXRpdGxl

PjxhYmJyLTE+Q29udHJhY2VwdGlvbjwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGlj

YWw+PGZ1bGwtdGl0bGU+Q29udHJhY2VwdGlvbjwvZnVsbC10aXRsZT48YWJici0xPkNvbnRyYWNl

cHRpb248L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4zNjMtNzE8L3BhZ2VzPjx2b2x1

bWU+ODA8L3ZvbHVtZT48bnVtYmVyPjQ8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+Q29udHJh

Y2VwdGl2ZXMsIE9yYWwsIENvbWJpbmVkLyp0aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdv

cmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPipHZXN0YXRpb25hbCBUcm9waG9ibGFzdGljIERp

c2Vhc2U8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPipJbnRyYXV0

ZXJpbmUgRGV2aWNlcywgQ29wcGVyPC9rZXl3b3JkPjxrZXl3b3JkPipJbnRyYXV0ZXJpbmUgRGV2

aWNlcywgTWVkaWNhdGVkPC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeTwva2V5d29yZD48a2V5

d29yZD5SaXNrPC9rZXl3b3JkPjxrZXl3b3JkPlJpc2sgRmFjdG9yczwva2V5d29yZD48L2tleXdv

cmRzPjxkYXRlcz48eWVhcj4yMDA5PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+T2N0PC9kYXRlPjwv

cHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTg3OS0wNTE4IChFbGVjdHJvbmljKSYjeEQ7MDAxMC03

ODI0IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4xOTc1MTg1OTwvYWNjZXNzaW9uLW51

bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1

Ym1lZC8xOTc1MTg1OTwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNv

dXJjZS1udW0+MTAuMTAxNi9qLmNvbnRyYWNlcHRpb24uMjAwOS4wMy4wMjI8L2VsZWN0cm9uaWMt

cmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE.DATA (15,16).IUCDs should be avoided until the menstrual pattern and tumour hCG are normal to reduce risk of uterine perforation. If chosen as contraception (after normalisation of hCG) advise insertion of IUCD by a gynaecologist.Barrier Methods are the preferred method of contraception during chemotherapy.13PREGNANCY ADVICE AFTER MOLAR PREGNANCYWomen should be advised not to conceive until their follow up is completeFuture pregnanciesIn all subsequent pregnancies patients should have an early (6-8 week) and mid trimester scan looking for molar tissue After all future pregnancy events (including TOP, miscarriage etc) patients should have a tumour hCG blood test 6-8 weeks The chances of conception after molar pregnancy do not differ from the general population. The risk of a further molar pregnancy in future pregnancies is 1:70. Subsequent pregnancies result in full-term live births in about 70% of women, with major and minor congenital malformations detected in 0.4-2.5% of infants. These figures do not differ significantly from the normal population. Outcomes other than full-term live births include first trimester spontaneous abortions in about 15%, 2-8% premature deliveries, and smaller numbers of stillbirths and ectopic pregnancies.14PREGNANCY DURING FOLLOW-UP AFTER MOLAR PREGNANCYPregnancies occurring before completion of recommended follow-up may be allowed to continue under careful surveillance.Background : Tuncer ADDIN EN.CITE <EndNote><Cite><Author>Tuncer</Author><Year>1999</Year><RecNum>2119</RecNum><DisplayText>(17)</DisplayText><record><rec-number>2119</rec-number><foreign-keys><key app="EN" db-id="0fs5a0t5drvzvveffz1vawr8tzrvpw00tp2v" timestamp="1539229700">2119</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Tuncer, Z. S.</author><author>Bernstein, M. R.</author><author>Goldstein, D. P.</author><author>Lu, K. H.</author><author>Berkowitz, R. S.</author></authors></contributors><auth-address>New England Trophoblastic Disease Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women&apos;s Hospital, Boston, Massachusetts 02115, USA.</auth-address><titles><title>Outcome of pregnancies occurring within 1 year of hydatidiform mole</title><secondary-title>Obstet Gynecol</secondary-title><alt-title>Obstetrics and gynecology</alt-title></titles><periodical><full-title>Obstet Gynecol</full-title><abbr-1>Obstetrics and gynecology</abbr-1></periodical><alt-periodical><full-title>Obstet Gynecol</full-title><abbr-1>Obstetrics and gynecology</abbr-1></alt-periodical><pages>588-90</pages><volume>94</volume><number>4</number><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Female</keyword><keyword>Follow-Up Studies</keyword><keyword>Humans</keyword><keyword>*Hydatidiform Mole</keyword><keyword>Pregnancy</keyword><keyword>*Pregnancy Outcome</keyword><keyword>Retrospective Studies</keyword><keyword>Time Factors</keyword><keyword>*Uterine Neoplasms</keyword></keywords><dates><year>1999</year><pub-dates><date>Oct</date></pub-dates></dates><isbn>0029-7844 (Print)&#xD;0029-7844 (Linking)</isbn><accession-num>10511364</accession-num><urls><related-urls><url>;(17) reviewed 44 pregnancies conceived within 6 months of normal tumour hCG (mean 3 months normal hCG). Seventy five percent of 44 patients had live births and there were 10 spontaneous abortions. None of these patients developed persistent or recurrent GTD, and none of the live births demonstrated any foetal abnormalities.Patients should have an early and mid-trimester scan looking for molar tissue. Other surveillance is difficult during pregnancy, and will depend on the managing specialist’s estimation of the risk of recurrence.see also Pregnancy Advice after Molar Pregnancy Routine follow-up should be resumed after the pregnancy until the total follow-up duration initially planned. 15COEXISTING VIABLE PREGNANCY AND MOLAR PREGNANCYThe recommendation is that the pregnancy should be allowed to proceed after loss of the molar tissue, if it is otherwise safe and the mother wishes, following appropriate counselling. Backgroundrare occurrence 1 in 22,000 – 100,000 pregnancies PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TdGVpZ3JhZDwvQXV0aG9yPjxZZWFyPjIwMDQ8L1llYXI+

PFJlY051bT4yMTIwPC9SZWNOdW0+PERpc3BsYXlUZXh0PigxOCk8L0Rpc3BsYXlUZXh0PjxyZWNv

cmQ+PHJlYy1udW1iZXI+MjEyMDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF

TiIgZGItaWQ9IjBmczVhMHQ1ZHJ2enZ2ZWZmejF2YXdyOHR6cnZwdzAwdHAydiIgdGltZXN0YW1w

PSIxNTM5MjI5ODA1Ij4yMTIwPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9Ikpv

dXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhv

cj5TdGVpZ3JhZCwgUy4gSi48L2F1dGhvcj48YXV0aG9yPlJvYmVydHNvbiwgRy48L2F1dGhvcj48

YXV0aG9yPktheWUsIEEuIEwuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRo

LWFkZHJlc3M+VHJvcGhvYmxhc3RpYyBEaXNlYXNlIFJlZmVycmFsIFVuaXQsIFJveWFsIEhvc3Bp

dGFsIGZvciBXb21lbiwgUmFuZHdpY2ssIE5ldyBTb3V0aCBXYWxlcywgQXVzdHJhbGlhLiBzdGVp

Z3JhZHNAc2VzYWhzLm5zdy5nb3YuYXU8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5TZXJp

YWwgaENHIGFuZCB1bHRyYXNvdW5kIG1lYXN1cmVtZW50cyBmb3IgcHJlZGljdGluZyBtYWxpZ25h

bnQgcG90ZW50aWFsIGluIG11bHRpcGxlIHByZWduYW5jaWVzIGFzc29jaWF0ZWQgd2l0aCBjb21w

bGV0ZSBoeWRhdGlkaWZvcm0gbW9sZTogYSByZXBvcnQgb2YgMiBjYXNlczwvdGl0bGU+PHNlY29u

ZGFyeS10aXRsZT5KIFJlcHJvZCBNZWQ8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPlRoZSBK

b3VybmFsIG9mIHJlcHJvZHVjdGl2ZSBtZWRpY2luZTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJp

b2RpY2FsPjxmdWxsLXRpdGxlPkogUmVwcm9kIE1lZDwvZnVsbC10aXRsZT48YWJici0xPlRoZSBK

b3VybmFsIG9mIHJlcHJvZHVjdGl2ZSBtZWRpY2luZTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0

LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SiBSZXByb2QgTWVkPC9mdWxsLXRpdGxlPjxhYmJyLTE+

VGhlIEpvdXJuYWwgb2YgcmVwcm9kdWN0aXZlIG1lZGljaW5lPC9hYmJyLTE+PC9hbHQtcGVyaW9k

aWNhbD48cGFnZXM+NTU0LTg8L3BhZ2VzPjx2b2x1bWU+NDk8L3ZvbHVtZT48bnVtYmVyPjc8L251

bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2VsbCBUcmFu

c2Zvcm1hdGlvbiwgTmVvcGxhc3RpYzwva2V5d29yZD48a2V5d29yZD5DaG9yaW9uaWMgR29uYWRv

dHJvcGluLCBiZXRhIFN1YnVuaXQsIEh1bWFuLypibG9vZDwva2V5d29yZD48a2V5d29yZD5GZW1h

bGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkh5ZGF0aWRpZm9y

bSBNb2xlL2Jsb29kLypkaWFnbm9zdGljIGltYWdpbmc8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZGlj

dGl2ZSBWYWx1ZSBvZiBUZXN0czwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3k8L2tleXdvcmQ+

PGtleXdvcmQ+UHJlZ25hbmN5IENvbXBsaWNhdGlvbnMsIE5lb3BsYXN0aWMvYmxvb2QvKmRpYWdu

b3N0aWMgaW1hZ2luZzwva2V5d29yZD48a2V5d29yZD4qUHJlZ25hbmN5LCBNdWx0aXBsZTwva2V5

d29yZD48a2V5d29yZD5VbHRyYXNvbm9ncmFwaHk8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBO

ZW9wbGFzbXMvYmxvb2QvKmRpYWdub3N0aWMgaW1hZ2luZzwva2V5d29yZD48L2tleXdvcmRzPjxk

YXRlcz48eWVhcj4yMDA0PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRlPjwvcHViLWRh

dGVzPjwvZGF0ZXM+PGlzYm4+MDAyNC03NzU4IChQcmludCkmI3hEOzAwMjQtNzc1OCAoTGlua2lu

Zyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MTUzMDU4Mjc8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJl

bGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMTUzMDU4

Mjc8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TdGVpZ3JhZDwvQXV0aG9yPjxZZWFyPjIwMDQ8L1llYXI+

PFJlY051bT4yMTIwPC9SZWNOdW0+PERpc3BsYXlUZXh0PigxOCk8L0Rpc3BsYXlUZXh0PjxyZWNv

cmQ+PHJlYy1udW1iZXI+MjEyMDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF

TiIgZGItaWQ9IjBmczVhMHQ1ZHJ2enZ2ZWZmejF2YXdyOHR6cnZwdzAwdHAydiIgdGltZXN0YW1w

PSIxNTM5MjI5ODA1Ij4yMTIwPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9Ikpv

dXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhv

cj5TdGVpZ3JhZCwgUy4gSi48L2F1dGhvcj48YXV0aG9yPlJvYmVydHNvbiwgRy48L2F1dGhvcj48

YXV0aG9yPktheWUsIEEuIEwuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRo

LWFkZHJlc3M+VHJvcGhvYmxhc3RpYyBEaXNlYXNlIFJlZmVycmFsIFVuaXQsIFJveWFsIEhvc3Bp

dGFsIGZvciBXb21lbiwgUmFuZHdpY2ssIE5ldyBTb3V0aCBXYWxlcywgQXVzdHJhbGlhLiBzdGVp

Z3JhZHNAc2VzYWhzLm5zdy5nb3YuYXU8L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5TZXJp

YWwgaENHIGFuZCB1bHRyYXNvdW5kIG1lYXN1cmVtZW50cyBmb3IgcHJlZGljdGluZyBtYWxpZ25h

bnQgcG90ZW50aWFsIGluIG11bHRpcGxlIHByZWduYW5jaWVzIGFzc29jaWF0ZWQgd2l0aCBjb21w

bGV0ZSBoeWRhdGlkaWZvcm0gbW9sZTogYSByZXBvcnQgb2YgMiBjYXNlczwvdGl0bGU+PHNlY29u

ZGFyeS10aXRsZT5KIFJlcHJvZCBNZWQ8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPlRoZSBK

b3VybmFsIG9mIHJlcHJvZHVjdGl2ZSBtZWRpY2luZTwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJp

b2RpY2FsPjxmdWxsLXRpdGxlPkogUmVwcm9kIE1lZDwvZnVsbC10aXRsZT48YWJici0xPlRoZSBK

b3VybmFsIG9mIHJlcHJvZHVjdGl2ZSBtZWRpY2luZTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0

LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SiBSZXByb2QgTWVkPC9mdWxsLXRpdGxlPjxhYmJyLTE+

VGhlIEpvdXJuYWwgb2YgcmVwcm9kdWN0aXZlIG1lZGljaW5lPC9hYmJyLTE+PC9hbHQtcGVyaW9k

aWNhbD48cGFnZXM+NTU0LTg8L3BhZ2VzPjx2b2x1bWU+NDk8L3ZvbHVtZT48bnVtYmVyPjc8L251

bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+Q2VsbCBUcmFu

c2Zvcm1hdGlvbiwgTmVvcGxhc3RpYzwva2V5d29yZD48a2V5d29yZD5DaG9yaW9uaWMgR29uYWRv

dHJvcGluLCBiZXRhIFN1YnVuaXQsIEh1bWFuLypibG9vZDwva2V5d29yZD48a2V5d29yZD5GZW1h

bGU8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3b3JkPkh5ZGF0aWRpZm9y

bSBNb2xlL2Jsb29kLypkaWFnbm9zdGljIGltYWdpbmc8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZGlj

dGl2ZSBWYWx1ZSBvZiBUZXN0czwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3k8L2tleXdvcmQ+

PGtleXdvcmQ+UHJlZ25hbmN5IENvbXBsaWNhdGlvbnMsIE5lb3BsYXN0aWMvYmxvb2QvKmRpYWdu

b3N0aWMgaW1hZ2luZzwva2V5d29yZD48a2V5d29yZD4qUHJlZ25hbmN5LCBNdWx0aXBsZTwva2V5

d29yZD48a2V5d29yZD5VbHRyYXNvbm9ncmFwaHk8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBO

ZW9wbGFzbXMvYmxvb2QvKmRpYWdub3N0aWMgaW1hZ2luZzwva2V5d29yZD48L2tleXdvcmRzPjxk

YXRlcz48eWVhcj4yMDA0PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRlPjwvcHViLWRh

dGVzPjwvZGF0ZXM+PGlzYm4+MDAyNC03NzU4IChQcmludCkmI3hEOzAwMjQtNzc1OCAoTGlua2lu

Zyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MTUzMDU4Mjc8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJl

bGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJtZWQvMTUzMDU4

Mjc8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA (18)higher risk of developing maternal complications probability of achieving a viable baby 40% (most pregnancies result in preterm labour, or premature fetal death) PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TZWJpcmU8L0F1dGhvcj48WWVhcj4yMDAyPC9ZZWFyPjxS

ZWNOdW0+MjEyNDwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oMTksIDIwKTwvRGlzcGxheVRleHQ+PHJl

Y29yZD48cmVjLW51bWJlcj4yMTI0PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9

IkVOIiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3Rh

bXA9IjE1MzkyMjk4NzQiPjIxMjQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0i

Sm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0

aG9yPlNlYmlyZSwgTi4gSi48L2F1dGhvcj48YXV0aG9yPkZvc2tldHQsIE0uPC9hdXRob3I+PGF1

dGhvcj5QYXJhZGluYXMsIEYuIEouPC9hdXRob3I+PGF1dGhvcj5GaXNoZXIsIFIuIEEuPC9hdXRo

b3I+PGF1dGhvcj5GcmFuY2lzLCBSLiBKLjwvYXV0aG9yPjxhdXRob3I+U2hvcnQsIEQuPC9hdXRo

b3I+PGF1dGhvcj5OZXdsYW5kcywgRS4gUy48L2F1dGhvcj48YXV0aG9yPlNlY2tsLCBNLiBKLjwv

YXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPlRyb3Bob2JsYXN0

aWMgRGlzZWFzZSBVbml0LCBEZXBhcnRtZW50IG9mIEhpc3RvcGF0aG9sb2d5LCBJbXBlcmlhbCBD

b2xsZWdlIFNjaG9vbCBvZiBNZWRpY2luZSBhdCBDaGFyaW5nIENyb3NzIEhvc3BpdGFsLCBMb25k

b24gVzYgOFJGLCBVSy48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5PdXRjb21lIG9mIHR3

aW4gcHJlZ25hbmNpZXMgd2l0aCBjb21wbGV0ZSBoeWRhdGlkaWZvcm0gbW9sZSBhbmQgaGVhbHRo

eSBjby10d2luPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkxhbmNldDwvc2Vjb25kYXJ5LXRpdGxl

PjxhbHQtdGl0bGU+TGFuY2V0PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwt

dGl0bGU+TGFuY2V0PC9mdWxsLXRpdGxlPjxhYmJyLTE+TGFuY2V0PC9hYmJyLTE+PC9wZXJpb2Rp

Y2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5MYW5jZXQ8L2Z1bGwtdGl0bGU+PGFiYnIt

MT5MYW5jZXQ8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4yMTY1LTY8L3BhZ2VzPjx2

b2x1bWU+MzU5PC92b2x1bWU+PG51bWJlcj45MzI0PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3Jk

PkFib3J0aW9uLCBTcG9udGFuZW91cy8qZXRpb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxl

PC9rZXl3b3JkPjxrZXl3b3JkPkZldGFsIERlYXRoLypldGlvbG9neTwva2V5d29yZD48a2V5d29y

ZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SHlkYXRpZGlmb3JtIE1vbGUvKmNvbXBsaWNhdGlv

bnM8L2tleXdvcmQ+PGtleXdvcmQ+SW5mYW50LCBOZXdib3JuPC9rZXl3b3JkPjxrZXl3b3JkPlBy

ZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3kgQ29tcGxpY2F0aW9ucywgTmVvcGxh

c3RpYy8qcGh5c2lvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPipQcmVnbmFuY3kgT3V0Y29t

ZTwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+KlR3aW5z

PC9rZXl3b3JkPjxrZXl3b3JkPlV0ZXJpbmUgTmVvcGxhc21zLypjb21wbGljYXRpb25zPC9rZXl3

b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDI8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5K

dW4gMjI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMTQwLTY3MzYgKFByaW50KSYj

eEQ7MDE0MC02NzM2IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4xMjA5MDk4NDwvYWNj

ZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5u

aWguZ292L3B1Ym1lZC8xMjA5MDk4NDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ry

b25pYy1yZXNvdXJjZS1udW0+MTAuMTAxNi9TMDE0MC02NzM2KDAyKTA5MDg1LTI8L2VsZWN0cm9u

aWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlZlamVyc2xldjwv

QXV0aG9yPjxZZWFyPjE5OTE8L1llYXI+PFJlY051bT4yMTI2PC9SZWNOdW0+PHJlY29yZD48cmVj

LW51bWJlcj4yMTI2PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9IjE1Mzky

Mjk5MjQiPjIxMjY8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlZlamVy

c2xldiwgTC4gTy48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVz

cz5EZXBhcnRtZW50IG9mIE9ic3RldHJpY3MgYW5kIEd5bmVjb2xvZ3ksIEh2aWRvdnJlIEhvc3Bp

dGFsLCBVbml2ZXJzaXR5IG9mIENvcGVuaGFnZW4sIERlbm1hcmsuPC9hdXRoLWFkZHJlc3M+PHRp

dGxlcz48dGl0bGU+Q2xpbmljYWwgbWFuYWdlbWVudCBhbmQgZGlhZ25vc3RpYyBwb3NzaWJpbGl0

aWVzIGluIGh5ZGF0aWRpZm9ybSBtb2xlIHdpdGggY29leGlzdGVudCBmZXR1czwvdGl0bGU+PHNl

Y29uZGFyeS10aXRsZT5PYnN0ZXQgR3luZWNvbCBTdXJ2PC9zZWNvbmRhcnktdGl0bGU+PGFsdC10

aXRsZT5PYnN0ZXRyaWNhbCAmYW1wOyBneW5lY29sb2dpY2FsIHN1cnZleTwvYWx0LXRpdGxlPjwv

dGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPk9ic3RldCBHeW5lY29sIFN1cnY8L2Z1bGwt

dGl0bGU+PGFiYnItMT5PYnN0ZXRyaWNhbCAmYW1wOyBneW5lY29sb2dpY2FsIHN1cnZleTwvYWJi

ci0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+T2JzdGV0IEd5bmVj

b2wgU3VydjwvZnVsbC10aXRsZT48YWJici0xPk9ic3RldHJpY2FsICZhbXA7IGd5bmVjb2xvZ2lj

YWwgc3VydmV5PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+NTc3LTg4PC9wYWdlcz48

dm9sdW1lPjQ2PC92b2x1bWU+PG51bWJlcj45PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkNo

b3Jpb25pYyBHb25hZG90cm9waW4vYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3

b3JkPjxrZXl3b3JkPipGZXR1czwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtl

eXdvcmQ+SHlkYXRpZGlmb3JtIE1vbGUvKmRpYWdub3Npcy9nZW5ldGljczwva2V5d29yZD48a2V5

d29yZD5LYXJ5b3R5cGluZzwva2V5d29yZD48a2V5d29yZD5NYWduZXRpYyBSZXNvbmFuY2UgSW1h

Z2luZzwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25h

bmN5IENvbXBsaWNhdGlvbnM8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5IE91dGNvbWU8L2tl

eXdvcmQ+PGtleXdvcmQ+KlByZW5hdGFsIENhcmUvbWV0aG9kczwva2V5d29yZD48a2V5d29yZD4q

UHJlbmF0YWwgRGlhZ25vc2lzPC9rZXl3b3JkPjxrZXl3b3JkPlVsdHJhc29ub2dyYXBoeSwgUHJl

bmF0YWw8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBOZW9wbGFzbXMvKmRpYWdub3Npcy9nZW5l

dGljczwva2V5d29yZD48a2V5d29yZD5hbHBoYS1GZXRvcHJvdGVpbnMvbWV0YWJvbGlzbTwva2V5

d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4xOTkxPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+

U2VwPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MDAyOS03ODI4IChQcmludCkmI3hE

OzAwMjktNzgyOCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MTcyMDg4MzwvYWNjZXNz

aW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWgu

Z292L3B1Ym1lZC8xNzIwODgzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwv

Q2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TZWJpcmU8L0F1dGhvcj48WWVhcj4yMDAyPC9ZZWFyPjxS

ZWNOdW0+MjEyNDwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oMTksIDIwKTwvRGlzcGxheVRleHQ+PHJl

Y29yZD48cmVjLW51bWJlcj4yMTI0PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9

IkVOIiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3Rh

bXA9IjE1MzkyMjk4NzQiPjIxMjQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0i

Sm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0

aG9yPlNlYmlyZSwgTi4gSi48L2F1dGhvcj48YXV0aG9yPkZvc2tldHQsIE0uPC9hdXRob3I+PGF1

dGhvcj5QYXJhZGluYXMsIEYuIEouPC9hdXRob3I+PGF1dGhvcj5GaXNoZXIsIFIuIEEuPC9hdXRo

b3I+PGF1dGhvcj5GcmFuY2lzLCBSLiBKLjwvYXV0aG9yPjxhdXRob3I+U2hvcnQsIEQuPC9hdXRo

b3I+PGF1dGhvcj5OZXdsYW5kcywgRS4gUy48L2F1dGhvcj48YXV0aG9yPlNlY2tsLCBNLiBKLjwv

YXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPlRyb3Bob2JsYXN0

aWMgRGlzZWFzZSBVbml0LCBEZXBhcnRtZW50IG9mIEhpc3RvcGF0aG9sb2d5LCBJbXBlcmlhbCBD

b2xsZWdlIFNjaG9vbCBvZiBNZWRpY2luZSBhdCBDaGFyaW5nIENyb3NzIEhvc3BpdGFsLCBMb25k

b24gVzYgOFJGLCBVSy48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5PdXRjb21lIG9mIHR3

aW4gcHJlZ25hbmNpZXMgd2l0aCBjb21wbGV0ZSBoeWRhdGlkaWZvcm0gbW9sZSBhbmQgaGVhbHRo

eSBjby10d2luPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkxhbmNldDwvc2Vjb25kYXJ5LXRpdGxl

PjxhbHQtdGl0bGU+TGFuY2V0PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwt

dGl0bGU+TGFuY2V0PC9mdWxsLXRpdGxlPjxhYmJyLTE+TGFuY2V0PC9hYmJyLTE+PC9wZXJpb2Rp

Y2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5MYW5jZXQ8L2Z1bGwtdGl0bGU+PGFiYnIt

MT5MYW5jZXQ8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4yMTY1LTY8L3BhZ2VzPjx2

b2x1bWU+MzU5PC92b2x1bWU+PG51bWJlcj45MzI0PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3Jk

PkFib3J0aW9uLCBTcG9udGFuZW91cy8qZXRpb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxl

PC9rZXl3b3JkPjxrZXl3b3JkPkZldGFsIERlYXRoLypldGlvbG9neTwva2V5d29yZD48a2V5d29y

ZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SHlkYXRpZGlmb3JtIE1vbGUvKmNvbXBsaWNhdGlv

bnM8L2tleXdvcmQ+PGtleXdvcmQ+SW5mYW50LCBOZXdib3JuPC9rZXl3b3JkPjxrZXl3b3JkPlBy

ZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3kgQ29tcGxpY2F0aW9ucywgTmVvcGxh

c3RpYy8qcGh5c2lvcGF0aG9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPipQcmVnbmFuY3kgT3V0Y29t

ZTwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+KlR3aW5z

PC9rZXl3b3JkPjxrZXl3b3JkPlV0ZXJpbmUgTmVvcGxhc21zLypjb21wbGljYXRpb25zPC9rZXl3

b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDI8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5K

dW4gMjI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMTQwLTY3MzYgKFByaW50KSYj

eEQ7MDE0MC02NzM2IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4xMjA5MDk4NDwvYWNj

ZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5u

aWguZ292L3B1Ym1lZC8xMjA5MDk4NDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ry

b25pYy1yZXNvdXJjZS1udW0+MTAuMTAxNi9TMDE0MC02NzM2KDAyKTA5MDg1LTI8L2VsZWN0cm9u

aWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlZlamVyc2xldjwv

QXV0aG9yPjxZZWFyPjE5OTE8L1llYXI+PFJlY051bT4yMTI2PC9SZWNOdW0+PHJlY29yZD48cmVj

LW51bWJlcj4yMTI2PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p

ZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9IjE1Mzky

Mjk5MjQiPjIxMjY8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlZlamVy

c2xldiwgTC4gTy48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVz

cz5EZXBhcnRtZW50IG9mIE9ic3RldHJpY3MgYW5kIEd5bmVjb2xvZ3ksIEh2aWRvdnJlIEhvc3Bp

dGFsLCBVbml2ZXJzaXR5IG9mIENvcGVuaGFnZW4sIERlbm1hcmsuPC9hdXRoLWFkZHJlc3M+PHRp

dGxlcz48dGl0bGU+Q2xpbmljYWwgbWFuYWdlbWVudCBhbmQgZGlhZ25vc3RpYyBwb3NzaWJpbGl0

aWVzIGluIGh5ZGF0aWRpZm9ybSBtb2xlIHdpdGggY29leGlzdGVudCBmZXR1czwvdGl0bGU+PHNl

Y29uZGFyeS10aXRsZT5PYnN0ZXQgR3luZWNvbCBTdXJ2PC9zZWNvbmRhcnktdGl0bGU+PGFsdC10

aXRsZT5PYnN0ZXRyaWNhbCAmYW1wOyBneW5lY29sb2dpY2FsIHN1cnZleTwvYWx0LXRpdGxlPjwv

dGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPk9ic3RldCBHeW5lY29sIFN1cnY8L2Z1bGwt

dGl0bGU+PGFiYnItMT5PYnN0ZXRyaWNhbCAmYW1wOyBneW5lY29sb2dpY2FsIHN1cnZleTwvYWJi

ci0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+T2JzdGV0IEd5bmVj

b2wgU3VydjwvZnVsbC10aXRsZT48YWJici0xPk9ic3RldHJpY2FsICZhbXA7IGd5bmVjb2xvZ2lj

YWwgc3VydmV5PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+NTc3LTg4PC9wYWdlcz48

dm9sdW1lPjQ2PC92b2x1bWU+PG51bWJlcj45PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkNo

b3Jpb25pYyBHb25hZG90cm9waW4vYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3

b3JkPjxrZXl3b3JkPipGZXR1czwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtl

eXdvcmQ+SHlkYXRpZGlmb3JtIE1vbGUvKmRpYWdub3Npcy9nZW5ldGljczwva2V5d29yZD48a2V5

d29yZD5LYXJ5b3R5cGluZzwva2V5d29yZD48a2V5d29yZD5NYWduZXRpYyBSZXNvbmFuY2UgSW1h

Z2luZzwva2V5d29yZD48a2V5d29yZD5QcmVnbmFuY3k8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25h

bmN5IENvbXBsaWNhdGlvbnM8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5IE91dGNvbWU8L2tl

eXdvcmQ+PGtleXdvcmQ+KlByZW5hdGFsIENhcmUvbWV0aG9kczwva2V5d29yZD48a2V5d29yZD4q

UHJlbmF0YWwgRGlhZ25vc2lzPC9rZXl3b3JkPjxrZXl3b3JkPlVsdHJhc29ub2dyYXBoeSwgUHJl

bmF0YWw8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBOZW9wbGFzbXMvKmRpYWdub3Npcy9nZW5l

dGljczwva2V5d29yZD48a2V5d29yZD5hbHBoYS1GZXRvcHJvdGVpbnMvbWV0YWJvbGlzbTwva2V5

d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4xOTkxPC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+

U2VwPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MDAyOS03ODI4IChQcmludCkmI3hE

OzAwMjktNzgyOCAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MTcyMDg4MzwvYWNjZXNz

aW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWgu

Z292L3B1Ym1lZC8xNzIwODgzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwv

Q2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE.DATA (19, 20) 16DIAGNOSIS OF GESTATIONAL TROPHOBLASTIC NEOPLASIA (GTN)The table below represents the criteria agreed for diagnosis of GTN by the Committee of the International Federation of Gynecology and Obstetrics (FIGO) in September of 2000 Gestational trophoblastic neoplasia is treated by chemotherapy. Criteria for the diagnosis of post hydatidiform mole trophoblastic neoplasia (GTN)GTN may be diagnosed* when the plateau of human chorionic gonadatrophin (hCG) lasts for 4 measurements over a period of 3 weeks or longer, that is days 1,7,14,21.GTN may be diagnosed* when there is a rise of hCG on three consecutive weekly measurements, over a period of two weeks or longer, days 1,7,14.GTN is diagnosed if there is histologic diagnosis of choriocarcinoma.(GTN is diagnosed when the hCG level remains elevated for 6 months or more**)*The actual level of hCG or the amount of rise will be determined by the individualInvestigator, but a plateau is usually defined as +/- 10%, and rise >10%**This has subsequently been removed as a criteria in 2013 ADDIN EN.CITE <EndNote><Cite><Author>Agarwal</Author><Year>2012</Year><RecNum>2129</RecNum><DisplayText>(21)</DisplayText><record><rec-number>2129</rec-number><foreign-keys><key app="EN" db-id="0fs5a0t5drvzvveffz1vawr8tzrvpw00tp2v" timestamp="1539230034">2129</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Agarwal, R.</author><author>Teoh, S.</author><author>Short, D.</author><author>Harvey, R.</author><author>Savage, P. M.</author><author>Seckl, M. J.</author></authors></contributors><auth-address>Imperial College London, London, UK.</auth-address><titles><title>Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study</title><secondary-title>Lancet</secondary-title><alt-title>Lancet</alt-title></titles><periodical><full-title>Lancet</full-title><abbr-1>Lancet</abbr-1></periodical><alt-periodical><full-title>Lancet</full-title><abbr-1>Lancet</abbr-1></alt-periodical><pages>130-5</pages><volume>379</volume><number>9811</number><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Chorionic Gonadotropin/*analysis</keyword><keyword>Cohort Studies</keyword><keyword>Female</keyword><keyword>Humans</keyword><keyword>Hydatidiform Mole/*drug therapy/metabolism/*surgery</keyword><keyword>Middle Aged</keyword><keyword>Pregnancy</keyword><keyword>Retrospective Studies</keyword><keyword>Time Factors</keyword></keywords><dates><year>2012</year><pub-dates><date>Jan 14</date></pub-dates></dates><isbn>1474-547X (Electronic)&#xD;0140-6736 (Linking)</isbn><accession-num>22130490</accession-num><urls><related-urls><url>(11)61265-8</electronic-resource-num></record></Cite></EndNote>(21) Other factors may be also taken into account by the medical oncologist such as evidence of brain, liver, renal or gastro-intestinal tract metastases, lung metastases >2cm, or a serum tumour hCG > 20,000 IU/L more than four weeks after evacuation.The exclusion of a new pregnancy is essential when evaluating patients with a tumour hCG rise. 17STAGING OF GESTATIONAL TROPHOBLASTIC NEOPLASIAAll patients with GTN should have history and physical examination as above outlined under GTD.Blood tests Baseline t hCGFBC, U&EThyroid function testsCoagulation StatusHBsAgConsider cross-match if heavy bleeding. Radiology Chest X ray (relevant for scoring system below)Pelvic ultrasound (trans-vaginal is preferable) CT abdomen and pelvis and MRI Brain if pulmonary metastasis detected or abnormal findings on exam / symptoms Urine creatinine clearance in patients for EP/EMA or high dose methotrexate. Patients with recurrent GTN should be fully restaged, with all blood tests as above, CT chest abdomen and pelvis, MRI brain, and lumbar puncture for CSF hCG to exclude the CNS acting as a sanctuary site. 18RISK ASSESSMENT IN GESTATIONAL TROPHOBLASTIC NEOPLASIA If a patient on follow-up meets any of the criteria for chemotherapy, their risk will be assessed by the FIGO 2000 criteria below ADDIN EN.CITE <EndNote><Cite><Author>Kohorn</Author><Year>2001</Year><RecNum>2130</RecNum><DisplayText>(22)</DisplayText><record><rec-number>2130</rec-number><foreign-keys><key app="EN" db-id="0fs5a0t5drvzvveffz1vawr8tzrvpw00tp2v" timestamp="1539230113">2130</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kohorn, E. I.</author></authors></contributors><auth-address>Yale Trophoblast Center, Yale University School of Medicine, New Haven, Connecticut, USA. ernest.kohorn@yale.edu</auth-address><titles><title>The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment</title><secondary-title>Int J Gynecol Cancer</secondary-title><alt-title>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</alt-title></titles><periodical><full-title>Int J Gynecol Cancer</full-title><abbr-1>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</abbr-1></periodical><alt-periodical><full-title>Int J Gynecol Cancer</full-title><abbr-1>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</abbr-1></alt-periodical><pages>73-7</pages><volume>11</volume><number>1</number><keywords><keyword>Female</keyword><keyword>Humans</keyword><keyword>*Neoplasm Staging</keyword><keyword>*Practice Guidelines as Topic</keyword><keyword>Pregnancy</keyword><keyword>Risk Factors</keyword><keyword>Societies, Medical</keyword><keyword>Trophoblastic Neoplasms/*classification/*pathology</keyword><keyword>Uterine Neoplasms/*classification/*pathology</keyword></keywords><dates><year>2001</year><pub-dates><date>Jan-Feb</date></pub-dates></dates><isbn>1048-891X (Print)&#xD;1048-891X (Linking)</isbn><accession-num>11285037</accession-num><urls><related-urls><url>;(22). Low risk patients are those with a score of 6 or below, High risk patients have a score of 7 or over. FIGO score0124Age<40>40AntecedentpregnancyMoleAbortionTermInterval months from index pregnancy<4 mo4-<77-<13>13Pre-treatment serum hCG (IU/l)<103103 < 104104 -<105>105Largest tumour size (including uterine tumour)<3 cm3-<5cm>5 cmSite of metastasesLung *SpleenkidneyGITBrainliverNumber of metastases01 - 45 - 8>8Previous failed chemotherapySingle drug>2 drugsNotes: 1. The interval months from pregnancy is taken from when the pregnancy ended (not started)2. The score for site of metastases is not additive. The highest scoring organ is taken to be the score (e.g. A patient with gastrointestinal and brain metastases scores 4, not 6)3. * lung metastasis counted on CXR not on a Chest CT 19CHEMOTHERAPY IN GESTATIONAL TROPHOBLASTIC NEOPLASIA All patients requiring chemotherapy including methotrexate should be managed by a Medical OncologistMost patients will be low risk, and therefore treated with methotrexate intramuscularlyThis is a generally well tolerated 2 weekly outpatient regimen with few side effectsThis continues until hCG has normalised plus an additional 3 cycles (i.e 6 weeks after normalisation). About 1 in 3-4 of these women will become resistant to this chemotherapy, and will then generally then require combination chemotherapy with EMA-CO or Actinomycin. A small number of women may become intolerant of methotrexate and need to switch regimens. Patients with high risk score or recurrent disease need to be discussed at MDMSample guideline chemotherapy regimens are included in Appendix 3. 20FOLLOW-UP POST CHEMOTHERAPY Medical Oncologist will often refer back to General Gynaecologist or Gynae Oncologists for further follow up after completion of chemotherapyPatients undergoing follow-up after diagnosis of GTD or GTN should only have thCG measured (if this is available). Consistency is essential as treatment decisions are based on small changes in the hCG.Initial post chemo follow-up is recommended to re-check the sites of original disease (e.g. TVUSS, CT, MRI as appropriate) and give advice as in the section below.If the tumour hCG becomes abnormal again at any time after chemotherapy, pregnancy should be excluded first. The tumour hCG should be checked again immediately, and an urgent referral made to Medical Oncology. Follow up schedule: based on European and USA international guidelines. ( note Charing cross follow up indefinitely for data gathering purposes.)Low risk GTN: (post Mtx/actinomycin): Follow up with monthly tHCG’s for 12 months.High risk GTN: (post EMA-CO or equivalent): Follow up with monthly tHCG’s for 2 years.PSTT/ETT: Follow up for minimum of 5 years - HCG’s plus appropriate imaging.21ADVICE TO PATIENTS AFTER CHEMOTHERAPYRisk of relapseIn the largest published series of over 1700 patients, 60 (3.5%) relapsed 35 (58%) of initially low risk, and 25 (42%) of initially high risk. The median time to relapse was 4 months, 73% relapsed within a year of chemotherapy, and 85% within 2 years. Only 1 of the 60 relapses occurred after 5 years PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Qb3dsZXM8L0F1dGhvcj48WWVhcj4yMDA3PC9ZZWFyPjxS

ZWNOdW0+MjEzMjwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oMjMpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjIxMzI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0i

MTUzOTIzMDE4OSI+MjEzMjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

UG93bGVzLCBULjwvYXV0aG9yPjxhdXRob3I+U2F2YWdlLCBQLiBNLjwvYXV0aG9yPjxhdXRob3I+

U3RlYmJpbmcsIEouPC9hdXRob3I+PGF1dGhvcj5TaG9ydCwgRC48L2F1dGhvcj48YXV0aG9yPllv

dW5nLCBBLjwvYXV0aG9yPjxhdXRob3I+Qm93ZXIsIE0uPC9hdXRob3I+PGF1dGhvcj5QYXBwaW4s

IEMuPC9hdXRob3I+PGF1dGhvcj5TY2htaWQsIFAuPC9hdXRob3I+PGF1dGhvcj5TZWNrbCwgTS4g

Si48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRt

ZW50IG9mIE1lZGljYWwgT25jb2xvZ3ksIENoYXJpbmcgQ3Jvc3MgR2VzdGF0aW9uYWwgVHJvcGhv

Ymxhc3RpYyBEaXNlYXNlIENlbnRyZSwgSGFtbWVyc21pdGggSG9zcGl0YWxzIENhbXB1cyBvZiBJ

bXBlcmlhbCBDb2xsZWdlIExvbmRvbiwgTG9uZG9uLCBVSy4gdGhvbWFzLnBvd2VzQGJhcnRzYW5k

dGhlbG9uZG9uLm5ocy51azwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkEgY29tcGFyaXNv

biBvZiBwYXRpZW50cyB3aXRoIHJlbGFwc2VkIGFuZCBjaGVtby1yZWZyYWN0b3J5IGdlc3RhdGlv

bmFsIHRyb3Bob2JsYXN0aWMgbmVvcGxhc2lhPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkJyIEog

Q2FuY2VyPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5Ccml0aXNoIGpvdXJuYWwgb2YgY2Fu

Y2VyPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QnIgSiBDYW5j

ZXI8L2Z1bGwtdGl0bGU+PGFiYnItMT5Ccml0aXNoIGpvdXJuYWwgb2YgY2FuY2VyPC9hYmJyLTE+

PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5CciBKIENhbmNlcjwvZnVs

bC10aXRsZT48YWJici0xPkJyaXRpc2ggam91cm5hbCBvZiBjYW5jZXI8L2FiYnItMT48L2FsdC1w

ZXJpb2RpY2FsPjxwYWdlcz43MzItNzwvcGFnZXM+PHZvbHVtZT45Njwvdm9sdW1lPjxudW1iZXI+

NTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZ2Ugb2YgT25zZXQ8L2tleXdvcmQ+PGtleXdv

cmQ+QW50aW5lb3BsYXN0aWMgQ29tYmluZWQgQ2hlbW90aGVyYXB5IFByb3RvY29scy8qdGhlcmFw

ZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPkNob3Jpb25pYyBHb25hZG90cm9waW4vYmxvb2Q8

L2tleXdvcmQ+PGtleXdvcmQ+KkRydWcgUmVzaXN0YW5jZSwgTmVvcGxhc208L2tleXdvcmQ+PGtl

eXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkdlc3RhdGlvbmFsIFRyb3Bob2JsYXN0aWMg

RGlzZWFzZS8qZHJ1ZyB0aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48

a2V5d29yZD5OZW9wbGFzbSBSZWN1cnJlbmNlLCBMb2NhbC8qZHJ1ZyB0aGVyYXB5PC9rZXl3b3Jk

PjxrZXl3b3JkPlByZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5Qcm9nbm9zaXM8L2tleXdvcmQ+

PGtleXdvcmQ+VGltZSBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlRyZWF0bWVudCBPdXRjb21l

PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDc8L3llYXI+PHB1Yi1kYXRlcz48

ZGF0ZT5NYXIgMTI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMDA3LTA5MjAgKFBy

aW50KSYjeEQ7MDAwNy0wOTIwIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4xNzI5OTM5

NDwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2Jp

Lm5sbS5uaWguZ292L3B1Ym1lZC8xNzI5OTM5NDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48

Y3VzdG9tMj4yMzYwMDgyPC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDM4

L3NqLmJqYy42NjAzNjA4PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+

PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Qb3dsZXM8L0F1dGhvcj48WWVhcj4yMDA3PC9ZZWFyPjxS

ZWNOdW0+MjEzMjwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oMjMpPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjIxMzI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSIwZnM1YTB0NWRydnp2dmVmZnoxdmF3cjh0enJ2cHcwMHRwMnYiIHRpbWVzdGFtcD0i

MTUzOTIzMDE4OSI+MjEzMjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

UG93bGVzLCBULjwvYXV0aG9yPjxhdXRob3I+U2F2YWdlLCBQLiBNLjwvYXV0aG9yPjxhdXRob3I+

U3RlYmJpbmcsIEouPC9hdXRob3I+PGF1dGhvcj5TaG9ydCwgRC48L2F1dGhvcj48YXV0aG9yPllv

dW5nLCBBLjwvYXV0aG9yPjxhdXRob3I+Qm93ZXIsIE0uPC9hdXRob3I+PGF1dGhvcj5QYXBwaW4s

IEMuPC9hdXRob3I+PGF1dGhvcj5TY2htaWQsIFAuPC9hdXRob3I+PGF1dGhvcj5TZWNrbCwgTS4g

Si48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRt

ZW50IG9mIE1lZGljYWwgT25jb2xvZ3ksIENoYXJpbmcgQ3Jvc3MgR2VzdGF0aW9uYWwgVHJvcGhv

Ymxhc3RpYyBEaXNlYXNlIENlbnRyZSwgSGFtbWVyc21pdGggSG9zcGl0YWxzIENhbXB1cyBvZiBJ

bXBlcmlhbCBDb2xsZWdlIExvbmRvbiwgTG9uZG9uLCBVSy4gdGhvbWFzLnBvd2VzQGJhcnRzYW5k

dGhlbG9uZG9uLm5ocy51azwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPkEgY29tcGFyaXNv

biBvZiBwYXRpZW50cyB3aXRoIHJlbGFwc2VkIGFuZCBjaGVtby1yZWZyYWN0b3J5IGdlc3RhdGlv

bmFsIHRyb3Bob2JsYXN0aWMgbmVvcGxhc2lhPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkJyIEog

Q2FuY2VyPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5Ccml0aXNoIGpvdXJuYWwgb2YgY2Fu

Y2VyPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QnIgSiBDYW5j

ZXI8L2Z1bGwtdGl0bGU+PGFiYnItMT5Ccml0aXNoIGpvdXJuYWwgb2YgY2FuY2VyPC9hYmJyLTE+

PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5CciBKIENhbmNlcjwvZnVs

bC10aXRsZT48YWJici0xPkJyaXRpc2ggam91cm5hbCBvZiBjYW5jZXI8L2FiYnItMT48L2FsdC1w

ZXJpb2RpY2FsPjxwYWdlcz43MzItNzwvcGFnZXM+PHZvbHVtZT45Njwvdm9sdW1lPjxudW1iZXI+

NTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZ2Ugb2YgT25zZXQ8L2tleXdvcmQ+PGtleXdv

cmQ+QW50aW5lb3BsYXN0aWMgQ29tYmluZWQgQ2hlbW90aGVyYXB5IFByb3RvY29scy8qdGhlcmFw

ZXV0aWMgdXNlPC9rZXl3b3JkPjxrZXl3b3JkPkNob3Jpb25pYyBHb25hZG90cm9waW4vYmxvb2Q8

L2tleXdvcmQ+PGtleXdvcmQ+KkRydWcgUmVzaXN0YW5jZSwgTmVvcGxhc208L2tleXdvcmQ+PGtl

eXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkdlc3RhdGlvbmFsIFRyb3Bob2JsYXN0aWMg

RGlzZWFzZS8qZHJ1ZyB0aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48

a2V5d29yZD5OZW9wbGFzbSBSZWN1cnJlbmNlLCBMb2NhbC8qZHJ1ZyB0aGVyYXB5PC9rZXl3b3Jk

PjxrZXl3b3JkPlByZWduYW5jeTwva2V5d29yZD48a2V5d29yZD5Qcm9nbm9zaXM8L2tleXdvcmQ+

PGtleXdvcmQ+VGltZSBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlRyZWF0bWVudCBPdXRjb21l

PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMDc8L3llYXI+PHB1Yi1kYXRlcz48

ZGF0ZT5NYXIgMTI8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4wMDA3LTA5MjAgKFBy

aW50KSYjeEQ7MDAwNy0wOTIwIChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4xNzI5OTM5

NDwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2Jp

Lm5sbS5uaWguZ292L3B1Ym1lZC8xNzI5OTM5NDwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48

Y3VzdG9tMj4yMzYwMDgyPC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMDM4

L3NqLmJqYy42NjAzNjA4PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+

PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA (23).Time to relapseN =(%)Cumulative (%) 0 - 3 months3151.651.6 3 - 6 months1016.668.2 6 - 12 months 3 5.073.2 12 - 24 months 711.784.9 1 – 5 years 813.598.4> 5 years 1 1.6100ContraceptionAny method may be used after chemotherapy. A delay of at least 6 weeks post chemotherapy is advisable before fitting an IUD. Contraception should be advised for at least one year after the last dose of chemotherapy. This is both to prevent pregnancy obscuring relapse, and to reduce the incidence of abnormal pregnancies.PregnancySee section below. Hormonal Replacment TherapyProvided t hCG levels are normal, there is not known to be any increased risk of recurrence in the use of hormone replacement therapy for those patients with symptomatic premature menopause. Risk of second malignancyThere is no apparent increased risk after Methotrexate and folinic acid. After EMA-CO, the risk ratio over the normal population is 1.5. Myeloid leukaemia is the most common second malignancy followed by breast and colon cancer, and melanoma. 22PREGNANCY AFTER CHEMOTHERAPY FOR GESTATIONAL TROPHOBLASTIC NEOPLASIA Ability to conceive and effect on age of menopauseMost women successfully treated with chemotherapy for GTN can be reassured that their fertility is unlikely to be significantly affected by chemotherapy. A London study of 728 women treated with chemotherapy who subsequently wanted to become pregnant found that 93% conceived and 83% reported at least 1 live birth. There were no apparent differences in conception rates between those who received single agent, and multi-agent chemotherapy ADDIN EN.CITE <EndNote><Cite><Author>Woolas</Author><Year>1998</Year><RecNum>2133</RecNum><DisplayText>(24)</DisplayText><record><rec-number>2133</rec-number><foreign-keys><key app="EN" db-id="0fs5a0t5drvzvveffz1vawr8tzrvpw00tp2v" timestamp="1539230252">2133</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Woolas, R. P.</author><author>Bower, M.</author><author>Newlands, E. S.</author><author>Seckl, M.</author><author>Short, D.</author><author>Holden, L.</author></authors></contributors><auth-address>Department of Gynaecological Oncology, St Mary&apos;s Hospital, Portsmouth, UK.</auth-address><titles><title>Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome</title><secondary-title>Br J Obstet Gynaecol</secondary-title><alt-title>British journal of obstetrics and gynaecology</alt-title></titles><periodical><full-title>Br J Obstet Gynaecol</full-title><abbr-1>British journal of obstetrics and gynaecology</abbr-1></periodical><alt-periodical><full-title>Br J Obstet Gynaecol</full-title><abbr-1>British journal of obstetrics and gynaecology</abbr-1></alt-periodical><pages>1032-5</pages><volume>105</volume><number>9</number><keywords><keyword>Adolescent</keyword><keyword>Adult</keyword><keyword>Age of Onset</keyword><keyword>Antineoplastic Combined Chemotherapy Protocols/*therapeutic use</keyword><keyword>Female</keyword><keyword>Follow-Up Studies</keyword><keyword>Humans</keyword><keyword>Pregnancy</keyword><keyword>*Pregnancy Outcome</keyword><keyword>Reproductive Medicine</keyword><keyword>Trophoblastic Tumor, Placental Site/*drug therapy</keyword><keyword>Uterine Neoplasms/*drug therapy</keyword></keywords><dates><year>1998</year><pub-dates><date>Sep</date></pub-dates></dates><isbn>0306-5456 (Print)&#xD;0306-5456 (Linking)</isbn><accession-num>9763059</accession-num><urls><related-urls><url>;(24). While chemotherapy does hasten menopause, this is only by a small amount in the majority of patients (2-3 years) PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Cb3dlcjwvQXV0aG9yPjxZZWFyPjE5OTg8L1llYXI+PFJl

Y051bT4yMTM0PC9SZWNOdW0+PERpc3BsYXlUZXh0PigyNSk8L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+MjEzNDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIg

ZGItaWQ9IjBmczVhMHQ1ZHJ2enZ2ZWZmejF2YXdyOHR6cnZwdzAwdHAydiIgdGltZXN0YW1wPSIx

NTM5MjMwMzA0Ij4yMTM0PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu

YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5C

b3dlciwgTS48L2F1dGhvcj48YXV0aG9yPlJ1c3RpbiwgRy4gSi48L2F1dGhvcj48YXV0aG9yPk5l

d2xhbmRzLCBFLiBTLjwvYXV0aG9yPjxhdXRob3I+SG9sZGVuLCBMLjwvYXV0aG9yPjxhdXRob3I+

U2hvcnQsIEQuPC9hdXRob3I+PGF1dGhvcj5Gb3NrZXR0LCBNLjwvYXV0aG9yPjxhdXRob3I+QmFn

c2hhd2UsIEsuIEQuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJl

c3M+TWVkaWNhbCBPbmNvbG9neSBVbml0LCBDaGFyaW5nIENyb3NzIEhvc3BpdGFsLCBMb25kb24s

IFUuSy48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5DaGVtb3RoZXJhcHkgZm9yIGdlc3Rh

dGlvbmFsIHRyb3Bob2JsYXN0aWMgdHVtb3VycyBoYXN0ZW5zIG1lbm9wYXVzZSBieSAzIHllYXJz

PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkV1ciBKIENhbmNlcjwvc2Vjb25kYXJ5LXRpdGxlPjxh

bHQtdGl0bGU+RXVyb3BlYW4gam91cm5hbCBvZiBjYW5jZXI8L2FsdC10aXRsZT48L3RpdGxlcz48

cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5FdXIgSiBDYW5jZXI8L2Z1bGwtdGl0bGU+PGFiYnItMT5F

dXJvcGVhbiBqb3VybmFsIG9mIGNhbmNlcjwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+RXVyIEogQ2FuY2VyPC9mdWxsLXRpdGxlPjxhYmJyLTE+RXVyb3Bl

YW4gam91cm5hbCBvZiBjYW5jZXI8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4xMjA0

LTc8L3BhZ2VzPjx2b2x1bWU+MzQ8L3ZvbHVtZT48bnVtYmVyPjg8L251bWJlcj48a2V5d29yZHM+

PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMgQWdlbnRzLyph

ZHZlcnNlIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+Q2hvcmlvY2FyY2lub21hLypkcnVnIHRo

ZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+RGFjdGlub215Y2luL2FkdmVyc2UgZWZmZWN0czwva2V5

d29yZD48a2V5d29yZD5FdG9wb3NpZGUvYWR2ZXJzZSBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3Jk

PkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5Gb2xsb3ctVXAgU3R1ZGllczwva2V5d29yZD48a2V5

d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SHlkcm94eXVyZWEvYWR2ZXJzZSBlZmZlY3Rz

PC9rZXl3b3JkPjxrZXl3b3JkPkxldWNvdm9yaW4vYWR2ZXJzZSBlZmZlY3RzPC9rZXl3b3JkPjxr

ZXl3b3JkPk1lbm9wYXVzZSwgUHJlbWF0dXJlLypkcnVnIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdv

cmQ+TWVyY2FwdG9wdXJpbmUvYWR2ZXJzZSBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3JkPk1ldGhv

dHJleGF0ZS9hZHZlcnNlIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxlIEFnZWQ8L2tl

eXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlJldHJvc3BlY3RpdmUg

U3R1ZGllczwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+

VHJvcGhvYmxhc3RpYyBOZW9wbGFzbXMvKmRydWcgdGhlcmFweTwva2V5d29yZD48L2tleXdvcmRz

PjxkYXRlcz48eWVhcj4xOTk4PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRlPjwvcHVi

LWRhdGVzPjwvZGF0ZXM+PGlzYm4+MDk1OS04MDQ5IChQcmludCkmI3hEOzA5NTktODA0OSAoTGlu

a2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+OTg0OTQ4MDwvYWNjZXNzaW9uLW51bT48dXJscz48

cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC85ODQ5

NDgwPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Cb3dlcjwvQXV0aG9yPjxZZWFyPjE5OTg8L1llYXI+PFJl

Y051bT4yMTM0PC9SZWNOdW0+PERpc3BsYXlUZXh0PigyNSk8L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+MjEzNDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIg

ZGItaWQ9IjBmczVhMHQ1ZHJ2enZ2ZWZmejF2YXdyOHR6cnZwdzAwdHAydiIgdGltZXN0YW1wPSIx

NTM5MjMwMzA0Ij4yMTM0PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJu

YWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5C

b3dlciwgTS48L2F1dGhvcj48YXV0aG9yPlJ1c3RpbiwgRy4gSi48L2F1dGhvcj48YXV0aG9yPk5l

d2xhbmRzLCBFLiBTLjwvYXV0aG9yPjxhdXRob3I+SG9sZGVuLCBMLjwvYXV0aG9yPjxhdXRob3I+

U2hvcnQsIEQuPC9hdXRob3I+PGF1dGhvcj5Gb3NrZXR0LCBNLjwvYXV0aG9yPjxhdXRob3I+QmFn

c2hhd2UsIEsuIEQuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJl

c3M+TWVkaWNhbCBPbmNvbG9neSBVbml0LCBDaGFyaW5nIENyb3NzIEhvc3BpdGFsLCBMb25kb24s

IFUuSy48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5DaGVtb3RoZXJhcHkgZm9yIGdlc3Rh

dGlvbmFsIHRyb3Bob2JsYXN0aWMgdHVtb3VycyBoYXN0ZW5zIG1lbm9wYXVzZSBieSAzIHllYXJz

PC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkV1ciBKIENhbmNlcjwvc2Vjb25kYXJ5LXRpdGxlPjxh

bHQtdGl0bGU+RXVyb3BlYW4gam91cm5hbCBvZiBjYW5jZXI8L2FsdC10aXRsZT48L3RpdGxlcz48

cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5FdXIgSiBDYW5jZXI8L2Z1bGwtdGl0bGU+PGFiYnItMT5F

dXJvcGVhbiBqb3VybmFsIG9mIGNhbmNlcjwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlv

ZGljYWw+PGZ1bGwtdGl0bGU+RXVyIEogQ2FuY2VyPC9mdWxsLXRpdGxlPjxhYmJyLTE+RXVyb3Bl

YW4gam91cm5hbCBvZiBjYW5jZXI8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4xMjA0

LTc8L3BhZ2VzPjx2b2x1bWU+MzQ8L3ZvbHVtZT48bnVtYmVyPjg8L251bWJlcj48a2V5d29yZHM+

PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QW50aW5lb3BsYXN0aWMgQWdlbnRzLyph

ZHZlcnNlIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+Q2hvcmlvY2FyY2lub21hLypkcnVnIHRo

ZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+RGFjdGlub215Y2luL2FkdmVyc2UgZWZmZWN0czwva2V5

d29yZD48a2V5d29yZD5FdG9wb3NpZGUvYWR2ZXJzZSBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3Jk

PkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5Gb2xsb3ctVXAgU3R1ZGllczwva2V5d29yZD48a2V5

d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+SHlkcm94eXVyZWEvYWR2ZXJzZSBlZmZlY3Rz

PC9rZXl3b3JkPjxrZXl3b3JkPkxldWNvdm9yaW4vYWR2ZXJzZSBlZmZlY3RzPC9rZXl3b3JkPjxr

ZXl3b3JkPk1lbm9wYXVzZSwgUHJlbWF0dXJlLypkcnVnIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdv

cmQ+TWVyY2FwdG9wdXJpbmUvYWR2ZXJzZSBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3JkPk1ldGhv

dHJleGF0ZS9hZHZlcnNlIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxlIEFnZWQ8L2tl

eXdvcmQ+PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlJldHJvc3BlY3RpdmUg

U3R1ZGllczwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+

VHJvcGhvYmxhc3RpYyBOZW9wbGFzbXMvKmRydWcgdGhlcmFweTwva2V5d29yZD48L2tleXdvcmRz

PjxkYXRlcz48eWVhcj4xOTk4PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVsPC9kYXRlPjwvcHVi

LWRhdGVzPjwvZGF0ZXM+PGlzYm4+MDk1OS04MDQ5IChQcmludCkmI3hEOzA5NTktODA0OSAoTGlu

a2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+OTg0OTQ4MDwvYWNjZXNzaW9uLW51bT48dXJscz48

cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC85ODQ5

NDgwPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+

ADDIN EN.CITE.DATA (25). Pregnancy Advice and Outcome after ChemotherapyWomen should be advised not to become pregnant for at least a year after the last dose of chemotherapy. About 90% of patients who want to become pregnant after chemotherapy will do so. There is a 1:70 (1-2%) chance of conceiving a further molar pregnancy. Most studies suggest that as a group, women have normal reproductive outcomes after chemotherapy for GTN. Pregnancies result in about 70% term live births, with a 2.5% incidence of major and minor congenital abnormalities PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CZXJrb3dpdHo8L0F1dGhvcj48WWVhcj4yMDAwPC9ZZWFy

PjxSZWNOdW0+MjE0MTwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oMjYsIDI3KTwvRGlzcGxheVRleHQ+

PHJlY29yZD48cmVjLW51bWJlcj4yMTQxPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBh

cHA9IkVOIiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1l

c3RhbXA9IjE1MzkyMzAzNTkiPjIxNDE8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFt

ZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48

YXV0aG9yPkJlcmtvd2l0eiwgUi4gUy48L2F1dGhvcj48YXV0aG9yPlR1bmNlciwgWi4gUy48L2F1

dGhvcj48YXV0aG9yPkJlcm5zdGVpbiwgTS4gUi48L2F1dGhvcj48YXV0aG9yPkdvbGRzdGVpbiwg

RC4gUC48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5OZXcg

RW5nbGFuZCBUcm9waG9ibGFzdGljIERpc2Vhc2UgQ2VudGVyLCBEZXBhcnRtZW50IG9mIE9ic3Rl

dHJpY3MgYW5kIEd5bmVjb2xvZ3ksIEJyaWdoYW0gYW5kIFdvbWVuJmFwb3M7cyBIb3NwaXRhbCBh

bmQgRGFuYSBGYXJiZXIgQ2FuY2VyIEluc3RpdHV0ZSwgSGFydmFyZCBNZWRpY2FsIFNjaG9vbCwg

Qm9zdG9uLCBNQSwgVVNBLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPk1hbmFnZW1lbnQg

b2YgZ2VzdGF0aW9uYWwgdHJvcGhvYmxhc3RpYyBkaXNlYXNlczogc3Vic2VxdWVudCBwcmVnbmFu

Y3kgZXhwZXJpZW5jZTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5TZW1pbiBPbmNvbDwvc2Vjb25k

YXJ5LXRpdGxlPjxhbHQtdGl0bGU+U2VtaW5hcnMgaW4gb25jb2xvZ3k8L2FsdC10aXRsZT48L3Rp

dGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5TZW1pbiBPbmNvbDwvZnVsbC10aXRsZT48YWJi

ci0xPlNlbWluYXJzIGluIG9uY29sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9k

aWNhbD48ZnVsbC10aXRsZT5TZW1pbiBPbmNvbDwvZnVsbC10aXRsZT48YWJici0xPlNlbWluYXJz

IGluIG9uY29sb2d5PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+Njc4LTg1PC9wYWdl

cz48dm9sdW1lPjI3PC92b2x1bWU+PG51bWJlcj42PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3Jk

PkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25h

bmN5PC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeSBPdXRjb21lPC9rZXl3b3JkPjxrZXl3b3Jk

PipUcm9waG9ibGFzdGljIE5lb3BsYXNtcy9lcGlkZW1pb2xvZ3kvdGhlcmFweTwva2V5d29yZD48

a2V5d29yZD4qVXRlcmluZSBOZW9wbGFzbXMvZXBpZGVtaW9sb2d5L3RoZXJhcHk8L2tleXdvcmQ+

PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwMDwveWVhcj48cHViLWRhdGVzPjxkYXRlPkRlYzwv

ZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwOTMtNzc1NCAoUHJpbnQpJiN4RDswMDkz

LTc3NTQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjExMTMwNDc1PC9hY2Nlc3Npb24t

bnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3Yv

cHVibWVkLzExMTMwNDc1PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0

ZT48Q2l0ZT48QXV0aG9yPlNjaG9yZ2U8L0F1dGhvcj48WWVhcj4yMDAwPC9ZZWFyPjxSZWNOdW0+

MjE0NjwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MjE0NjwvcmVjLW51bWJlcj48Zm9yZWln

bi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjBmczVhMHQ1ZHJ2enZ2ZWZmejF2YXdyOHR6cnZw

dzAwdHAydiIgdGltZXN0YW1wPSIxNTM5MjMwMzkxIj4yMTQ2PC9rZXk+PC9mb3JlaWduLWtleXM+

PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRv

cnM+PGF1dGhvcnM+PGF1dGhvcj5TY2hvcmdlLCBKLiBPLjwvYXV0aG9yPjxhdXRob3I+R29sZHN0

ZWluLCBELiBQLjwvYXV0aG9yPjxhdXRob3I+QmVybnN0ZWluLCBNLiBSLjwvYXV0aG9yPjxhdXRo

b3I+QmVya293aXR6LCBSLiBTLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0

aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgT2JzdGV0cmljcyBhbmQgR3luZWNvbG9neSwgQnJpZ2hh

bSBhbmQgV29tZW4mYXBvcztzIEhvc3BpdGFsLCBCb3N0b24sIE1hc3NhY2h1c2V0dHMsIFVTQS48

L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5SZWNlbnQgYWR2YW5jZXMgaW4gZ2VzdGF0aW9u

YWwgdHJvcGhvYmxhc3RpYyBkaXNlYXNlPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkogUmVwcm9k

IE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+VGhlIEpvdXJuYWwgb2YgcmVwcm9kdWN0

aXZlIG1lZGljaW5lPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

SiBSZXByb2QgTWVkPC9mdWxsLXRpdGxlPjxhYmJyLTE+VGhlIEpvdXJuYWwgb2YgcmVwcm9kdWN0

aXZlIG1lZGljaW5lPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10

aXRsZT5KIFJlcHJvZCBNZWQ8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUgSm91cm5hbCBvZiByZXBy

b2R1Y3RpdmUgbWVkaWNpbmU8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz42OTItNzAw

PC9wYWdlcz48dm9sdW1lPjQ1PC92b2x1bWU+PG51bWJlcj45PC9udW1iZXI+PGtleXdvcmRzPjxr

ZXl3b3JkPkFudGluZW9wbGFzdGljIEFnZW50cy9hZHZlcnNlIGVmZmVjdHMvdGhlcmFwZXV0aWMg

dXNlPC9rZXl3b3JkPjxrZXl3b3JkPkNob3Jpb25pYyBHb25hZG90cm9waW4sIGJldGEgU3VidW5p

dCwgSHVtYW4vYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+RXRvcG9zaWRlL2FkdmVyc2UgZWZmZWN0

cy90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5JbmNpZGVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+

UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5d29yZD5S

aXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+VHJvcGhvYmxhc3RpYyBOZW9wbGFzbXMvZHJ1

ZyB0aGVyYXB5L2dlbmV0aWNzLypwaHlzaW9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+VXRl

cmluZSBOZW9wbGFzbXMvZHJ1ZyB0aGVyYXB5L2dlbmV0aWNzLypwaHlzaW9wYXRob2xvZ3k8L2tl

eXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwMDwveWVhcj48cHViLWRhdGVzPjxkYXRl

PlNlcDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMjQtNzc1OCAoUHJpbnQpJiN4

RDswMDI0LTc3NTggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjExMDI3MDc4PC9hY2Nl

c3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5p

aC5nb3YvcHVibWVkLzExMDI3MDc4PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3Jk

PjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CZXJrb3dpdHo8L0F1dGhvcj48WWVhcj4yMDAwPC9ZZWFy

PjxSZWNOdW0+MjE0MTwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oMjYsIDI3KTwvRGlzcGxheVRleHQ+

PHJlY29yZD48cmVjLW51bWJlcj4yMTQxPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBh

cHA9IkVOIiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1l

c3RhbXA9IjE1MzkyMzAzNTkiPjIxNDE8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFt

ZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48

YXV0aG9yPkJlcmtvd2l0eiwgUi4gUy48L2F1dGhvcj48YXV0aG9yPlR1bmNlciwgWi4gUy48L2F1

dGhvcj48YXV0aG9yPkJlcm5zdGVpbiwgTS4gUi48L2F1dGhvcj48YXV0aG9yPkdvbGRzdGVpbiwg

RC4gUC48L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5OZXcg

RW5nbGFuZCBUcm9waG9ibGFzdGljIERpc2Vhc2UgQ2VudGVyLCBEZXBhcnRtZW50IG9mIE9ic3Rl

dHJpY3MgYW5kIEd5bmVjb2xvZ3ksIEJyaWdoYW0gYW5kIFdvbWVuJmFwb3M7cyBIb3NwaXRhbCBh

bmQgRGFuYSBGYXJiZXIgQ2FuY2VyIEluc3RpdHV0ZSwgSGFydmFyZCBNZWRpY2FsIFNjaG9vbCwg

Qm9zdG9uLCBNQSwgVVNBLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPk1hbmFnZW1lbnQg

b2YgZ2VzdGF0aW9uYWwgdHJvcGhvYmxhc3RpYyBkaXNlYXNlczogc3Vic2VxdWVudCBwcmVnbmFu

Y3kgZXhwZXJpZW5jZTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5TZW1pbiBPbmNvbDwvc2Vjb25k

YXJ5LXRpdGxlPjxhbHQtdGl0bGU+U2VtaW5hcnMgaW4gb25jb2xvZ3k8L2FsdC10aXRsZT48L3Rp

dGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5TZW1pbiBPbmNvbDwvZnVsbC10aXRsZT48YWJi

ci0xPlNlbWluYXJzIGluIG9uY29sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9k

aWNhbD48ZnVsbC10aXRsZT5TZW1pbiBPbmNvbDwvZnVsbC10aXRsZT48YWJici0xPlNlbWluYXJz

IGluIG9uY29sb2d5PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+Njc4LTg1PC9wYWdl

cz48dm9sdW1lPjI3PC92b2x1bWU+PG51bWJlcj42PC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3Jk

PkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+UHJlZ25h

bmN5PC9rZXl3b3JkPjxrZXl3b3JkPlByZWduYW5jeSBPdXRjb21lPC9rZXl3b3JkPjxrZXl3b3Jk

PipUcm9waG9ibGFzdGljIE5lb3BsYXNtcy9lcGlkZW1pb2xvZ3kvdGhlcmFweTwva2V5d29yZD48

a2V5d29yZD4qVXRlcmluZSBOZW9wbGFzbXMvZXBpZGVtaW9sb2d5L3RoZXJhcHk8L2tleXdvcmQ+

PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwMDwveWVhcj48cHViLWRhdGVzPjxkYXRlPkRlYzwv

ZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwOTMtNzc1NCAoUHJpbnQpJiN4RDswMDkz

LTc3NTQgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjExMTMwNDc1PC9hY2Nlc3Npb24t

bnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3Yv

cHVibWVkLzExMTMwNDc1PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0

ZT48Q2l0ZT48QXV0aG9yPlNjaG9yZ2U8L0F1dGhvcj48WWVhcj4yMDAwPC9ZZWFyPjxSZWNOdW0+

MjE0NjwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MjE0NjwvcmVjLW51bWJlcj48Zm9yZWln

bi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IjBmczVhMHQ1ZHJ2enZ2ZWZmejF2YXdyOHR6cnZw

dzAwdHAydiIgdGltZXN0YW1wPSIxNTM5MjMwMzkxIj4yMTQ2PC9rZXk+PC9mb3JlaWduLWtleXM+

PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRv

cnM+PGF1dGhvcnM+PGF1dGhvcj5TY2hvcmdlLCBKLiBPLjwvYXV0aG9yPjxhdXRob3I+R29sZHN0

ZWluLCBELiBQLjwvYXV0aG9yPjxhdXRob3I+QmVybnN0ZWluLCBNLiBSLjwvYXV0aG9yPjxhdXRo

b3I+QmVya293aXR6LCBSLiBTLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0

aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgT2JzdGV0cmljcyBhbmQgR3luZWNvbG9neSwgQnJpZ2hh

bSBhbmQgV29tZW4mYXBvcztzIEhvc3BpdGFsLCBCb3N0b24sIE1hc3NhY2h1c2V0dHMsIFVTQS48

L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5SZWNlbnQgYWR2YW5jZXMgaW4gZ2VzdGF0aW9u

YWwgdHJvcGhvYmxhc3RpYyBkaXNlYXNlPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkogUmVwcm9k

IE1lZDwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+VGhlIEpvdXJuYWwgb2YgcmVwcm9kdWN0

aXZlIG1lZGljaW5lPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+

SiBSZXByb2QgTWVkPC9mdWxsLXRpdGxlPjxhYmJyLTE+VGhlIEpvdXJuYWwgb2YgcmVwcm9kdWN0

aXZlIG1lZGljaW5lPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10

aXRsZT5KIFJlcHJvZCBNZWQ8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUgSm91cm5hbCBvZiByZXBy

b2R1Y3RpdmUgbWVkaWNpbmU8L2FiYnItMT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz42OTItNzAw

PC9wYWdlcz48dm9sdW1lPjQ1PC92b2x1bWU+PG51bWJlcj45PC9udW1iZXI+PGtleXdvcmRzPjxr

ZXl3b3JkPkFudGluZW9wbGFzdGljIEFnZW50cy9hZHZlcnNlIGVmZmVjdHMvdGhlcmFwZXV0aWMg

dXNlPC9rZXl3b3JkPjxrZXl3b3JkPkNob3Jpb25pYyBHb25hZG90cm9waW4sIGJldGEgU3VidW5p

dCwgSHVtYW4vYmxvb2Q8L2tleXdvcmQ+PGtleXdvcmQ+RXRvcG9zaWRlL2FkdmVyc2UgZWZmZWN0

cy90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5JbmNpZGVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+

UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlByb2dub3Npczwva2V5d29yZD48a2V5d29yZD5S

aXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+VHJvcGhvYmxhc3RpYyBOZW9wbGFzbXMvZHJ1

ZyB0aGVyYXB5L2dlbmV0aWNzLypwaHlzaW9wYXRob2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+VXRl

cmluZSBOZW9wbGFzbXMvZHJ1ZyB0aGVyYXB5L2dlbmV0aWNzLypwaHlzaW9wYXRob2xvZ3k8L2tl

eXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAwMDwveWVhcj48cHViLWRhdGVzPjxkYXRl

PlNlcDwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjAwMjQtNzc1OCAoUHJpbnQpJiN4

RDswMDI0LTc3NTggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjExMDI3MDc4PC9hY2Nl

c3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5p

aC5nb3YvcHVibWVkLzExMDI3MDc4PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3Jk

PjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE.DATA (26, 27). These figures do not differ significantly from those in the normal population. Management future pregnancies see aboveIf a pregnancy (against advice) within 12 months after completion of Chemotherapy for GTN :RecommendationThere is no indication for a recommendation of a termination of pregnancy. The patient needs to be advised about increased risks (spontaneous abortion, stillbirth and repeat mole)Please see chapters “Pregnancy advice after molar pregnancy” and “Pregnancy during Follow up after molar pregnancy” for surveillance recommendationsBackground< 12 months vs. > 12 months No significant changes where found between women who conceived within 12 months of completing chemotherapy to the comparator groups, in a study conducted by the Charing Cross PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CbGFnZGVuPC9BdXRob3I+PFllYXI+MjAwMjwvWWVhcj48

UmVjTnVtPjIxNDc8L1JlY051bT48RGlzcGxheVRleHQ+KDI4KTwvRGlzcGxheVRleHQ+PHJlY29y

ZD48cmVjLW51bWJlcj4yMTQ3PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9

IjE1MzkyMzA0NDQiPjIxNDc8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PkJsYWdkZW4sIFMuIFAuPC9hdXRob3I+PGF1dGhvcj5Gb3NrZXR0LCBNLiBBLjwvYXV0aG9yPjxh

dXRob3I+RmlzaGVyLCBSLiBBLjwvYXV0aG9yPjxhdXRob3I+U2hvcnQsIEQuPC9hdXRob3I+PGF1

dGhvcj5GdWxsZXIsIFMuPC9hdXRob3I+PGF1dGhvcj5OZXdsYW5kcywgRS4gUy48L2F1dGhvcj48

YXV0aG9yPlNlY2tsLCBNLiBKLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0

aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgTWVkaWNhbCBPbmNvbG9neSwgQ2hhcmluZyBDcm9zcyBI

b3NwaXRhbCwgTG9uZG9uIFc2IDhSRiwgVUsuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+

VGhlIGVmZmVjdCBvZiBlYXJseSBwcmVnbmFuY3kgZm9sbG93aW5nIGNoZW1vdGhlcmFweSBvbiBk

aXNlYXNlIHJlbGFwc2UgYW5kIGZvZXRhbCBvdXRjb21lIGluIHdvbWVuIHRyZWF0ZWQgZm9yIGdl

c3RhdGlvbmFsIHRyb3Bob2JsYXN0aWMgdHVtb3VyczwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5C

ciBKIENhbmNlcjwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+QnJpdGlzaCBqb3VybmFsIG9m

IGNhbmNlcjwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkJyIEog

Q2FuY2VyPC9mdWxsLXRpdGxlPjxhYmJyLTE+QnJpdGlzaCBqb3VybmFsIG9mIGNhbmNlcjwvYWJi

ci0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QnIgSiBDYW5jZXI8

L2Z1bGwtdGl0bGU+PGFiYnItMT5Ccml0aXNoIGpvdXJuYWwgb2YgY2FuY2VyPC9hYmJyLTE+PC9h

bHQtcGVyaW9kaWNhbD48cGFnZXM+MjYtMzA8L3BhZ2VzPjx2b2x1bWU+ODY8L3ZvbHVtZT48bnVt

YmVyPjE8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWJvcnRpb24sIFNwb250YW5lb3VzL2V0

aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1

bHQ8L2tleXdvcmQ+PGtleXdvcmQ+Q29uZ2VuaXRhbCBBYm5vcm1hbGl0aWVzL2V0aW9sb2d5PC9r

ZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5GZXRhbCBEZWF0aC9ldGlv

bG9neTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxlIEFn

ZWQ8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20gUmVjdXJyZW5jZSwgTG9jYWw8L2tleXdvcmQ+

PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlJldHJvc3BlY3RpdmUgU3R1ZGll

czwva2V5d29yZD48a2V5d29yZD5Ucm9waG9ibGFzdGljIE5lb3BsYXNtcy9jb21wbGljYXRpb25z

LypkcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBOZW9wbGFzbXMvY29tcGxp

Y2F0aW9ucy8qZHJ1ZyB0aGVyYXB5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIw

MDI8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5KYW4gNzwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVz

Pjxpc2JuPjAwMDctMDkyMCAoUHJpbnQpJiN4RDswMDA3LTA5MjAgKExpbmtpbmcpPC9pc2JuPjxh

Y2Nlc3Npb24tbnVtPjExODU3MDA3PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+

PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzExODU3MDA3PC91cmw+PC9y

ZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPjI3NDY1Mzg8L2N1c3RvbTI+PGVsZWN0cm9uaWMt

cmVzb3VyY2UtbnVtPjEwLjEwMzgvc2ouYmpjLjY2MDAwNDE8L2VsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CbGFnZGVuPC9BdXRob3I+PFllYXI+MjAwMjwvWWVhcj48

UmVjTnVtPjIxNDc8L1JlY051bT48RGlzcGxheVRleHQ+KDI4KTwvRGlzcGxheVRleHQ+PHJlY29y

ZD48cmVjLW51bWJlcj4yMTQ3PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0iMGZzNWEwdDVkcnZ6dnZlZmZ6MXZhd3I4dHpydnB3MDB0cDJ2IiB0aW1lc3RhbXA9

IjE1MzkyMzA0NDQiPjIxNDc8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PkJsYWdkZW4sIFMuIFAuPC9hdXRob3I+PGF1dGhvcj5Gb3NrZXR0LCBNLiBBLjwvYXV0aG9yPjxh

dXRob3I+RmlzaGVyLCBSLiBBLjwvYXV0aG9yPjxhdXRob3I+U2hvcnQsIEQuPC9hdXRob3I+PGF1

dGhvcj5GdWxsZXIsIFMuPC9hdXRob3I+PGF1dGhvcj5OZXdsYW5kcywgRS4gUy48L2F1dGhvcj48

YXV0aG9yPlNlY2tsLCBNLiBKLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0

aC1hZGRyZXNzPkRlcGFydG1lbnQgb2YgTWVkaWNhbCBPbmNvbG9neSwgQ2hhcmluZyBDcm9zcyBI

b3NwaXRhbCwgTG9uZG9uIFc2IDhSRiwgVUsuPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+

VGhlIGVmZmVjdCBvZiBlYXJseSBwcmVnbmFuY3kgZm9sbG93aW5nIGNoZW1vdGhlcmFweSBvbiBk

aXNlYXNlIHJlbGFwc2UgYW5kIGZvZXRhbCBvdXRjb21lIGluIHdvbWVuIHRyZWF0ZWQgZm9yIGdl

c3RhdGlvbmFsIHRyb3Bob2JsYXN0aWMgdHVtb3VyczwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5C

ciBKIENhbmNlcjwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+QnJpdGlzaCBqb3VybmFsIG9m

IGNhbmNlcjwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkJyIEog

Q2FuY2VyPC9mdWxsLXRpdGxlPjxhYmJyLTE+QnJpdGlzaCBqb3VybmFsIG9mIGNhbmNlcjwvYWJi

ci0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QnIgSiBDYW5jZXI8

L2Z1bGwtdGl0bGU+PGFiYnItMT5Ccml0aXNoIGpvdXJuYWwgb2YgY2FuY2VyPC9hYmJyLTE+PC9h

bHQtcGVyaW9kaWNhbD48cGFnZXM+MjYtMzA8L3BhZ2VzPjx2b2x1bWU+ODY8L3ZvbHVtZT48bnVt

YmVyPjE8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWJvcnRpb24sIFNwb250YW5lb3VzL2V0

aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkFkb2xlc2NlbnQ8L2tleXdvcmQ+PGtleXdvcmQ+QWR1

bHQ8L2tleXdvcmQ+PGtleXdvcmQ+Q29uZ2VuaXRhbCBBYm5vcm1hbGl0aWVzL2V0aW9sb2d5PC9r

ZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5GZXRhbCBEZWF0aC9ldGlv

bG9neTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TWlkZGxlIEFn

ZWQ8L2tleXdvcmQ+PGtleXdvcmQ+TmVvcGxhc20gUmVjdXJyZW5jZSwgTG9jYWw8L2tleXdvcmQ+

PGtleXdvcmQ+UHJlZ25hbmN5PC9rZXl3b3JkPjxrZXl3b3JkPlJldHJvc3BlY3RpdmUgU3R1ZGll

czwva2V5d29yZD48a2V5d29yZD5Ucm9waG9ibGFzdGljIE5lb3BsYXNtcy9jb21wbGljYXRpb25z

LypkcnVnIHRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+VXRlcmluZSBOZW9wbGFzbXMvY29tcGxp

Y2F0aW9ucy8qZHJ1ZyB0aGVyYXB5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIw

MDI8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5KYW4gNzwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVz

Pjxpc2JuPjAwMDctMDkyMCAoUHJpbnQpJiN4RDswMDA3LTA5MjAgKExpbmtpbmcpPC9pc2JuPjxh

Y2Nlc3Npb24tbnVtPjExODU3MDA3PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+

PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzExODU3MDA3PC91cmw+PC9y

ZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPjI3NDY1Mzg8L2N1c3RvbTI+PGVsZWN0cm9uaWMt

cmVzb3VyY2UtbnVtPjEwLjEwMzgvc2ouYmpjLjY2MDAwNDE8L2VsZWN0cm9uaWMtcmVzb3VyY2Ut

bnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE.DATA (28).< 6 months vs. > 12 monthsAnother retrospective analysis found incidence of abnormal pregnancies (spontaneous abortion, stillbirth and repeat mole) was higher in those women who conceived within 6 months vs > 12 months of completing chemotherapy (37.5% vs 10.5 %) Of these women 85% had been treated with methotrexate, the remainder with MEA ADDIN EN.CITE <EndNote><Cite><Author>Matsui</Author><Year>2004</Year><RecNum>2149</RecNum><DisplayText>(29)</DisplayText><record><rec-number>2149</rec-number><foreign-keys><key app="EN" db-id="0fs5a0t5drvzvveffz1vawr8tzrvpw00tp2v" timestamp="1539230479">2149</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Matsui, H.</author><author>Iitsuka, Y.</author><author>Suzuka, K.</author><author>Yamazawa, K.</author><author>Tanaka, N.</author><author>Mitsuhashi, A.</author><author>Sekiya, S.</author></authors></contributors><auth-address>Department of Reproductive Medicine, Chiba University Graduate School of Medicine, Chiba, Japan. hmatsui@med.m.chiba-u.ac.jp</auth-address><titles><title>Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor</title><secondary-title>J Reprod Med</secondary-title><alt-title>The Journal of reproductive medicine</alt-title></titles><periodical><full-title>J Reprod Med</full-title><abbr-1>The Journal of reproductive medicine</abbr-1></periodical><alt-periodical><full-title>J Reprod Med</full-title><abbr-1>The Journal of reproductive medicine</abbr-1></alt-periodical><pages>531-4</pages><volume>49</volume><number>7</number><keywords><keyword>Antineoplastic Agents/*adverse effects</keyword><keyword>Female</keyword><keyword>Gestational Trophoblastic Disease/*drug therapy</keyword><keyword>Humans</keyword><keyword>Pregnancy</keyword><keyword>Pregnancy Complications/*chemically induced</keyword><keyword>*Pregnancy Outcome</keyword><keyword>Time Factors</keyword><keyword>Uterine Neoplasms/*drug therapy</keyword></keywords><dates><year>2004</year><pub-dates><date>Jul</date></pub-dates></dates><isbn>0024-7758 (Print)&#xD;0024-7758 (Linking)</isbn><accession-num>15305824</accession-num><urls><related-urls><url>;(29).23PROGNOSIS IN GESTATIONAL TROPHOBLASTIC NEOPLASIA low risk diseaseChances of cure are close to 100%. This is the case if they are treated with MTX alone, or if they require change to second line chemotherapy. high risk disease Survival varies widely according to tumour burden and site of metastasesOverall cure is close to 85%. VERSION and AUTHORSVersion 3Kathryn Chrystal for the NZGCG GroupCorrespondence kchrystal@t.nzBased on first version from 2006, V2 update 2014 (Michelle Vaughan and Simone Petrich)ACKNOWLEDGEMENTSThank you to Dr Philip Savage from the Charing Cross in London, for editing and access to the Charing Cross Trophoblast Disease Clinic Guide, upon which much of the first edition of the guidelines were based. Thanks to Maria Treloar for clerical support and Fran Anderson and Kate Coffey for the patient information booklet.APPENDICESPatient information Patient record REFERENCES ADDIN EN.REFLIST 1.Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE, Hancock BW. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecologic oncology. 2000;78(3 Pt 1):309-12.2.Attwood HD, Park WW. Embolism to the lungs by trophoblast. The Journal of obstetrics and gynaecology of the British Commonwealth. 1961;68:611-7.3.Hancock BW, Newlands ES, Berkowitz RS, Cole LA. Gestational Trophoblastic Diseases. . 2nd ed. Sheffield: International Society for the Study of Trophoblastic Diseases; 2003.4.Osborne RJ, Filiaci VL, Schink JC, Mannel RS, Behbakht K, Hoffman JS, et al. Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. Obstetrics and gynecology. 2016;128(3):535-42.5.Stafford L, McNally OM, Gibson P, Judd F. Long-term psychological morbidity, sexual functioning, and relationship outcomes in women with gestational trophoblastic disease. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(7):1256-63.6.Schmitt C, Doret M, Massardier J, Hajri T, Schott AM, Raudrant D, et al. Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type. Gynecologic oncology. 2013;130(1):86-9.7.Wielsma S, Kerkmeijer L, Bekkers R, Pyman J, Tan J, Quinn M. Persistent trophoblast disease following partial molar pregnancy. The Australian & New Zealand journal of obstetrics & gynaecology. 2006;46(2):119-23.8.Curry SL, Hammond CB, Tyrey L, Creasman WT, Parker RT. Hydatidiform mole: diagnosis, management, and long-term followup of 347 patients. Obstetrics and gynecology. 1975;45(1):1-8.9.Bahar AM, el-Ashnehi MS, Senthilselvan A. Hydatidiform mole in the elderly: hysterectomy or evacuation? International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 1989;29(3):233-8.10.Wang Q, Fu J, Hu L, Fang F, Xie L, Chen H, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. The Cochrane database of systematic reviews. 2017;9:CD007289.11.Kashimura Y, Kashimura M, Sugimori H, Tsukamoto N, Matsuyama T, Matsukuma K, et al. Prophylactic chemotherapy for hydatidiform mole. Five to 15 years follow-up. Cancer. 1986;58(3):624-9.12.Berkowitz RS, Goldstein DP, DuBeshter B, Bernstein MR. Management of complete molar pregnancy. The Journal of reproductive medicine. 1987;32(9):634-9.13.Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. The Journal of reproductive medicine. 2001;46(2):110-6.14.Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and gynecology. 1986;67(5):690-4.15.Costa HL, Doyle P. Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia--a systematic review. Gynecologic oncology. 2006;100(3):579-85.16.Gaffield ME, Kapp N, Curtis KM. Combined oral contraceptive and intrauterine device use among women with gestational trophoblastic disease. Contraception. 2009;80(4):363-71.17.Tuncer ZS, Bernstein MR, Goldstein DP, Lu KH, Berkowitz RS. Outcome of pregnancies occurring within 1 year of hydatidiform mole. Obstetrics and gynecology. 1999;94(4):588-90.18.Steigrad SJ, Robertson G, Kaye AL. Serial hCG and ultrasound measurements for predicting malignant potential in multiple pregnancies associated with complete hydatidiform mole: a report of 2 cases. The Journal of reproductive medicine. 2004;49(7):554-8.19.Sebire NJ, Foskett M, Paradinas FJ, Fisher RA, Francis RJ, Short D, et al. Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet. 2002;359(9324):2165-6.20.Vejerslev LO. Clinical management and diagnostic possibilities in hydatidiform mole with coexistent fetus. Obstetrical & gynecological survey. 1991;46(9):577-88.21.Agarwal R, Teoh S, Short D, Harvey R, Savage PM, Seckl MJ. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet. 2012;379(9811):130-5.22.Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2001;11(1):73-7.23.Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. British journal of cancer. 2007;96(5):732-7.24.Woolas RP, Bower M, Newlands ES, Seckl M, Short D, Holden L. Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. British journal of obstetrics and gynaecology. 1998;105(9):1032-5.25.Bower M, Rustin GJ, Newlands ES, Holden L, Short D, Foskett M, et al. Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years. European journal of cancer. 1998;34(8):1204-7.26.Berkowitz RS, Tuncer ZS, Bernstein MR, Goldstein DP. Management of gestational trophoblastic diseases: subsequent pregnancy experience. Seminars in oncology. 2000;27(6):678-85.27.Schorge JO, Goldstein DP, Bernstein MR, Berkowitz RS. Recent advances in gestational trophoblastic disease. The Journal of reproductive medicine. 2000;45(9):692-700.28.Blagden SP, Foskett MA, Fisher RA, Short D, Fuller S, Newlands ES, et al. The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. British journal of cancer. 2002;86(1):26-30.29.Matsui H, Iitsuka Y, Suzuka K, Yamazawa K, Tanaka N, Mitsuhashi A, et al. Early pregnancy outcomes after chemotherapy for gestational trophoblastic tumor. The Journal of reproductive medicine. 2004;49(7):531-4. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download